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El hueso es un tejido activo que está en continua renovación en un proceso 
equilibrado, llevada a cabo por los osteoblastos, encargados de formar nuevo 
hueso, y por los osteoclastos, encargados de la resorción ósea. La diferenciación 
de las células madre mesenquimales (MSCs), precursores de los osteoblastos, 
es esencial para el mantenimiento de la masa ósea. En la osteoporosis hay un 
desequilibrio en el proceso de remodelado óseo, con una predominancia de la 
actividad osteoclástica sobre la osteoblástica. Esto conduce a una pérdida de la 
densidad mineral ósea y una mayor susceptibilidad a padecer fracturas. Los 
mecanismos epigenéticos son esenciales para la regulación celular y, por tanto, 
también son claves en el desarrollo de diversas enfermedades. Entre estos 
mecanismos se encuentran la metilación de ADN y la expresión de ARN largos 
no codificantes (lncRNAs). La capacidad funcional de las MSCs puede verse 
comprometida en personas de edad avanzada, en relación con los cambios 
epigenéticos asociados con el envejecimiento. Sin embargo, el papel de las 
MSCs en la patogenia de la osteoporosis no está bien definido. Por lo tanto, 
nuestro objetivo fue caracterizar las marcas de metilación, el patrón de expresión 
génica (codificante y no codificante de proteína) y la capacidad de diferenciación 
de las MSC de médula ósea (BMSCs) de pacientes con fracturas de cadera 
osteoporóticas.  
Obtuvimos BMSCs de las cabezas femorales de mujeres que se sometieron a 
un reemplazo de cadera debido a fracturas de cadera y de controles con artrosis 
de cadera. La metilación del ADN se exploró con el microchip Infinium 450K 
(Illumina). El análisis del transcriptoma se realizó mediante secuenciación de 
ARN.  
Las BMSCs de pacientes con fracturas mostraron una mayor proliferación y 
expresión de los genes reguladores osteogénicos RUNX2/OSX. Cuando se 
cultivaron en medio osteogénico, las BMSCs de pacientes con fracturas 
mostraron una capacidad de diferenciación alterada, con una actividad de 
fosfatasa alcalina reducida y una acumulación deficiente de una matriz 
mineralizada. Además, mostraron algunos signos de envejecimiento acelerado 





Los análisis de metilación de ADN revelaron que la mayoría de los sitios 
diferencialmente metilados se dan en regiones genómicas con actividad 
reguladora (“enhancer”), a distancia de los promotores de genes. Estas regiones   
se asociaron, a su vez, con genes expresados diferencialmente, que estaban 
sobre-representados en vías relacionadas con el crecimiento de BMSCs y la 
diferenciación osteogénica.  
Cuando nos centramos en la expresión de la parte no codificante del genoma, 
vimos que la mayoría de los tránscritos eran de tipo antisentido. Los genes 
codificantes de proteínas en posición cis de estos lncRNAs antisentido, que 
también se expresaban diferencialmente en fracturas y artrosis, estaban 
altamente representados en vías relacionadas con la formación ósea. 
En general, nuestros resultados sugieren que los mecanismos epigenéticos, y 
específicamente el estado de metilación de las regiones reguladoras y los 
lncRNAs juegan un papel importante en la determinación del patrón de expresión 
génica de BMSCs de pacientes con osteoporosis. Un mejor conocimiento de 
estas vías no sólo contribuirá a comprender mejor los mecanismos patogénicos 
de la osteoporosis, sino que puede llevar a identificar nuevas dianas para el 
























Bone is an active tissue, continuously renewed in a balanced process carried out 
by the osteoblasts, bone forming cells, and by the osteoclasts, responsible for 
bone resorption. Mesenchymal stem cells (MSCs), precursors of osteoblasts, are 
essential for the maintenance of bone mass. In osteoporosis, exists an imbalance 
in the bone remodeling process, with a predominance of osteoclast activity over 
osteoblastic bone formation. This leads to low bone mineral density and an 
increased susceptibility to fractures. Epigenetic mechanisms are essential for cell 
differentiation and activity and, therefore, are also important for the pathogenesis 
of different diseases. These mechanisms include DNA methylation and the 
expression of long non-coding RNAs (lncRNAs), among others. In theory, the 
functional capacity of MSCs may be compromised in elderly people, in relation to 
the epigenetic changes associated with aging. However, the role of these cells in 
the pathogenesis of osteoporosis is not well established. Therefore, the aim of 
this thesis was to analyze DNA methylation marks, gene expression (protein 
coding and non-protein coding) and the differentiation capacity of bone marrow 
MSCs (BMSCs) of patients with osteoporotic hip fractures.  
We obtained BMSCs from the femoral heads of women undergoing hip 
replacement surgery due to hip fractures and from controls with hip osteoarthritis. 
DNA methylation was explored with the Infinium 450K array (Illumina). 
Transcriptome analysis was performed by RNA sequencing. 
BMSCs of patients with fractures showed greater cell proliferation and gene 
expression of the master regulator genes RUNX2/OSX. When cultured in 
osteogenic medium, BMSCs of patients with fractures showed an altered 
differentiation capacity, with reduced alkaline phosphatase activity and a deficient 
accumulation of a mineralized matrix. In addition, they showed some signs of 
accelerated epigenetic aging, as assessed by the methylation of some CpGs.  
Genome-wide methylation analysis showed that most sites differentially 
methylated in BMSCs from patients with osteoporotic fractures, in comparison 
with controls with osteoarthritis, are located in genomic regions with enhancer 
activity. In turn, those enhancer regions were associated with differentially 
expressed genes, and these genes were enriched in bone related pathways, such 





Regarding the non-protein coding specific gene expression, we saw that most 
transcripts are antisense type. The protein coding genes in cis position 
associated with those antisense lncRNAs, which are also differentially expressed, 
are highly represented in pathways related to bone formation.  
In general, our results suggest that both epigenetic mechanisms, DNA 
methylation marks of enhancer regions and lncRNAs, play an important role in 
the regulation of gene expression of BMSCs derived from patients with 
osteoporosis. A better knowledge of these pathways will not only improve our 
understanding of the pathogenesis of osteoporosis, but may also help to identify 



























Bone is a mineralized connective tissue whose particular structure and 
composition allow to succeed in its important functions in a vertebrate organism. 
Bones have specific properties that make them capable to have mechanical, 
metabolic and hematopoietic functions: a) they support and protect internal soft 
organs, like heart, brain or lungs; b) they are the niche for the bone marrow cells 
and haematopoiesis; c) they also are the most important calcium and phosphorus 
reservoir and contribute to mineral homeostasis; d) they serve as energy 
reservoir, represented by the marrow fat; e) finally, bones also permit the body 
movement by anchoring muscles, ligaments and tendons.  
Bone tissue originates from the mesodermal layer in the gastrulation during 
embryogenesis. The mesoderm is the intermediate layer which forms the 
skeleton (with exception of the craniofacial region) and muscles. Distinguishing 
the mesoderm in different parts, depending on the distance to the centre of the 
embryo, we differentiate the lateral plate of the mesoderm, which forms the 
appendicular skeleton (limbs), and the paraxial mesoderm, where the sclerotome 
that will give rise to the axial skeleton is situated. Craniofacial bones are formed 
from the cells of the neural crest. There are two forms of bone formation or 
ossification, intramembranous ossification and endochondral ossification. 
Intramembranous ossification is characterized by bone formed directly from 
undifferentiated connective tissue; this is, mesenchymal progenitors differentiate 
into osteoblasts to form the membranous bone. On the other hand, in the 
endochondral ossification cartilage is formed by chondrocytes before bone, then 
bone replaces the hyaline cartilage. Cartilage is not transformed into bone, but it 
is a template to be replaced by bone afterwards.  
Bone composition is distinct from that of any other tissue because it has the only 
extracellular matrix that is mineralized. Bone matrix is mainly composed of 
mineral, collagen, noncollagenous proteins, water, and depending on the site, a 
small proportion of lipids. The mineral phase consists basically of hydroxyapatite 
[Ca10(PO4)6(OH)2], with some substitutions like carbonate, magnesium and acid 





a readily available source of ions, such as calcium, magnesium and phosphate, 
that helps maintaining the serum levels of minerals. 
In addition to the matrix, there are three main types bone cells: the bone forming 
osteoblasts; osteocytes, which are mature bone cells immersed in mineralized 
bone; and the bone-destroying osteoclasts.  
Bones have two types of tissue, compact or cortical bone, and cancellous or 
trabecular bone, which differ in how tightly the tissue is packed, so they have a 
different tissue density. Compact bone has closely packed osteons, forming a 
solid, compacted mass. Trabecular bone consists of a highly porous structure of 
rod-shaped trabeculae, adjacent to irregular cavities that contain red bone 
marrow. Obviously, trabecular bone is less dense (this is, has a smaller amount 
of mineralized tissue per volume) and more flexible than compact bone. 
Bones in the skeleton can be classified in five different types according to their 
shape: long, short, irregular, sesamoid and flat bones. Long bones are 
characterized by having a central elongation filled with bone marrow, called 
diaphysis and at both ends a wider region known as epiphysis. Between the 
epiphysis and the diaphysis is the metaphysis, which is formed by trabecular 
bone and, during the growth period, a cartilaginous disc that allows the 
lengthening of the bone. The outside of the bone has a layer of connective tissue 
called the periosteum, which contains blood vessels that supply bone, as well as 
the nerve endings. There is also a membranous layer that covers the inner 
surface of the bone that is in contact with the marrow, known as the endosteum. 
Some examples of long bones are the femur, tibia and humerus.  
Short bones are about as wide as long, formed by a thin layer of cortical bone 
filled with trabecular bone. They provide support with less movement and include 
the bones of the hands or feet for example. Sesamoid bones are bones buried in 
a tendon to protect it, like the patella (knee cap). Flat bones are thin and curved. 
They are composed of two thin layers of compact bone and an inner layer of 
spongy bone. Within this group are the bones of the skull. And finally, irregular 
bones are those bones that cannot be classified within the previous groups, such 
as the vertebrae or the bones of the face. 
Bone is a highly dynamic tissue. Adult bone is continuously remodelled by a 
regulated process coordinated by bone forming osteoblasts and bone resorbing 





lesions, the process leads to bone repair or regeneration. Any imbalance in the 
bone remodelling process leads to bone diseases, such as osteoporosis, among 
others 1.   
 
The osteoblastic lineage 
The lineage of bone forming cells include mesenchymal stem cells (MSCs), 
osteoblasts and osteocytes. MSCs differentiate into osteoblasts (bone forming 
cells), which secrete most components of the non-mineralized bone matrix 
(osteoid), and finally they become embedded as osteocytes in the matrix that 
becomes progressively mineralized 2,3.  
Osteoblasts are cuboid cells that are responsible for bone formation. This type of 
cell is the result of the differentiation of MSCs, a pluripotent cell that can be found 
in a variety of tissues, including bone marrow, muscles, and fat. MSCs can 
differentiate into different cell components of the mesoderm, including bone, 
cartilage, muscle, fat, ligaments, and tendons. Thus, the stages of the 
osteoblastic lineage include different cell types, such as mesenchymal 
progenitors, osteo/chondroprogenitors, pre-osteoblasts, immature osteoblasts, 
osteoblasts, bone lining cells and osteocytes. The differentiation of MSCs into 
osteoblasts is controlled by specific cytokines and transcription factors, at each 
stage of differentiation. Among the humoral endocrine and paracrine factors 
involved in osteoblast differentiation are the Hedgehogs, BMPs, TGF-β, PTH and 
WNTs. These developmental signals regulate the expression of specific 
transcription factors, such as, RUNX2, OSX, NFAT and SOX9 4. 
 
Transcription factors in bone differentiation 
RUNX2 is indispensable for osteoblast differentiation. This protein acts as a 
transcription factor that regulates the activation or inhibition of its target genes. In 
1997 studies of several groups elucidated the role of RUNX2 in osteoblast 
differentiation and consequently bone formation 5,6. They demonstrated that mice 
with a homozygous mutation in RUNX2 died just after birth and presented an 
absence of ossification. They also showed specific skeletal deformities, which are 
characteristic in cleidocranial dysplasia (CCD), a human heritable skeletal 





marker genes: osteocalcin, bone sialoprotein, osteopontin and type 1 collagen 7. 
During the differentiation process, distinct transcription factors are expressed at 
different developmental stages and with different functions. SOX9 is necessary 
for chondrogenesis, and it seems to be also important in the first stage of 
differentiation of the mesenchymal progenitors to osteoblasts. In fact, deletion of 
SOX9 in the limb bud mesenchyme causes a lack of chondrocytes and 
osteoblasts. So, it is thought that SOX9 is important for the formation of osteo-
chondroprogenitor cells, but it is not further expressed in the osteoblastic 
lineage8.  
Osterix (OSX) is a zinc finger transcription factor expressed in osteoblasts and is 
also required for bone formation, as RUNX2 factor. OSX works specifically in 
osteoblasts and acts downstream of RUNX2. It means that OSX expression 
depends on the expression of RUNX2, but not vice versa 9. First, mesenchymal 
progenitors express RUNX2 and differentiate into preosteoblasts that do not 
express osteoblast marker genes yet. Then, RUNX2- and OSX-expressing 
preosteoblasts in both endochondral and intramembranous ossification 
differentiate into mature osteoblasts, this is, cells that express osteoblast specific 
marker genes 10.  
 
Other signalling factors 
Hedgehog (Hh) signalling proteins bind to the receptor PTCH1, which regulates 
the expression of the GLI family of transcriptions factors. There are three Hh 
proteins in mammals (Sonic, Indian, and Desert hedgehog) that play critical roles 
in organ development. Indian hedgehog (Ihh) is essential for the development of 
the osteoblast lineage in the endochondral skeleton by promoting osteoblast 
differentiation and inhibiting the alternative chondrocyte pathway 11.  
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor 
beta (TGF-β) superfamily and are essential components of various biological 
processes including bone formation. BMP2, BMP6, BMP7 and BMP9 stimulate 
osteoblastic differentiation. They increase alkaline phosphatase activity in pre-
osteoblasts, and also other early markers of osteoblast differentiation. Not all 






Notch proteins mediate communication between cells. They are transmembrane 
proteins that undergo proteolytic cleavage by presenilin. The resultant Notch 
intracellular domain translocates into the nucleus and regulates the expression 
of transcription factors like Hes or Hey family of transcription factors. MSC 
differentiation into osteoblasts is inhibited via Hey1. In fact, Runx2 transcriptional 
activity is physically antagonized by the protein encoded by Notch target gene 
Hey1 4.  
WNTs are glycoproteins with important roles in regulating the osteoblastic 
lineage. WNT ligands are transduced by a family of seven-pass transmembrane 
receptor of the frizzled family, and the co-receptors low-density lipoprotein 
receptor-related proteins (LRP4-6). The binding of a WNT ligand to a frizzled 
receptor and LRP activates an intracellular signalling cascade, which can include 
the canonical β-catenin-dependent pathway or the noncanonical β-catenin-
independent pathways. Some rare monogenic disorders underscore the 
important role of Wnt pathways in skeletal homeostasis. Thus, inactivating 
mutations of the WNT co-receptor LRP5 result in osteoporosis pseudoglioma 
syndrome. On the other hand, gain-of-function mutations cause a high bone mass 
phenotype. In addition, mutations in the sclerostin gene (SOST), an inhibitor of 
this pathway, cause sclerosteosis or Van Buchem disease (also high bone mass 
disorders) depending on whether the mutation is in coding or in regulatory regions 
of the gene, respectively 13,14.  
At the end of the bone formation phase, destiny of osteoblasts can be one of the 
three following stages (Figure 1). 
1. Become embedded in bone as osteocytes. Osteocytes are the most 
abundant cells in bone (90-95% of the total number of cells), as well as 
the most long lived, with a life span of up to 25 years. However, in high 
bone turnover states, the life of osteocytes may be shorter. Osteocytes are 
spider-shaped cells embedded in the mineralized bone matrix, with 
several long and branched cell processes located inside canaliculi, which 
permit to establish cell-cell communication between different osteocytes 
or between osteocytes and cells located on the bone surface. Osteocytes 
are mechanosensing cells involved in the skeletal responses to 
mechanical stimuli, by translating the physical signals such as mechanical 





paracrine signals that control the differentiation of osteoblasts and 
osteoclasts 2,15.  
2. Become quiescent osteoblasts in the bone surface as “bone lining cells”. 
The majority of cancellous and endocortical bone surfaces are covered by 
flat bone lining cells. These abundant cells may play an important role in 
matrix metabolism during bone remodelling process 16. Also, there is some 
evidence that bone lining cells, under certain stimuli, can be activated and 
transformed into active osteoblasts 17.  
3. Finally, some osteoblasts experience apoptosis and die after they finish 
forming bone matrix. 
 
Figure 1. Diagram of the morphological changes associated with osteogenic differentiation, and 
markers that usually characterize each of the different stages through which a mesenchymal stem 
cell commits to the osteoblastic lineage. Adapted from 18. 
 
Bone resorption 
Bone resorption is the process of degradation of bone tissue as a necessary step 
for tissue renovation. Osteoclasts are terminally differentiated multinucleated 
cells, responsible for resorbing bone, and are related to the 
monocyte/macrophage family. Due to its terminal stage, they are unable of self-
replication. Osteoclasts degrade bone tissue by secreting H+, Cl−, cathepsin K 
and matrix metalloproteinases (MMPs) to dissolve the mineral and organic 
components of the bone matrix 19. Consequently, severe dysfunction of 
osteoclasts causes osteopetrosis, a disorder characterized by high bone mass 





investigations of human and mice models of osteopetrosis have identified 
macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear 
factor (NF)-κB (RANK), RANK ligand (RANKL) and tumour necrosis factor-α 
(TNF- α) as essential factors for osteoclastogenesis and osteoclast survival 20.  
Osteoclasts derive from hematopoietic precursors of the myeloid lineage, 
specifically of the monocytic line. The first stages of differentiation require critical 
genes, such as M-CSF, colony stimulating factor 1 R (Csf1r) and the transcription 
factor PU.1. PU.1 binds to the promoter Csf1r to upregulate its transcription. 
M-CSF induces the proliferation of osteoclast progenitors and upregulates the 
expression of RANK, which is a very important receptor for the complete 
differentiation of osteoclasts. M-CSF also activates Microphthalmia-associated 
transcription factor (MITF), that regulates the anti-apoptotic protein BCL-2 in the 
osteoclast and thus promotes cell survival 21. 
The next step of osteoclast maturation involves RANKL and RANK, ligand and 
receptor, respectively, that are members of the TNF superfamily. RANKL binds 
to its receptor (RANK), expressed by osteoclast precursors. Activated RANK, like 
other TNF family receptors, recruits TNF receptor-activating factors (TRAFs), 
which activate an intracellular cascade of protein-kinases and transcription 
factors. Specifically, TRAF6 signalling activates NF-κB and the 
calcineurin/nuclear factor of activated T cell c1 (NFATc1) signalling to induce 
osteoclast formation 20. In summary, RANKL enhances NFATc1 transcription, 
which regulates several osteoclast-specific genes, including tartrate-resistant 
acid phosphatase (TRAP), cathepsin K and osteoclast-associated receptor 
(OSCAR) (Figure 2).  
RANKL/RANK is a regulated system, in which osteoprotegerin (OPG) has an 
important inhibitory role. OPG is a decoy receptor for RANKL, so that it prevents 
the binding of RANKL to its receptor RANK and consequently inhibits osteoclast 
formation. The important role of OPG is revealed by the fact that transgenic mice 
that overexpress OPG exhibit osteopetrosis. On the contrary, OPG-deficient mice 






Figure 2. Diagram of osteoclastic lineage associated with the stage-specific key molecules for 
osteoclast differentiation and function. Adapted from 23. 
 
Bone remodelling 
Bone remodelling is the process of bone tissue renovation to preserve bone 
quality and maintain skeletal homeostatic equilibrium. Bone is an active tissue 
that undergoes continuous remodelling by the activity of osteoblasts and 
osteoclasts. Bone resorption and formation are balanced in a homeostatic 
equilibrium so that old bone is continuously replaced by new tissue and, thus, 
microfractures are repaired. This contributes to the maintenance of the mineral 
composition, bone density and quality throughout adult life. 
Osteoblasts and osteoclasts cooperate in the remodelling process in what is 
called basic multicellular unit (BMU). The spatial organization of BMUs is 
somewhat different in cortical and trabecular bone. Trabecular bone is more 
actively remodelled than cortical bone due to a larger ratio of surface/volume, and 
the BMUs are located on the surface, where osteoclasts are resorbing bone. After 
the resorption, the cells of the environment prepare the surface for bone 
formation, by providing signals for osteoblast differentiation and function. Finally, 
the surface is covered with flattened lining cells. In the cortical bone, during a 
remodelling cycle, several osteoclasts dig a circular tunnel that move through 
bone, followed by numerous osteoblasts that fill the tunnel, in conjunction with 
vessels and nerves that are also filling the space 24,25. 
Bone remodelling process needs to select the regions to be remodelled. 





a canopy of cells, probably including lining cells, and with nearby capillaries. 
Those capillaries and nearby bone marrow provide the hematopoietic precursors 
for osteoclast formation, and contribute to provide molecular signals needed for 
osteoclast differentiation. Other cells, including osteocytes, osteoblasts and 
vascular cells likely contribute to regulate the differentiation of osteoclast 
precursors 25.  
 
Figure 3. Bone remodelling scheme with various key molecules, known to regulate bone formation 
and bone resorption. Surrounded in black rectangles are important genes and transcription 
factors. Coloured in red, some coding and non-coding regulators, with dot-ended lines pointing 
inhibition over genes or cell processes.  
 
Osteocytes are the most abundant cells in bone. They are responsible for the 
adaptation of bone to mechanical forces, and the response to several hormones 
and they also regulate bone remodelling through different molecular 
mechanisms. Mature osteocytes embedded in the bone matrix secrete sclerostin, 
the protein encoded by SOST gene, which is a strong inhibitor of bone formation, 
through the inhibition of the canonical Wnt signalling. So, osteocytes regulate 
bone formation through the secretion of sclerostin. On the other side, they also 
regulate bone resorption through RANKL signalling. Osteocyte apoptosis induce 
osteoclastogenesis by stimulating other stromal or osteoblastic cells to secrete 
RANKL. Moreover, osteocytes directly secrete RANKL to regulate osteoclast 





implicated in the regulation of bone remodelling. In fact, there is a complex 
biochemical network regulating bone formation and bone resorption. The genes 
involved include protein coding genes, non-protein coding genes, such as 
microRNAs, and proteins that are regulating other epigenetic marks, including 
HDAC5 or SIRT1 (Figure 3). 
 
Mesenchymal stem cells 
Stem cells are unspecialized cells with the potential to divide in exact copies, or 
to differentiate into specialized cells with a specific function. Stem cells are 
essential for development, maintenance and repair of our organs. That is the 
reason why stem cells have become the focus of cell-based therapy for 
regenerative medicine. Stem cells can be classified based on their potency or 
their sources. Potency refers to the range of differentiation options into diverse 
cell types. Regarding this classification, there are four main types, totipotent, 
pluripotent, multipotent and unipotent cells:  
a. Totipotent cells have the ability to differentiate into all the possible cell 
types, including the extraembryonic cells. These cells are the first division 
of the zygote. 
b. Pluripotent stem cells can differentiate into all body cells, including 
embryonic stem cells (ESCs) and all the cells derived from the three germ 
layers (mesoderm, endoderm and ectoderm).  
c. Multipotent stem cells can differentiate into more than one cell type from 
the same germ layer.  
d. Unipotent stem cells may differentiate into a single cell type.  
 
However, the easiest way to classify stem cells is in two types: embryonic and 
non-embryonic or adult stem cells. Embryonic stem cells (ESCs) are from the 
inner cell mass of the blastocyst, they are pluripotent and may differentiate into 
all cell types of the three germ layers. Adult stem cells (ASCs) are obtained from 
postnatal tissues; they are necessary to maintain tissue and organ mass 27. 
One specific type of ASCs, denominated mesenchymal stem cells (MSCs), have 
raised a huge interest in the field of regenerative medicine. In the 60s, 





heterotopic transplantation of a specific colony of bone marrow cells, that were 
called osteogenic stem cells. They observed that these cells have a rapid 
adherence to tissue culture vessels and, when placed into a diffusion chamber, 
reticular or bone tissue is formed instead of haemopoietic elements 28. Later, the 
name MSCs was first used in the early 90’s by Caplan 29, who demonstrated that 
these cells are capable to differentiate into different lineages of the mesenchyme, 
such as bone and cartilage.  
MSCs are characterized in vitro by their adherent properties and fibroblastic 
morphology. They express specific surface markers (CD90+, CD73+, CD105+, 
CD34-, CD45- and CD14-, among others) and they may differentiate into different 
cells of the mesenchymal lineage, including osteoblasts, adipocytes or 
chondrocytes. MSCs have immunomodulatory properties, so they have been 
related to the immune dis-regulation of some diseases 30. They lack 
immunogenicity because they express low levels of the major histocompatibility 
complex-I and show absence of expression of the major histocompatibility 
complex-II. They also interact with T and B lymphocytes to modulate its 
proliferation or activation 31.  
In addition, MSCs have the capacity to migrate to target tissues, by transmigration 
across the endothelium, a process involving integrins and selectins 32. Another 
distinctive property of MSCs is the secretion of bioactive molecules, such as 
cytokines, chemokines and growth factors that affect local and systemic 
homeostasis. The secretome of MSCs may modulate immune responses, 
apoptosis, wound healing, tissue repair and angiogenesis 33. Thus, MSCs have 
been the focus of many investigations of regenerative medicine and cellular 
therapy, both autologous and allogeneic 34.  
For many years, bone marrow has been considered the main source of MSCs, 
but more recent investigations have found the presence of MSCs in other tissues, 
such as adipose tissue, peripheral blood, synovial membrane, dental pulp, 
pancreatic islets, umbilical cord and placenta 35. The adipose tissue seems to be 
one of the most interesting sources due to the large amount of cells obtained with 
relatively easy and safe collecting procedures 36.  
Nowadays, the scientific community has realized that MSCs isolated from distinct 
tissues show differences in their functions and developmental potential, and 





name MSCs 37. Caplan suggested to change the name of MSCs to “Medicinal 
signalling cells” to precisely point the fact that these cells migrate into sites of 
injury and secrete molecules with specific properties to heal and regenerate the 
tissue 38. Another prominent study has pointed that MSCs, from different sources 
of origin, have dissimilar differentiation properties 39. They conclude that “MSCs” 
terminology should be abandoned and replaced by a new and more explicit 
nomenclature. Furthermore, Bianco and Robey also called to abandon the term 
“MSCs”. Mesenchymal cells from non-skeletal tissues may be moved to 
osteogenesis by signalling molecules that induce bone differentiation, such as 
bone morphogenetic protein (BMP). However, they are not skeletal progenitor 
themselves, and differ from the mesenchymal precursors in the bone marrow, 
which naturally express the osteogenic transcription factor, runt-related 
transcription factor 2 (Runx2), and do not require the induction of exogenous 
factors. Therefore, some investigators suggested to replace the general term 
MSCs by skeletal stem cells (SSCs) 40. Thus, SSCs are multipotent cells located 
in the bone marrow, which could differentiate into cartilage, bone, stromal cells 
and marrow adipocytes. These cells will likely become very important in the 
skeletal development and regenerative medicine approaches, because they 
home to skeletal injury sites and obviously have bone formation properties 41. 
From now on, whenever possible, MSCs will be referred to in this thesis according 
to the source of origin, usually the bone marrow, as bone marrow stem cells 
(BMSCs).  
As already explained, BMSCs may differentiate into different tissues of the 
mesoderm lineage, including adipose, cartilage and bone tissue. During the 
differentiation process towards a specific cell type, there are several factors with 
both, stimulation or inhibition roles 42. In the first steps of osteoblastic 
differentiation, the transcription factors Runx2 and Osx play critical roles (Figure 
1) 8. The importance of mesenchymal stem cells in tissue engineering and 
regenerative medicine is emphasized by the fact that there are currently 273 
completed trials including “mesenchymal stem cells” in the clinicaltrials.gov 






Aging and prevalent bone disorders: Osteoporosis and 
osteoarthritis 
The aging process is characterized by a progressive decline in the physiological 
integrity, which causes a loss of normal tissue function and greater susceptibility 
to disease. However, molecular mechanisms involved in this aging process are 
not well understood yet. Structural changes associated with aging are visible, 
both macro and microscopically, and are associated with a loss of normal tissue 
function. Lopez-Otín and colleagues pointed at nine hallmarks of cellular and 
molecular aging (genomic instability, altered intercellular communication, stem 
cell exhaustion, cellular senescence, mitochondrial dysfunction, deregulated 
nutrient-sensing, loss of proteostasis, epigenetic alterations, and telomere 
attrition). Each hallmark contributes to the aging process itself, and the 
exacerbation of the hallmark accelerate tissue aging. They are interconnected 
and related each other 43. Aging impairs the functionality of stem cells. For 
example, some authors reported that BMSCs suffer a drift in their functionality 
and show a decreased proliferation capacity with preferential differentiation 
towards adipogenesis instead of osteogenesis. This could translate into 
decreased bone formation, thus increasing the risk of fractures 44. 
Due to the progressive aging of society, the prevalence of aging-related diseases 
has increased significantly in recent years. Regarding the skeleton, the most 
prevalent diseases are osteoporosis and osteoarthritis. Both are highly prevalent 
diseases, and they are considered as “complex diseases”. Complex diseases are 
disorders caused by a combined effect of different factors, including genetic and 
environmental factors, that interact in complex ways finally resulting in disease. 
 
Osteoporosis 
Osteoporosis is the most prevalent bone disorder, characterized by a progressive 
decrease in bone mineral density (BMD), a more porous bone, and consequently 
an increased susceptibility to fractures. Patients with osteoporosis may suffer 
bone fractures after low-energy trauma (or sometimes even during normal activity 
in the absence of trauma). The International Foundation of Osteoporosis (IOF) 
estimates that 1 in 3 women and 1 in 5 men over 50 years of age are at risk of an 





osteoporosis in the United States and in Europe. The most common fractures 
associated with osteoporotic fragility occur at the hip, wrist and the spine. Hip 
fractures are of concern due to their impact on life expectancy and quality of life. 
These fractures usually require surgery and represent an important proportion of 
the activity of Traumatology departments.   
Osteoporosis can be classified as primary and secondary. Primary osteoporosis 
is related to changes occurring with aging, such as the decrease in sex 
hormones, renal function, intestinal absorption of calcium and muscle mass, as 
well as, perhaps, age-related changes in the intrinsic properties of bone cells 
responsible for remodeling 45.  
There is a long list of diseases and other factors associated with secondary 
osteoporosis. They include endocrine, nutritional, haematological, renal and 
autoimmune disorders; drugs, such as glucocorticoids and blockers of sex 
hormone synthesis, among others 46. 
In current practice, osteoporosis is diagnosed by the occurrence of fragility 
fractures (i.e. fractures in the absence of high-energy trauma) or a decreased 
bone mass, as measured by DXA or other suitable procedure. In this regard, 
osteoporosis is usually diagnosed when the patient has a t-score below -2.5. 
However, it must be emphasized that, even though there is an exponential 
inverse relationship between DXA scores and fracture risk, most fragility fractures 
occur in individuals with “osteopenia” (T-scores between -1 and -2.5) or even with 
normal DXA scores. 
Osteoporosis is caused by a combined action of genetic and environmental 
factors. Environmental factors act on a genetically susceptible individual to cause 
disease. Among acquired factors influencing bone mass and fracture risk, there 
are both external and internal ones, including nutrition, exercise, toxic 
consumption, diseases and drugs. Genome-wide association studies (GWAS) 
are being important tools to confirm the role of different genes and pathways in 
osteoporosis and other complex disorders. Thus, several individual GWAS and 
the subsequent combined meta-analyses have confirmed the skeletal role of 
known pathways such as estrogen, Wnt, RANK/RANKL and other novel genes 
not previously associated with bone biology 47,48. The mechanisms mediating the 





individual susceptibility to disease are largely unknown. Nevertheless, they likely 
involve epigenetic mechanisms that are described below 49,50.  
 
Osteoarthritis 
Osteoarthritis (OA) is the most common joint disease. It is characterized by the 
progressive degeneration of articular cartilage. The prevalence is very high, 
affecting about 10% men and 18% women over 60 years of age. Due to the high 
prevalence, OA is a major cause of disability and socioeconomic costs in 
developed countries 51. Risk factors for OA include some influencing the overall 
skeleton and others that influence just a single joint or a group of joints (including 
injury and abnormal loading, among the most representative ones) 52. Specific 
person-level risk factors include age, gender, obesity and genetics. Age is a 
multidimensional risk factor, for aging is associated with multiple changes 
involved in the disease, such as sarcopenia, thinning of cartilage and oxidative 
stress. OA is more prevalent in females than in males, but the frequency of OA 
increases with age in both sexes. Obesity is strongly associated with knee OA. 
In addition, OA has a strong genetic predisposition. Joint injury is another risk 
factor for developing OA. It is thought that traumatic lesions damage the cartilage. 
Subsequently, an abnormal response of chondrocytes, which form new cartilage, 
cause the release of enzymes that promote cartilage degradation.   
Several candidate gene studies and GWAS have shown multiple genes involved 
in OA susceptibility 53. 
Although cartilage alterations are considered a crucial characteristic of OA, other 
joint structures, including bone and synovial membrane, are also involved. Bone 
changes include thickening of the subchondral bone and the appearance of 
osteophytes (immature bone protrusions), already in early stages of cartilage 
degeneration 54. Those changes characteristic of OA go in the opposite direction 
of those observed in osteoporosis, characterized by bone loss. Several studies 
have also shown an association between OA and a trend for higher bone mass 






Epigenetics: definition and mechanisms 
Epigenetics literally means ‘above the genetics’, but this definition is incomplete 
and controversial. Nowadays, epigenetics is conceived as the study of heritable 
changes in gene expression (activation or deactivation of gene expression) that 
do not modify the DNA sequence. Briefly, epigenetics is responsible for activating 
genes that cells have to use and turning down genes that are not needed. This 
modifies the phenotype without altering the genotype. The term “epigenetics” was 
first adopted by Conrad Waddington in 1942. He defined it as the “whole complex 
of developmental processes that lie between genotype and phenotype” and 
proposed the concept of epigenetic landscape. It was illustrated by a ball on top 
of an inclined surface; when rolling down there are different ways the ball could 
take (Figure 4). Similarly, according to Conrad’s “epigenetic landscape” a cell can 
develop and differentiate flowing a number of defined pathways 57. However, 
recent studies have shown that cell biology is less deterministic than previously 
suggested, and there are numerous examples of de-differentiation and trans-
differentiation of cells 58. 
 
Figure 4. The epigenetic landscape proposed by C. H. Waddington (1940) 
 
Epigenetic changes switch genes “on” or “off” and determine which proteins are 
transcribed. Thus, epigenetic mechanisms and changes of epigenetic marks are 
elements of normal cell biology. They are influenced by internal and external 
factors, like age, lifestyle, environment and disease. On the other hand, they 
participate in the pathogenesis of numerous neoplastic and non-neoplastic 
conditions. Epigenetic marks are reversible, so, unlike the genotype, the 
epigenome changes with age and environmental factors. 
The best known and most studied epigenetic mechanisms are DNA methylation, 





etc.) and non-coding RNA (ncRNA) expression. They act at different levels of the 
genetic code; at the chromatin level, as marks that either facilitate or inhibit 
transcription; or at the post-transcriptional level, modulating protein translation. 
DNA methylation and histone modifications mainly regulate chromatin assembly 
and gene transcription. ncRNAs act at the transcriptional or post-transcriptional 
level 49.  
Epigenetic mechanisms do not work alone, they are all related with each other, 
and if one of them fails, the regulation fails. Genomic imprinting represents one 
of the first-known and strongest evidences for the role of epigenetics in human 
biology and pathophysiology. Genomic imprinting consists in an epigenetic 
regulation characterized by the restriction of gene expression to one of the two 
parental chromosomes, this is, the one inherited from the mother or the one 
inherited from the father. The discovery of uniparental disomy leads to uncover 
disorders of genomic imprinting, such as Prader-Willy syndrome, Angelman 
syndrome, pseudohypoparathyroidism or Beckwith-Wiedemann syndrome 59.  
Normal and abnormal phenotypic differences among individuals are due to 
genotypic differences, environmental factors, and epigenetic differences. In this 
line, Fraga and collaborators found, in a large cohort of twins, that different 
phenotypes can originate from the same genotype by altering epigenetic marks 
and thus modulating gene expression 60. 
One of the most striking properties of genomes is their capacity to create a range 
of different cell types in a highly ordered manner. Understanding this process has 
helped to encourage new advances in epigenetics. When fertilization occurs, 
gametes fuse to form the first cell of the embryo, called zygote. Fused gametes 
undergo epigenetic reorganisation and restore cell totipotency. In mouse 
embryos, transcriptional activity begins in the first cell cycle when paternal and 
maternal chromatin are still in separate nuclear entities in the same cytoplasm. 
Paternal or maternal gametes do not show hyperacetylated histone H4, but 
immediately after fertilization, paternal chromatin shows hyperacetylation in H4 
(a modification associated with active gene transcription). When transcriptional 
differences in S/G2 phase occur, male and female pronuclei have similar levels 
of H4 hyperacetylation 61. Furthermore, DNA methylation levels are different in 
the paternal and maternal pronucleus of the zygote 62,63. Nowadays, it is not well 





8-16-cell morula, that give rise to the embryo and extraembryonic lineages 64. 
Additionally, epigenetic mechanisms are regulating all embryo differentiation 
states, such as the formation of the distinct layers occurring in the inner cell mass 
during fetal development. 
Environmental factors impact the epigenome not only during postnatal life, but 
also in utero. Several epidemiological studies have disclosed the influence of 
maternal nutrition on the epigenome later in life. One of the most significant 
studies was carried out in individuals who were prenatally exposed to hunger 
during the Dutch Hunger Winter in 1944-45. Investigators showed that these 
individuals, studied more than 6 decades later, presented less DNA methylation 
of the imprinted IGF2 gene and had an increased prevalence of high body mass 
index (BMI), insulin resistance or hypercholesterolemia. These data were among 
the first to provide empirical support for the relationship between early-life 
environmental conditions and epigenetic changes in humans, and their 
persistence throughout life 65. On the other hand, more recently maternal obesity 
and gestational weight gain have also been associated with epigenetic changes 
in offspring. Various studies suggest that an important component of metabolic 
disease risk has a prenatal developmental basis and is associated with later 
obesity 66,67. Besides, several studies support that protein restriction is associated 
with impaired fetal growth and development of diabetes and hypertension in 
childhood. For example, fetal protein restriction changed DNA methylation and 
gene expression levels of the AGTR1B gene, implicated in hypertension. Low 
protein maternal diet also changes the methylation and expression of 
glucocorticoid receptor (GR) and PPAR genes, which are important for the 
regulation of blood pressure and lipids in adults 66.  
Bone development alterations during intrauterine life is a factor for osteoporosis. 
Maternal calcium and vitamin D intake are important in the building of fetal bones. 
The mechanisms involved are unclear, but may include epigenetic changes, such 
as modifications of DNA methylation of genes near to vitamin D response 
elements, and genes encoding placental calcium transporters 68.  
Nutrition, and other lifestyle factors are also very important in postnatal 
individuals. For example, vitamin B12 and folate deficiency increases 
homocysteine levels and reduces SAM (the methyl group donor), thus causing a 





methylation levels at many regions of the genome, and these changes are 
persistent many years after stopping smoking 70. Childhood abuse is associated 
with adult disease risk, and has been associated with some DNA methylation 
profiles, suggesting that abuse in childhood has long-lasting epigenetic 
influences 71. Another stressful situation in human minds are suicidal thoughts or 
suicidal depression. Gene expression and DNA methylation changes have been 
reported in the brains of suicide completers, which may help to explain 
behavioural changes increasing suicidal thoughts 72.  
Stressful experiences, and other life factors, induce changes in the methylation 
and expression of genes that are also implicated in the regulation of bone. Thus, 
epigenetic changes are a link between these factors and the skeletal condition.  
 
Chromatin structure, post-translational histone modifications 
and bone tissue 
Chromatin is the state of DNA within the cell nucleus. It is composed by DNA and 
proteins that very condensed, organised and wrapped, form the chromosomes. 
Nucleosomes, the smallest structural unit of the chromatin, are octamers of a 
core formed by four histones (H3, H4, H2A and H2B) wrapped with about 147 
base pairs of double stranded DNA. Histones are basic proteins and their positive 
charges allow them to associate with DNA. Histones are chemically modified in 
their terminal N and C tails by different types of enzymes, and these modifications 
regulate chromatin’s state. There are more than 60 different aminoacids on 
histone tails where these modifications occur. Most common modifications are 
acetylation and methylation of lysines and arginines and phosphorylation of 
serines and threonines. However, there are also other types of modifications, 
including ribosylation, ubiquitynation and sumoylation of lysines. Moreover, 
methylation modifications are particularly complex because they may have three 
different forms: mono-, di- or trimethyl for lysines and mono- or di-methyl for 
arginines 73. Some marks promote gene expression (H3K27ac and H3K4me1), 
whereas other marks (H3K9me3 and H3K27me3) repress gene expression.  
Lysine residues have a positive charge that interacts with the negatively charged 
phosphate of nucleotides. Covalent modifications, above explained, lead to 





reversible and have capacity of folding (heterochromatin) and unfolding 
(euchromatin) chromosomes 74.  
Moreover, several histone post-translational modifications can generate an 
anchor site for nuclear proteins that modulate chromatin. These adaptors are 
usually part of large protein complexes implicated in the chromatin regulation. 
PcG (Polycomb Group) family is responsible for both di- and trimethylation of 
H3K27, controlling gene expression. Most PcG proteins form two major polycomb 
repressive complexes, PRC1 and PRC2. The first one, PRC1, mediates the 
monoubiquitylation of histone H2A, impairs transcriptional elongation and repress 
gene expression. By contrast, PRC2, is responsible for the above described di- 
and tri-methylation of lysine 27 in histone H3. PcG proteins are epigenetic 
regulators of transcription with important roles in stem cell regulation, 
development and differentiation 75,76.  
Spatial organization of the chromatin also plays a role in the nucleus by 
modulating gene expression. Chromosome conformation capture (3C) 
techniques can assess spatial organization of entire genomes. They have 
revealed that chromatin is not occupying a random space in the nucleus but is 
placed in distinct “chromosome territories” (CTs). Gene rich chromosome regions 
are situated preferentially in the centre of the nucleus, whereas gene-poor 
regions tend to be near the nuclear lamina. Another method that studies the 
three-dimensional architecture of whole genomes by coupling proximity-based 
ligation with massively parallel sequencing, Hi-C, has revealed the existence of 
different regions within chromosomes that interact with each other. There are 
transcriptionally active regions with a higher GC content, enriched in open 
chromatin, genes and active chromatin marks. Other regions are less 
transcriptionally active and are enriched in the repressive histone mark 
H3K9me3. Repressed regions are positioned in lamina-associated domains 
(LADs), so they are localized, preferentially, at the nuclear periphery 77. In 
addition, the genome is divided into topological associated domains (TADs), 
which are megabase scale chromatin regions that interact more frequently with 
themselves. TADs are cell specific and are conserved across cell types and 
species. Enhancers usually contact genes located within TADs. Distant 
enhancers and their specific gene promoters are in contact one with the other 





PTMs and chromatin structure play an important role in bone tissue regulation, 
controlling osteoblast and osteoclast differentiation. They may also participate in 
the pathogenesis of osteoporosis 79. For instance, the deletion of a TAD boundary 
has been proposed to cause Liebenberg syndrome, an autosomal dominant 
upper-limb malformation that shows arms with morphological characteristics of a 
leg 80.  
Furthermore, histone modifying enzymes can influence skeletal development, 
bone mineral density, ossification and bone resorption. As an example, 
osteocytes secrete paracrine factors that regulate the balance between bone 
formation and destruction. Among these molecules, sclerostin inhibits the 
formation of bone matrix by osteoblasts. Wein and collaborators demonstrated 
that histone deacetylase 5 (HDAC5) downregulates sclerostin levels in 
osteocytes. Inhibiting HDAC5 with shRNA increases SOST, while the 
overexpression of HDAC5 decreases the expression of SOST. HDAC5 knockout 
mice show increased levels of SOST mRNA and sclerostin-positive osteocytes, 
reduced Wnt activity, trabecular bone density and osteoblast bone formation 81. 
This thesis focuses on DNA methylation and long non-coding RNA Therefore, 
both epigenetic marks are further explained below.  
 
DNA methylation and bone 
DNA methylation is an epigenetic mechanism that consists in the addition of a 
methyl group onto the C5 position of the cytosine ring to form 5-methylcytosine 
(5mC). This covalent modification does not take place in any DNA cytosine, but 
occurs mostly in cytosines that precede a guanine, which is known as "CpG" 
dinucleotide. In humans, 5mC is found in 80% of all CpG dinucleotides, and the 
proportion of 5mC is approximately 1% of all DNA bases, which are distributed in 
the human genome asymmetrically. 5mC is a relatively stable epigenetic mark 
whose patterns are inheritable during cell division. There are regions with a high 
density of these dinucleotides, called CpG islands. CpG islands are segments 
approximately 1000 base pairs long that have a higher CpG density than the rest 
of the genome and are located in the promoter region of approximately one half 
of the genes. CpG rich promoter regions are normally demethylated, while the 





been associated with the repression of gene expression. In addition, alterations 
of these DNA methylation patterns are associated with the appearance of 
numerous diseases, such as cancer; in which a global hypomethylation takes 
place, together with a hypermethylation of CpG islands of gene promoters, 
resulting in the inhibition of tumour-repressor genes 82.  
DNA methylation is catalysed by a family of enzymes called DNA 
methyltransferases (DNMTs), which transfer the methyl group from the donor S-
adenosyl methionine (SAM) to the fifth carbon of cytosine. There are two types 
of DNMTs: those involved in de novo methylation (DNMT3A and DNMT3B), and 
DNMT1, which is responsible for maintaining the methylation pattern during cell 
division. There is a global passive demethylation of the existing 5mC over time. 
Furthermore, active demethylation of the 5mC takes place by two mechanisms, 
deamination and direct demethylation. Deamination by activation-induced 
cytidine deaminase/apolipoprotein B mRNA-editing enzyme complex 
(AID/APOBEC) transform 5mC into thymine and this cause a G/T mismatch, 
which is corrected by the base excision repair (BER) pathway. 5mC can also be 
demethylated directly by the action of the ten-eleven translocation (TET) 
enzymes. TET enzymes oxidize 5mC to form 5-hydroxymethyl-cytosine (5hmC), 
then another two oxidation steps proceed to oxidize 5hmC to 5-formyl-cytosine 
(5fC) and then to 5-carboxy-cytosine (5caC). 5hmC could be deaminated by 
AID/APOBEC, as 5mC, to form 5-hydroxymethyl-uracil. BER pathway uses 
thymine DNA glycosylase (TDG) to replace 5-hydroxymethyl-uracil, 5fC and 






Figure 5. Cytosine cycle. 5mC could take two ways: through oxidation catalyzed by the TET family 
of oxygenases forming 5hmC, or deamination by members of the AID/APOBEC family and the 
resulting Thymine (Thy) is excised by thymine-DNA glycosylase (TDG). Then base excision repair 
process (BER), replace for an unmethylated cytosine (Cyt). 5hmC could be further oxidized into 
5fC and 5caC, respectively. 5hMC, 5fC and 5caC may be specially recognized and excised by 
TDG and subsequent BER activity 83. 
 
DNA methylation is essential for regulating tissue-specific gene expression. But 
this regulation may be different depending on the localization of these methylated 
genomic regions. For example, when promoter CpG islands are hypomethylated, 
gene expression is activated. However, DNA methylation of the gene body or 
enhancer regions is, in some cases, associated with a higher level of gene 
expression in dividing cells 84.  
Aging and age-related diseases have also been related with specific changes in 
DNA methylation marks. Since 2008 studies have shown that methylation at 
specific loci in the human genome change with age 85. There are some 
“epigenetic clocks”, but the most widely used is the epigenetic clock by Steve 
Horvath, which has been developed and can be applied to tissues other than 
blood 86. Horvath developed a multi-tissue predictor of age that allows to estimate 





of the 27k and 450k arrays of Illumina, to characterize the “epigenetic age” and 
correlate it with the chronologic age. The comparison between both ages permit 
to establish an accelerated or decelerated age of the tissue studied.  
In non-terminally differentiated cells, DNA methylation marks increase 
progressively in specific genes, thus leading to the loss of the developmental 
potential and adoption of a more differentiated state. Due to the critical role of 
DNA methylation in gene expression and cell differentiation, it is obvious that 
errors in methylation marks can disrupt gene regulation and consequently lead to 
various diseases. Thus, DNA methylation has a relevant function in bone tissue, 
skeletal disorders and age-related bone diseases, among others. In bone tissue, 
DNA methylation has been shown to play an important role in the regulation of 
genes such as alkaline phosphatase, sclerostin, osterix, estrogen receptor 1, 
osteopontin, RANKL, osteoprotegerin and leptin, among others 50.  
A few studies have explored DNA methylation in prevalent skeletal disorders, 
such as osteoporosis and osteoarthritis. In a previous study of our group, we 
determined bone DNA methylation profiles (by Illumina 27K array) in 26 patients 
with hip osteoarthritis (OA) and 27 patients with osteoporotic hip fractures (OP), 
as well as the transcriptome in pooled samples. The study revealed an inverse 
relationship between methylation and gene expression in both groups of patients. 
The comparison of OP and OA bones revealed 241 CpG sites, located in 228 
genes, with significant differences in methylation. Of these, 217 were less 
methylated and 24 more methylated in OP than in OA. The pathways analysis 
revealed an enrichment in the genes involved in the metabolism of glycoproteins 
or in cell differentiation, and in the Homeobox superfamily of transcription factors. 
Likewise, differentially methylated regions were enriched in genes related to cell 
differentiation and skeletal embryogenesis, which suggests the existence of a 
developmental component in the predisposition to this disorder 87.  
Reppe and collaborators explored the epigenetic regulation of SOST expression 
in bone of postmenopausal women. They measured serum sclerostin and 
markers of bone remodelling in two groups of post-menopausal women: healthy 
(T-score of BMD> -1) and established OP (T-score of BMD < -2.5, with at least a 
typical fracture). They found that the promoter region of the SOST gene showed 
an increased methylation in OP patients. Free serum sclerostin levels and 





after adjusting for age and body mass index, they found an inverse association 
of sclerostin levels with total bone mineral density. They concluded that the 
genetic and epigenetic variations of SOST influence gene expression and 
sclerostin serum levels in postmenopausal women. They also suggested that the 
increase in DNA methylation of the SOST promoter was a compensatory 
mechanism, which reduces serum concentrations of sclerostin and reduces the 
inhibition of Wnt signalling in an attempt to promote bone formation 88. 
More recently, Cheishvili et al. determined the methylation pattern in blood 
samples from 22 post-menopausal women with osteoporosis and compared them 
with 22 postmenopausal women without osteoporosis. The analysis identified 77 
differentially methylated CpG sites. They also used the 13 most significant genes 
to build a weighted score of the DNA methylation of these genes suitable to 
predict osteoporosis at an early stage with high sensitivity and specificity and 
correlated it with bone mineral density 89. Although those results look quite 
promising, replication studies in other populations are badly needed to establish 
their actual relevance and the potential role in clinical practice. 
Age-related bone loss is related to an imbalance between bone formation and 
bone resorption, where the latter is predominant. Although mesenchymal stem 
cells from the bone marrow (BMSCs) are quite appealing as the precursors of the 
bone forming cells, there are very few studies of DNA methylation marks in these 
precursors. Roforth and collaborators analysed RNA and DNA methylation 
profiles in BMSCs from young people and elderly women 90. They identified 
various cellular pathways associated with aging, some that are known and other 
that are completely new, thus pointing at new age-related pathways in BMSCs, 
and osteoblast formation and function.  
 
Expression of non-coding RNAs in bone 
The Genetic code is defined as the set of rules by which information encoded in 
the DNA sequence is translated into 20 aminoacids, which are basic building 
blocks of proteins. The central dogma of genetic biology had recognized the 
importance of RNA as an intermediate molecule in this flow of information. At the 
beginning, transcription and translation processes distinguished between three 





ribosomal RNA (rRNA). However, the vast majority of DNA does not code for 
proteins and was previously considered as “junk” DNA, without a known function. 
The Encyclopedia of DNA Elements (ENCODE) project delineated all functional 
elements encoded in the human genome and established new functions for the 
so-called “junk” DNA. ENCODE project concluded that most of those DNA 
regions, at least 80%, have a biochemical function and many of them are 
transcribed into RNA. Recent studies estimated that 93% of the human genome 
is actively transcribed. Among these transcripts, 1% represent protein-coding 
exons and 39% entire genes including from promoters to poly(A) signal. The rest 
(54%) are non-coding transcripts 91,92. 
RNA molecules that are not being translated, are known as non-coding RNA 
(ncRNA). They are classified in two main groups. Long non-coding RNAs 
(lncRNA), which exceed 200 nucleotides in length, and small ncRNAs that are 
those with less than 200 nucleotides. Small ncRNAs can be further classified into 
micro RNAs (miRNAs), small interfering RNAs (siRNAs), piwi RNAs (piRNAs), 
and small nucleolar RNAs (snoRNAs) 93.  
 
Small noncoding RNAs 
snoRNAs  
SnoRNAs are small noncoding RNAs of 60 to 200 nucleotides, allocated in the 
nucleolus, associated with a set of proteins forming small nucleolar RNPs 
(snoRNPs). They are indispensable for the nucleolytic processing of rRNAs and 
also in the post-transcriptional modification in rRNAs, small nuclear RNAs 
(snRNAs) and some mRNAs. snoRNAs are not transcribed independently, but 
are usually processed from other transcribed fragments, as introns from pre-
mRNA. There are two major classes of snoRNAs, which have different 
evolutionarily conserved sequences. C/D box snoRNAs (SNORDs) and H/ACA 
box snoRNAs (SNORAs), related to the methylation and pseudouridylation of 
ribosomal RNAs, respectively 94. They act as guides for binding RNAs to form a 
complex where the target is modified by RNA binding proteins (RBP), which act 
as enzymes. snoRNAs are important for a variety of cell functions and might 
become useful as disease biomarkers. In fact, distinct changes in snoRNAs have 
been described in some human cancers. Several studies have explored the 





including oncological processes, viral diseases, neurodegenerative diseases, 
and others 95. The recent discovery of stable snoRNAs in serum, have increased 
the interest in their study as biomarkers in cancer. In addition, some studies 
showed specific snoRNAs associated with aging and osteoarthritic joints. Zhang 
et. al. examined serum noncoding RNAs as biomarkers for cartilage deterioration 
after an anterior cruciate ligament (ACL) injury. They analysed serum of 80 
patients a year after surgery and 60 serum of control individuals. They found that 
snoRNAs U38 and U48 were significantly increased in serum of patients 
developing cartilage damage. Hence, they suggested that serum levels of 
snoRNA U38 might be  useful to aid in the diagnosis of patients with cartilage 
deterioration after ACL injury 96. 
 
piRNAs 
Another class of small ncRNAs are PIWI-interacting RNAs (piRNAs). This class 
of animal specific small ncRNA guide PIWI-clade Argonautes (PIWI proteins). 
They are 21-35 nucleotides in length and contribute to silence transposable 
elements, fight viral infection and regulate gene expression. Most argonaute 
(AGO) proteins associate with miRNAs and siRNAs, but there is a subclass of 
AGO proteins termed PIWI which are required for germ cell development. piRNAs 
in mammals have been shown to silence transposons in male germ cells. 
However, many piRNAs non related with transposon sequences have been also 
found in mammalian testis, and they are thought to regulate expression of their 
host mRNA 97. PIWI-piRNAs complexes directly target and degrade 
retrotransposons in the cytoplasm. In addition, they also guide genomic silencing 
at specific loci through the regulation of DNA methylation marks and specific 
repressive histone modifications, such as, H3K9me3. In piRNA-deficient mice 
there exists an increased retrotranscription. PIWI-piRNA is necessary for male 
fertility 98. Apart from the well-known mechanism of piRNAs in spermatogenesis, 
Rajasethupathy et. al. found that PIWI-piRNA complex facilitates stable changes 
in neurons for memory tenacity. Specifically, they concluded that this complex 
ease serotonin-dependent methylation of CREB2 promoter, which inhibits the 
memory mechanism. This leads to enhanced synaptic processes in memory 






siRNA and miRNA 
There is also a small interfering RNA class (siRNA), characterized by a length of 
20-30 nucleotides, which are always associated with the family of Argonaute 
proteins. siRNA derive from exogenous double stranded RNA (dsRNA) that is 
cleaved into double stranded siRNA by a dsRNA-specific RNAse III family 
ribonuclease (Dicer). Dicer cleave a double strand sequence of 20-25 
nucleotides, each strand is carrying two free bases at the 3' hydroxyl ends and 
bearing 5' phosphate end. A strand is the guide and directs silencing, whereas 
the other strand is the passenger and is destroyed. Target silencing by siRNAs 
is mediated by RNA-induced silencing complex (RISC), which is a family of 
heterogeneous complexes. This complex has to be at least an Argonaute protein 
bound to a small RNA, and this is sufficient for target RNA silencing. However, 
Argonaute proteins may have diverse binding proteins with their own function 
within complex. After recognition, mRNA is sliced or degraded, breaking the 
reading sequence of the protein. Therefore, a gene could be silenced by siRNAs-
RISC mechanism, preventing protein translation through mRNA degradation 100.  
Double-stranded siRNAs are endogenously synthesized by RNA-dependent 
RNA polymerase (RdRP), but this molecule has been identified in plants and 
nematodes, but not in mammals. However, synthetic siRNAs have been 
extensively used for gene silencing in human cells 101.  
Nevertheless, the most studied class of small ncRNAs are miRNAs which are 
very important regulators of gene expression and contribute controlling numerous 
physiological cell processes. miRNAs are single stranded RNA molecules with 
about 20 to 23 nucleotides. They also bind to Argonaute proteins to form RISC 
complex, necessary to post-transcriptional silencing, as occurs with siRNAs, but 
they differ in their origin and biogenesis. miRNAs are processed in the nucleus 
and first of all, they need the specific transcription of a double stranded primary 
miRNA (pri-miRNA) by RNA polymerases II or III. Both polymerases recognize 
specific promoters differently, promoting a wide variety of miRNA species. Then, 
pri-miRNA are modified by adenosine deaminases acting on RNAs (ADARs), 
which transform adenosine into inosine, and this permit to change the sequence 
and base pairing capacities. Pri-miRNA is transformed into pre-miRNA through 
the cleavage action of the complex formed by RNAse III enzyme Drosha and the 





cytoplasm by exportin-5. In the cytoplasm, pre-miRNA is cleaved by Dicer in 
association with the action of Tar RNA binding protein (TRBP) and protein 
activator of PKR (PACT). This complex recruits Ago2 to constitute RISC loading 
complex. The first endonucleolytic action is done by Ago2 activity that cleaves 
the passenger strand in the middle, and this facilitates Dicer action to form the 
mature miRNA-Ago2 complex. Finally, RISC mediates mRNA degradation or 
deadenylation and translational inhibition (Figure 6) 102. These steps described 
for miRNA biogenesis are not universal. Some steps can be replaced or modified 
in various ways. For example, some miRNAs are localized in the cell nucleus, 
evidencing that these miRNAs are also regulating gene expression within the 
nucleus.  
 
Figure 6. Biogenesis of siRNAs and miRNAs pointing out the differences between both pathways. 
Adapted from 103. 
 
More than 2000 miRNAs have been reported in humans. A half of the human 
expressed miRNAs are transcribed from non-protein-coding genes and the rest 
from introns of coding genes. Overall, miRNAs, are estimated to regulate 





functions and participate in the regulation of development, differentiation and 
metabolism of cells. Thus, deficiencies or excesses of miRNA expression have 
been associated with different human pathologies including cardiovascular 
disorders, autoimmune diseases, cancer, skin, muscle and neurologic disorders 
102,104. In addition, there are diverse studies relating miRNA expression patterns 
with skeletal diseases, such as osteoporosis. Several miRNAs target molecules 
implicated in the β-catenin pathway. For example, Let-7f reduces Axin-2 levels, 
which tends to increase β-catenin and promote osteoblast differentiation 105. 
Some miRNAs also target different inhibitors of the Wnt signal, including Dikkopf 
(DKK1), Kremen2, sclerostin (SOST) or secreted frizzled related protein (sFRP). 
In addition, numerous miRNA inhibit osteogenesis through BMP receptors 
Smad1 and 5, distal less homeobox 5 (DLX5), the Homeobox family, Nuclear 
Factor Kappa B (NF-κB) pathway and the master transcription factors RUNX2 or 
OSX, among others 50,106,107. As for osteoblasts, several miRNAs are involved in 
osteoclast differentiation affecting RANK/RANKL and Macrophage colony-
stimulating factor (M-CSF) pathways 106.  
Garmilla-Ezquerra et. al. explored the expression of 760 miRNAs in patients with 
osteoporotic hip fractures and non-fracture controls with hip osteoarthritis by real-
time PCR. After the validation stage, they confirmed statistically significant 
differences between osteoporosis and controls for two miRNAs (miR-187 and 
miR-518f) 108. 
Therapeutic properties of miRNA have been also studied. Kazuki et. al. identified 
miRNA-182 as a regulator of osteoclastogenesis and bone homeostasis. They 
showed how the deletion of this miRNA in ovariectomized mice protects the 
mouse from excessive bone resorption. In addition, this target also serves to find 
new pathways involved in bone pathology. In this case they identify PKR protein 
kinase, which is an inhibitor of osteoclastogenesis via interferon beta regulation, 
as the target of miRNA-182 109. 
Another study about miRNAs and osteoporosis identified specific miRNAs in 
osteoporotic patients compared to controls with osteoarthritis. Total RNA was 
extracted from serum. The levels of 179 serum miRNAs were analyzed by real-
time PCR, and 12 passed the false discovery rate test for multiple comparisons. 
After the replication stage, they identified 3 miRNAs (miR-122-5p, miR-125b-5p, 





difference between both groups independently of age, and with high 
discriminative capacity. Additionally, their levels were correlated with those of the 
bone resorption marker CTx.  
miRNAs are of great interest as candidate disease biomarkers, as they are stable 
in fluids such as serum, can be detected in samples easy to obtain, such as 
peripheral blood, and in some cases are quite specific for tissue and disease 110. 
 
Long non-coding RNAs 
Long non-coding RNAs (lncRNAs) are transcribed RNAs that are not translated 
into proteins because they do not have a protein coding sequence. They are 
longer than 200 nucleotides in length. In 1990s first non-coding gene was 
discovered (H19), but it was not classified as a ncRNA. Brannan and 
collaborators looked for the protein of the H19 transcript, but they found diverse 
translation stop signals and 35 small open reading frames. They cloned H19 gene 
to sequence it and revealed no conserved open reading frame. H19 was not 
associated with the translational machinery. They concluded that because H19 
is transcribed by RNA polymerase II and is polyadenylated, it may be a non-
classical mRNA 111. Furthermore, in the same decade, early 1990s, X 
chromosome inactivation in females was associated with X Inactive Specific 
Transcript (XIST) activity, which is exclusively expressed in the inactive X 
chromosome. Human XIST include several conserved tandem repeats. It does 
not contain significant conserved open read frames and does not appear to 
encode a protein. Therefore, researchers concluded that XIST works as a 
structural RNA in the nucleus, and demonstrated that XIST is localized in the X 
inactivation-associated Barr body 112. ncRNA research has revealed that these 
species are involved in a huge number of cellular processes, regulating gene 
expression at the chromatin level, transcriptional level, RNA splicing, mRNA 
degradation, and translational control 113,114.  
LncRNAs are less conserved than protein-coding genes as shown in a study 
looking at the non-coding transcriptome of 185 samples from 11 species (human, 
chimpanzee, bonobo, gorilla, orangutan, macaque, mouse, opossum, platypus, 
chicken and frog), which raised questions about their biological relevance 115. 
Recently, another study showed, by comparing 16 vertebrate species, that more 





50 million years ago. However, thousands of human lncRNAs have homologs in 
other species. These homologs are conserved in short sequences of the 5’ 
position while the rest of the gene architecture has been restructured mostly by 
transposable element exonization. They suggest that lncRNA functions require 
only short conserved fragments of specific sequences and may tolerate changes 
in the rest of gene architecture 116. Certainly, the most conserved lncRNA type 
are from long intergenic subfamily, involved in developmental functions. lncRNA 
transcripts are proposed to arise through several mechanisms, including DNA-
based duplication of existing sequence, metamorphosis of protein-coding genes 
to pseudogenes, transposable element exaptation or exaptation of noncoding 
DNA 116.  
Pseudogenes are an example of protein coding genes metamorphosis that arise 
from the accumulation of disruptions restraining its potential to be translated into 
protein. Pseudogene transcription might produce lncRNAs, which is the case of 
PTENP1, which has been found to be biologically active by regulating coding 
gene expression, and has also been found to be lost in human cancer 116.  
Transposable elements are located throughout the genome and they are often 
enclosed in noncoding RNAs, more specifically they appear in approximately a 
30% of lncRNA sequences. This is the reason why they are considered a major 
cause of lncRNA development in vertebrates. Transposable elements contribute 
to signaling for lncRNA biogenesis, including transcription initiation, 
polyadenylation or splicing 116. 
In addition, another mechanism is exaptation of non-coding sequences into 
lncRNA through recruitment of regulatory elements that permit expression in a 
region which was previously silent. The testis specific multi-exonic lncRNA Poldi 
is an example of these de novo origin of lncRNAs, but its transformation 
mechanism from noncoding DNA into functional lncRNAs is not exactly 
understood yet 117.  
The vast majority of genomic regions used for RNA production remain under-
explored. Annotation of the universe of lncRNAs is still at its beginning, and there 
are different classifications based on their length, genomic locations, properties 
and functions. 
For the purposes of this thesis, we focused on the classification according to 





used in bioinformatic databases, including the GENCODE/Ensembl annotations 
(Figure 7). Transcripts were first classified as intergenic or intragenic. Long 
intergenic non-coding RNAs (LincRNAs) do not overlap with protein coding genes 
or other ncRNA genes. They are transcribed independently by RNA polymerase 
II, 5’ capped, 3’ polyadenylated and spliced. As explained before, there are 
several LincRNAs with conserved sequences (although rarely the whole 
sequence), commonly in the 5’ position, nested in exons 118. Many of them have 
been found in the nucleus. That is the case, for example, of LincRNA-p21, which 
regulates p53-dependent transcriptional responses 119.  
On the other hand, intragenic lncRNAs overlap with protein coding genes. They 
can be further classified as antisense, intronic and sense overlapping lncRNAs. 
Intragenic lncRNAs can be transcribed in the opposite direction of a protein 
coding gene promoter, head to head, originating bidirectional lncRNAs. They can 
originate from the antisense strand of a protein coding gene (Antisense lncRNA), 
or transcribed from the sense strand of a protein coding gene, thus overlapping 
introns (intronic lncRNAs) 120.  
 
Figure7. LncRNAs classification: (A)Divergent lncRNA originate from the opposite strand of the 
same promoter region of the protein coding gene as the adjacent and Convergent lncRNA, 
encoded on the opposite strand of the protein coding gene and facing each other. (B) Intronic 
lncRNAs are transcribed in intronic regions of other protein coding genes. (C) Intergenic lncRNAs 
are located between other two genes, usually >10 kilobases. (D) Overlapping antisense lncRNAs 
are overlapping on the opposite strand of other protein coding genes and transcribed in the 
opposite way (complementary sequence). (E) Overlapping sense are overlapping on the opposite 






Another common studied lncRNA type are enhancer derived lncRNAs. Numerous 
transcripts classified as lncRNAs have an effect at the DNA level as enhancers, 
independently of the lncRNA type according to their genomic location. Enhancer-
derived RNAs (eRNAs) are a group of RNAs transcribed by RNA polymerase II 
and constitute a major type of cis-regulatory elements in the genome 122,123. 
However, eRNAs function is still poorly understood, and only the function of a few 
eRNAs, such as FOXC1e and NRIP1e, has been elucidated 124. 
Some studies have revised lncRNA stability in different species. In mouse, Clark 
MB and collaborators determined the half-life of approximately 800 lncRNAs and 
12000 mRNAs, by inhibiting ongoing transcription with actinomycin D. They found 
that a minority of lncRNAs are unstable. Their half-lives vary over a wide range, 
with some lncRNAs having half-life of less than 30 minutes and others showing 
extreme stability with a half-life over 48 hours. The median lncRNA half-life was 
3.5 h, whereas the median half-life for protein-coding transcripts was 5.1 h. So, 
lncRNAs are not particularly unstable, although their half-lives are shorter than 
those of protein-coding RNAs. When investigators analyzed different types of 
lncRNAs, they realized that intergenic and bidirectional lncRNAs are more stable 
than intronic lncRNAs. Regarding cellular localization, nuclear lncRNAs are more 
unstable 125. Similar results were obtained by Ayupe and collaborators in human 
cells. They used a microarray to investigate biogenesis, processing, stability, 
conservation and cellular localization of approximately 6000 intronic lncRNAs and 
10000 antisense lncRNAs. Antisense lncRNAs (median t1/2 = 3.9 h) were more 
stable than mRNAs (median t1/2 = 3.2 h), whereas intronic lncRNAs (median t1/2 
= 2.1 h) comprised a more heterogeneous class with both stable (t1/2 > 3 h) and 
unstable (t1/2 < 1 h) transcripts 126.  
LncRNA expression patterns are extremely specific of cell or tissue type and 
state, so they have a spatio-temporal specificity, usually higher than protein 
coding genes. Few lncRNAs are expressed in a wide variety of tissues, many are 
present in a few tissues, and some are expressed only in a single tissue type. On 
the other hand, many protein coding genes are much more frequently expressed 
in a variety of different tissues. Not only lncRNAs exhibit cell or tissue specificity, 
but their expression is state and time dependent, displaying a highly dynamic 
expression. Ubiquitous lncRNAs, this is, lncRNAs that are expressed in various 





low expression levels 127. Brain and testis are complex tissues with a high amount 
of specific lncRNAs. Particularly, brain is the richest source of lncRNAs in the 
body. In general, the high lncRNAs gene expression specificity suggests 
regulatory roles of these molecules in various biological processes, including 
normal or pathological development 128.  
 
LncRNAs: mechanisms of action 
The evolution of lncRNAs from transcriptional noise to functional regulators of 
gene expression has open a whole new field of study. Despite many studies 
demonstrating the important functions of some lncRNAs, the actual biological role 
of many lncRNAs is unknown yet.  
The mechanisms involved in the regulatory pathways of lncRNAs are multiple. 
They regulate chromatin structure through histone modifications. From the first 
documentation of lncRNA on mammalian X chromosome inactivation, as 
described above, XIST has been associated with Polycomb Repressive Complex 
2 (PRC2) recruitment, which mediates methylation of lysine 27 in histone 3 129. 
However, numerous lncRNAs have been related with PRC2 or PRC1 actions or 
other histone modifying enzymes, including lncRNAs HOTAIR, LincRNA Pint, 
FENDRR, SRA, HOTTIP, FAL1 and ANRIL among others 130. Some of these 
lncRNAs have been shown to bind more than one histone-modifying complex. 
For example, HOTAIR physically associates with PRC2 and with Lys-specific 
demethylase 1 (LSD1). However, the detailed mechanism of how lncRNAs   
target specific DNA regions, remains unclear.  
Apart from modulating chromatin, lncRNAs regulate transcription through multiple 
mechanisms. They can interact with the transcriptional machinery directly or can 
regulate the activity of transcription factors. For instance, lncRNA Evf2 can act 
either as an activator or repressor, depending on whether it recruits the 
transcriptional activator DLX2 or the transcriptional repressor MeCP2 (methyl-
CpG binding-protein 2) to specific DNA regulatory elements 131.  
Antisense lncRNA, as the name suggests, are transcribed from the opposite 
strand (antisense strand). The host gene in the ‘sense’ strand may be a protein 
coding gene or a noncoding one. However, most commonly in the mammalian 
genome is a non-protein-coding antisense gene with a protein-coding gene in the 





antisense transcripts. Antisense lncRNAs can act in a cis manner, when they are 
complementary to their sense partner, or trans-manner, when they interact with 
transcripts from a different, distant, locus. Interestingly, cis-acting antisense 
transcripts regulate the expression of their sense partners, either in a discordant 
or concordant manner. Thus, depending on the particular coding-noncoding pair, 
antisense knockdown results in sense-transcript increase or decrease 132. 
The ability of lncRNAs to bind to proteins provide them multiple regulatory 
capacities. They may act as decoys that preclude the access of regulatory 
proteins to DNA. For example, after DNA damage five lncRNAs are promoted 
from the CDKN1A gene promoter, and one of them is induced in a p53-dependent 
manner (lncRNA PANDA). PANDA interacts with the transcription factor NF-YA 
to inhibit the expression of pro-apoptotic genes. Additionally, if PANDA is 
depleted, human fibroblasts are sensitized to apoptosis by doxorubicin 133.  
Moreover, lncRNAs can function as scaffolds to bring together different elements 
of protein complexes. The telomerase RNA (TERC) is an example of an RNA 
working as a scaffold that assembles the telomerase complex 134. Another 
example of lncRNA scaffold is, as described before, HOTAIR, which binds both 
PRC2 and LSD1, and these interactions induce H3K27 methylation and 
H3K4me2 demethylation, causing gene silencing. An additional example is 
ANRIL, which combines interactions with PRC2 and PRC1 135.  
Finally, another lncRNA-protein binding function is as guides. Many lncRNAs are 
required for the proper localization of specific protein complexes. LncRNAs 
involved in imprinting, such as XIST, serve as guides to target gene silencing 
activity. LincRNA-p21 is directly induced by p53 upon DNA damage, and it 
physically associates with nuclear factor hnRNP-K to drive this protein to specific 
promoters 136.  
Numerous lncRNAs are exported to the cytoplasm, where they regulate mRNA 
translation and stability. An important regulation function of lncRNA in the 
cytoplasm, is as miRNA sponges. They act as competing endogenous RNAs 
(ceRNAs) with miRNA response elements, so that this lncRNA titrate competing 






Figure 8. Networks of mRNA/miRNA/lncRNA, competing endogenous RNA (ceRNA), showing 
the regulation of lncRNAs as sponges. Excess of lncRNAs in comparation with miRNAs levels 
result in derepression of mRNA translation, whereas, excess of miRNAs compared to lncRNAs 
leads to mRNA translation and protein synthesis. Adapted from 137.  
 
Enhancer-derived lncRNAs (eRNAs) participate in the interactions between 
enhancers and promoters through chromosome looping 138. Actually, there are 
three current views on the functional implications of enhancer transcription: 
a. Enhancer transcription represents noise; it is due to the Pol II action over 
open and accessible chromatin;  
b. Enhancer transcription effects are independent of RNA synthesis. Rather, 
they are related to chromatin remodelling induced by RNA polymerases 
and the associated proteins that provoke histone tail modifications and 
other changes.   
c. eRNAs are functional molecules involved in transcriptional control either 
locally or at distant locations 139. 
 
lncRNAs in bone tissue and aging 
Several investigators have explored the role of lncRNAs in aging and related 
phenotypes 140,141. This association of lncRNAs and aging is illustrated by their 
regulatory effects over aging-related genes or pathways. In this line, lncRNAs 
have been related to almost all the molecular hallmarks of aging 43,141, including 
stem cell state, telomere stability, DNA damage, proteostasis, intercellular 
communication, cellular senescence and epigenetic alterations.  
Telomeres are DNA-protein complexes that protect the ends of chromosomes 





replication and cell senescence. This means that telomeric shortening is 
associated with a high rate of proliferation eventually causing cellular 
senescence. The length of telomeres is regulated by the association of 
telomerase RNA component (TERC) and telomerase reverse transcriptase 
(TERT), as well as, the lncRNA telomeric repeat containing RNA (TERRA). 
lncRNA TERC plays a role in the maintenance of telomere length, working as a 
template and scaffold between telomeric repeats and the proteins that form the 
telomerase complex 142. On the other hand, lncRNA TERRA is a competitive 
inhibitor for telomeric DNA and suppresses telomere elongation. It contains 5’-
UUAGGG-3’ repeats which are complementary to telomeric sequences to 
suppress elongation 143. 
As already discussed, epigenetic mechanisms control gene transcription and 
chromatin structure, and are implicated in a large variety of processes concerning 
aging and disease. DNA methylation changes with aging and cellular 
senescence. Several lncRNAs regulate DNA methylation (XIST, H19, PAPAS, 
Airn or TARID among others) 141. However, it is important to keep in mind that the 
information flow is dual, this means that DNA methylation can also regulate the 
expression of various lncRNAs implicated in aging and/or disease. Similarly, 
some specific post-translational histone modifications have also been associated 
with aging such as lncRNA PINT, which activates genes of the p53 pathway by 
directly interacting with PRC2 for repression 144. Thus, other lncRNAs regulate 
DNA damage response. LncRNA RoR is a p53 repressor, which inhibits p53 
translation to protein due to its interaction with the heterogeneous nuclear 
ribonucleoprotein I (hnRNPI) 145. Additionally, antisense non-coding RNA in the 
INK4 locus (ANRIL) is involved in the repression of INK4B-ARF-INK4A locus, 
tumor suppressor genes that trigger the anti-proliferative functions of p53 and 
Retinoblastoma protein (RB) 146.  
Human aging is characterized by a low-grade chronic inflammatory state, 
sometimes referred to as ‘inflammaging’, which may be an important factor 
contributing to the pathogenesis of age-related diseases. Therefore, it is 
important to explore pathways controlling the inflammation process in order to 
benefit elderly people 147. In this regard, some lncRNAs have been related to the 
inflammation process and its regulation. TNFα- and hnRNPL-related 





expression of many immune response genes like specific cytokines and 
transcriptional regulators of TNFα expression. Another lncRNA, p50-associated 
COX-2 extragenic RNA (PACER), has been characterized as an inflammation 
regulator. PACER interacts with the repressive subunit of NF-κβ p50, activating 
p65/p50 dimers, and this block NF-κβ from the COX2 promoter 148,149. 
Several lncRNAs have a significant role in stemness regulation and aging. They 
regulate directly the level of transcription factors or participate within the network 
of reprogramming processes. This is confirmed with the association of 
pluripotency transcription factors (Oct4, Sox2 or Nanog) to specific lncRNAs 
promoters, suggesting their direct relationship in stemness preservation 150,151. 
Likewise, Mesenchymal-to-epithelial transition (MET) is an important cell event in 
cells undergoing reprogramming. E-cadherin expression and Zeb2 
downregulation augments MET efficiency. lncRNA Zeb2-AS, which is a natural 
antisense transcript of Zeb2, controls its expression and consequently improves 
reprogramming processes 152.  
 
Figure 9. lncRNAs classified by their osteogenic properties. They could be pro-osteogenic (A) or 
anti-osteogenic (B), this is, they can promote or inhibit osteogenesis, respectively. lncRNAs are 
key transcriptional and translational regulators. They usually work with other regulators, such as 
miRNAs. The pro-osteogenic molecules are coloured in green and anti-osteogenic molecules in 
red. Adapted from 153. 
 
Rapid advances in genome sequencing and transcriptome analysis have settled 
lncRNAs as significant intermediaries in gene regulation. In recent years, a 
number of studies have pointed at lncRNAs as molecules playing a role in the 





pathogenesis of skeletal disorders. Also this opens a window to the discovery of 
new drug targets. Different lncRNAs may have a positive or negative impact on 
osteogenic differentiation processes, as reviewed by Silva AM and collaborators  
153 (Figure 9).  
Some anti-osteogenic lncRNAs are DANCR, HOTAIR, MIR31HG and HOXA-
AS3, among others. Anti-differentiation noncoding RNA (ANCR), also 
denominated differentiation antagonizing non-protein coding RNA (DANCR), 
have been shown to promote osteogenesis when downregulated. DANCR is 
associated with Enhancer of Zeste Homolog 2 (EZH2), which results in the 
inhibition of RUNX2 expression inhibition, thus blocking osteoblast differentiation 
154. In addition, DANCR regulates osteogenic differentiation of human BMSCs via 
the p38 MAPK pathway 155. However, DANCR downregulation in dental tissue-
derived stem cells has been shown to promote not only the osteogenic 
differentiation, but also adipogenic and neurogenic differentiation. This indicate 
that DANCR is a very important regulatory factor in different stem cell 
differentiation processes, not exclusively in the differentiation towards bone cell 
lineage 156. Likewise, HOXA-AS3 expression has been shown to play a role in 
the switch between adipo- and osteogenic differentiation 157. This lncRNA is 
upregulated in adipogenic differentiation, but unaltered in the osteogenic one. 
Moreover, silencing HOXA-AS3 in BMSCs suppresses adipogenesis and 
adipogenic markers like PPARG, CEBPA and ADIPOQ. On the contrary, this 
silencing effect in BMSCs enhanced osteogenesis and the expression of 
osteogenic markers such as RUNX2, SPP1, SP7 and COL1A1 157.   
On the other hand, several lncRNAs promote osteogenesis, including lncRNA-
OG, MALAT1, MODR, AK141205, KCNQ1OT1, HULC, LINC-ROR and MEG3 
153.  
Specifically, lncRNA MALAT1 is able to promote the expression of Osterix, by 
inhibiting miRNA-143 in BMSCs. When the expression of MALAT1 is inhibited in 
these cells, the relative expression of Osterix also decreases. However, when it 
is co-transfected with an inhibitor of miRNA143, the relative expression of Osterix 
increases again. Osterix expression is linked to the expression of ALP (alkaline 
phosphatase) and other osteogenic markers 158. 
A more frequently studied lncRNA gene is maternally expressed gene 3 (MEG3), 





lncRNA. MEG3 knockdown in MSCs from multiple myeloma patients reduces the 
expression of RUNX2, osterix and osteocalcin, whereas promoting MEG3 
expression enhanced the expression of these osteogenic markers. 
Mechanistically, MEG3 dissociates the transcription factor SOX2, which is a 
repressor, from the Bone morphogenetic protein 4 (BMP4) promoter and this 
permits to activate its expression. Those results suggest that MEG3 plays an 
essential role in the osteogenic differentiation of BMSCs, from patients with 
multiple myeloma, by indirectly activating BMP4 transcription 159. In line with the 
positive effect of MEG3 on osteogenesis, another study showed that MEG3 is 
downregulated during adipogenic differentiation, but upregulated with osteogenic 
differentiation of human adipose-derived mesenchymal stem cells (hASCs). 
Apparently, MEG3 acts via miR-140-5p, which is upregulated during 
adipogenesis and downregulated during osteogenesis, thus with an inverse 
correlation 160. However, the actual effect of MEG3 on bone is controversial. The 
microRNA mIR-133a-3p has been related with an abnormal osteogenic 
differentiation. In a study of human BMSCs, there was a positive correlation 
between MEG3 and miR-133a-3p expression; and both RNAs were down-
regulated after osteogenic differentiation. Thus, these data suggested that MEG3 
regulates miR-133a-3p expression, and inhibits osteogenesis of BMSCs from 
post-menopausal women 161. The reasons explaining those contradicting results 
are unclear, but may depend on the patients’ characteristics, because lncRNA 
expression is rather tissue- and time-specific, as already discussed. 
Tang et. al. found that a novel osteogenesis-associated lncRNA (lncRNA-OG) is 
upregulated during osteogenic differentiation of BMSCs, and functionally 
lncRNA-OG promotes this process. This lncRNA interacts with heterogeneous 
nuclear ribonucleoprotein K (hnRNPK) protein to regulate bone morphogenetic 
protein signaling pathway 162.  
Although the role of lncRNAs in osteoporosis remains largely unexplored, several 
studies suggested that lncRNAs are implicated in other skeletal disorders, such 
as rheumatoid arthritis or osteoarthritis 163. Recently, a small study suggested 
that some lncRNAs are differentially expressed in osteoporosis 164. They 
performed a RNA sequencing to obtain the expression profile in blood samples 
of postmenopausal osteoporotic patients (diagnosed as defined by the World 





differentially expressed lncRNAs, including LINC00963, LOC105376834, 
LOC101929866, LOC105374771 and LOC100506113, which may be involved in 
the pathogenesis of postmenopausal osteoporosis, by regulating the expression 
of other five co-expressed, differentially expressed, mRNAs (ALPL, SOCS3, 


























Osteoporosis is a bone disease characterized by low bone mass and a higher 
risk of fracture. Bone remodelling involves a regulated activity of osteoclasts and 
osteoblasts, responsible of bone resorption and bone formation, respectively. 
Bone marrow stem cells (BMSCs) are the precursors of osteoblasts and, 
consequently, are needed to maintain an adequate bone formation. Epigenetic 
mechanisms play an important role in cell physiology, the specification of the 
gene expression pattern and cell differentiation. Among epigenetic mechanisms, 
DNA methylation and certain long non-coding RNAs (lncRNAs) have been 
postulated as important regulators of the differentiation and activity of BMSCs. 
Therefore, the general hypothesis underlying this project is that DNA methylation 
patterns and the specific expression of certain lncRNAs by BMSCs are involved 
in the pathogenesis of osteoporosis, by influencing the ability of BMSCs to 
differentiate into osteoblasts and therefore to maintain bone mass. 
OBJECTIVES 
The main objective is to study differential epigenetic marks (specifically DNA 
methylation and expression of lncRNAs) by the BMSCs of patients with two 
prevalent skeletal disorders, namely osteoporosis and osteoarthritis, which tend 
to present with opposing changes in bone mass. This general objective translates 
into the following specific objectives. 
1- To analyse the methylation pattern of BMSCs of patients with hip fractures 
and controls with osteoarthritis, and their relationship with the expression 
of genes involved in bone metabolism. 
2- To explore the epigenetic aging of BMSCs of patients and controls. 
3- To determine the gene expression signature of BMSCs from patients with 
osteoporotic fractures in comparison with controls 
4- To characterize the lncRNA signature of BMSCs from patients and 
controls, as well as its relationship with the DNA methylation patterns 
5- To explore the changes of the lncRNAs signature of BMSCs after their 































Bone samples and bone marrow mesenchymal stem cell (BMSC) 
isolation and culture 
Bone tissue samples were obtained from the femoral head of patients undergoing 
hip replacement surgery due to osteoporotic hip fractures or hip osteoarthritis.  
The study was approved by the institutional review board (Comité de Etica en 
Investigación Clínica de Cantabria) and all donors gave informed consent. 
Patients with secondary osteoporosis, high-impact fractures or secondary 
osteoarthritis were excluded. Cylinders of trabecular bone were extracted with a 
trephine, after removing the subchondral and subfracture edges. They were 
washed with 50 mL of phosphate-buffered saline (PBS) to obtain a cell 
suspension. Cells were subjected to a Ficoll density gradient. Then, cells at the 
interface, between the aqueous phase and the Ficoll-Paque layer, were cultured 
on polystyrene culture flasks in Mesencult™ MSC Basal media completed with 
10% of Mesenchymal Stem Cell Stimulatory supplements (Stem Cell 
Technologies®, Vancouver, Canada)165. In some experiments, cells were 
maintained in Dulbecco's Modified Eagle Medium (DMEM®, Merck KGaA, 
Darmstadt, Germany) with high glucose 4.5g/L, phenol red and L-glutamine. 
Media were supplemented with 10% of Fetal bovine serum (FBS) (Merck KGaA, 
Darmstadt, Germany) and 1% Penicillin-Streptomycin (Merck KGaA, Darmstadt, 
Germany). 
When cultures attained 80% confluence, cell differentiation experiments and 
nucleic acid isolation were carried out. Only cells of the two first passages were 
used.  
In addition, the trabecular bone were cut into approximately 1 cm fragments,  
snap-frozen into liquid nitrogen, and stored at −80°C until nucleic acid isolation 
from bone cells 87. 
Representative samples of BMSCs were characterized by staining for surface 
markers of BMSCs in a FACSCanto II flow cytometer (Becton Dickinson, New 
Jersey, USA). Results were analyzed using the FACSDiva 6.1.3 software. The 
antibodies used were: CD45 labelled with peridinin chlorophyll protein complex 





with allophycocyanin (APC), CD90 labelled with phycoerytrina (PE) and CD105 
labelled with violet blue. All the antibodies were purchased from Miltenyi Biotec 
(Bergisch Gladbach, Germany).  
 
Osteogenic differentiation of BMSCs 
BMSCs were plated at a density of 100,000 cells/well in a 6 well plate and kept 
in culture for 2 days to reach confluence. Then, osteogenic induction medium was 
added. This medium was composed of DMEM supplemented with 100 nM of 
dexamethasone, 50 μM of ascorbic acid and 10 mM of glycerol 2-phosphate (all 
from Sigma-Aldrich, which now is Merck KGaA, Darmstadt, Germany). The 
medium was changed twice a week for up to 3 weeks. At several time points, 
cells were used for DNA extraction, RNA extraction or staining with alizarin red 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). Alizarin red staining 
procedure was used to measure the calcium deposition into cell matrix. Cell 
cultures were fixed with ethanol 70% for 1 hour, washed with distilled water three 
times and then exposed to alizarin red 2% solution (pH 4.2) for 10 minutes. 
Finally, stained cells were washed with distilled water three times and dried at 
room temperature. The staining was semiquantitatively evaluated by 2 
independent observers who were blind of the culture origin 165.  
 
Proliferation analysis 
The proliferation status of BMSCs was assessed by immunocytochemistry using 
an anti Ki-67 antibody (Thermo Fisher Scientific, Waltham, Massachusetts, USA), 
a nuclear protein associated with cell proliferation. Briefly, cells were 
permeabilized with 0.5% Triton X-100 in PBS for 15 minutes. After this step, cells 
were thoroughly washed with PBS three times. A final wash with PBS-Tween 20 
0.05% was performed for 5 minutes. Cells were incubated in the same buffer in 
the presence of a Ki67 antibody at 4º for 12 hours. After the incubation with the 
antibody, cells were washed as previously. Secondary rabbit antibody labelled 
with fluorescein isothiocyanate (FITC) was added to the cells and incubated for 
45 minutes at room temperature. After incubation with the secondary antibody, 





in PBS for 5 minutes. After mounting, the proportion of Ki67-positive cells was 
determined under a fluorescence microscope. 
The results were confirmed by a cell proliferation colorimetric assay based on the 
reduction of the tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to insoluble formazan. Cells were plated in triplicate 
on a 96-well plate (3x103 cells per well) with their normal growth medium. On 
days 3, 5, 7 and 9, cells were treated with 1 mg/mL of MTT at 37º for 5 hours. 
Next, the dye was extracted with 100 µL Isopropanol to solubilize the formazan 
for 10 minutes at 37ºC. Optical density was measured at a wavelength of 550 nm. 
 
Cell lines cultures 
For some parallel experiments and replications several cell lines were used. They 
included human osteoblastic cell lines, such as HOS, SAOS-2 and MG-63 
(osteosarcoma derived cells), and non-osteoblastic cell lines, such as HEK-293T 
(derived from human embryonic kidney cells). All cell lines, excepting HOS, were 
cultured with DMEM (Merck KGaA, Darmstadt, Germany) with high glucose 
4.5g/L, phenol red and L-glutamine, supplemented with 10% FBS (Merck KGaA, 
Darmstadt, Germany) and 1% Penicillin-Streptomycin to control bacterial 
contamination (Merck KGaA, Darmstadt, Germany). Human osteoblastic cell line 
HOS was maintained in culture with Eagle minimum essential medium (MEM, 
Merck KGaA, Darmstadt, Germany), supplemented with 10% FBS and 1% 
antibiotics. All cells were kept and grown in a humidified incubator, with 5% of 
CO2 and 37ºC of temperature 166.  
 
DNA isolation  
Genomic DNA from cell cultures was obtained after cell lysis with Proteinase K 
(0.2 mg/mL) and a lysis buffer (Tris-HCl 2 M, EDTA 0.5 M, sodium acetate 0.3 M 
and 10% of SDS). The mix was incubated for 1 hour in a water bath at 56ºC. DNA 
isolation was performed with Phenol:Chloroform:Isoamyl alcohol (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA), as previously reported 87. Pellet of 
DNA was cleaned with 75% ethanol and resuspended with 50 µL of distilled 
water. All centrifugation steps were done at 4ºC to avoid DNA degradation.  
On the other hand, to extract DNA from the frozen bone fragments, they were 





Alemania), in 1mL sterile PBS over ice. After this step, the same procedure was 
used to isolate DNA.  
To determine DNA concentration, we used spectrophotometric analysis 
(DeNovix, Wilmington, USA), which is based on the axiom that nucleic acids 
absorb ultraviolet light, and then Lambert Beer law is employed to calculate 
concentrations without standard curves. Nucleic acids absorb at a wavelength of 
260 nm and the quantity of absorption is proportional to DNA/RNA quantity. For 
more accurate quantification, the Qubit fluorometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) technique was used. Qubit is an instrument that 
uses fluorescent dyes to determine DNA, RNA or protein quantification. 
 
RNA extraction and purification  
RNA extraction from cell cultures was performed with 1mL TRIzol™ Reagent 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) for the cell lysis, 
following the instructions provided by the manufacturer. Summarising, after the 
lysis, the separation phase was done with 0.2 mL of chloroform and RNA 
precipitation from the aqueous phase with isopropyl alcohol. This precipitation 
may be improved with an incubation of an hour in the freezer. The RNA pellet 
was then cleaned with 1 mL cold 75% ethanol. At the end of the procedure, RNA 
pellet was dried and resuspended in RNAse-free water by leaving it a few hours 
on ice. It is important not to let the pellet dry completely because that would 
prevent its proper dissolution. All centrifugation steps were done at 4ºC as with 
DNA procedure. 
A similar procedure was used to extract RNA from bone tissue samples. Frozen 
bone fragments were mechanically homogenized with a polytron as with the DNA 
procedure, but in this case into 2 mL of TRIzol™ and then the extraction 
procedure was followed as described above. 
For some experiments, RNA samples were further cleaned and purified. RNA 
was purified with the RNA Clean & Concentrator kit (Zymo Research, Irvine, 
California, USA), which is a RNA clean up kit with an efficient procedure for the 
preparation of high-quality DNA-free RNA. The procedure uses a spin column 
technology for the recovery of total RNA, small RNAs and long RNAs. Over the 





buffer, ethanol wash and elution of pure RNA. DNAse I (provided in the kit) 
treatment was carried out for complete elimination of DNA contamination.   
To determine RNA concentration, we used spectrophotometric analysis 
(DeNovix, Wilmington, USA), and for more accurate quantification, the Qubit 
fluorometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) technique 
was used. 
 
Genome-wide DNA methylation analysis 
BMSCs at first passages were used for DNA methylation experiments. Thus, 22 
osteoporotic fractures (FRX) and 17 osteoarthritis (OA) samples were used for 
the analyses of DNA methylation (patient age: 62 to 95 years). DNA was 
extracted as explained before with Phenol:Chloroform:Isoamyl alcohol and 
bisulfite-converted before genome-wide analysis of methylation with the Infinium 
Human Methylation450 BeadChip array (Illumina®, San Diego, CA, USA) at the 
Spanish “Centro Nacional de Genotipado” (CEGEN-ISCIII).  
 
Figure 10. Bisulfite conversion scheme on a random sequence, showing how this conversion 
works. In the original sequence there are cytosines (coloured in red) and methyl cytosines 
(coloured in blue). After the bisulfite conversion, the methylated cytosines (blue) still remain as 
cytosines (blue), whereas the unmethylated cytosines (red), are transformed into uracils, which 
are read as thymine after the PCR reaction.  
 
Bisulfite conversion was performed with EZ DNA Methylation-Gold Kit (Zymo 
Research, Irvine, California, USA) with 1 µg of DNA per sample. Sodium bisulfite 
is able to deaminate cytosines into uracil, but this do not occur in methylated 
cytosines. Hence, after DNA deamination with bisulfite, unmethylated cytosines 
are converted into uracil that after a polymerase chain reaction (PCR) are read 
as thymine, but 5-methylcytosines are still cytosines, so depending on the 
thymine/cytosine ratio we can calculate the DNA methylation levels in the original 





manufacturer and is briefly explained below. In brief, 1 μg of DNA is diluted in 20 
μL of water and mixed with ‘CT Conversion Reagent’ and then incubated 10 
minutes at 98ºC and 2.5 hours at 64ºC. The samples are loaded in a spin column 
and are consequently washed, desulphonated, washed and finally eluted into a 
new clean tube. 
 
Infinium Human Methylation450k BeadChip array targets more than 450,000 
CpG methylation sites with a high genome coverage and can analyse twelve 
samples in parallel. This array uses two different types of chemical assays 
(Infinium types I and II assays), both are designed to distinguish Cytosine and 
Thymine, the two species generated after DNA bisulfite conversion. Infinium I 
uses two types of probes, one hybridizes the methylated allele (Cytosine) and the 
other the unmethylated allele (Thymine), next base extension is the same for both 
alleles. Infinium II assay uses only a single probe for both alleles, and in this case, 
base extension depends on the methylation state with different two colours, so it 
could generate A-T signal (colour 1) or C-G signal (colour 2) 167 (Figure 11).  
 
Figure 11. Infinium types I and II assays. Infinium I uses two types of probes (U and M), one 
hybridizes the methylated allele (M) and the other the unmethylated allele (U). Next base 
extension is the same for both alleles. Infinium II assay uses only a single probe for both alleles. 






Human Methylation 450k array included 485,577 hybridization sites, from which 
482,421 were CpG sites, 3091 non-CpG sites and 65 random SNPs. This 
coverage is distributed along the genome and covered almost all protein coding 
genes and the known CpG islands. Specifically, the array covers 21,231 RefSeq 
genes (99%), 26,658 CpG islands (96%), 26,249 CpG island shores (92%), 
24,018 CpG island shelves (86%), 62,600 Hidden Markov Model-defined CpG 
islands, 9426 high CpG content FANTOM 4 promoters, 2328 low CpG content 
FANTOM 4 promoters, 80,538 in silico-identified enhancers, and other regions of 
potential interest, like DNAse hypersensitive sites, Ensemble regulatory features 
and almost all HumanMethylation27k loci, 168 (previous designed methylation 
array). 
Due to the two probe types of this array, there are some type II bias during data 
processing. Therefore, several softwares have beed developed for array data 
normalisation. Likewise, a number of analysis pipelines have been suggested 
Most software packages are freely available and written in R language 
(methylumi, minfi, watermelon, ChAMP, RnBeads, and others) 169–172. Relevant 
steps of the 450k analysis pipeline are: import raw data files (IDAT files), probe 
filtering, background correction, adjustment for type II bias, batch effect analysis 
and correction, and identification of differentially methylated sites and regions 173. 
DNA methylation levels are commonly expressed as β value, which ranges 
between 0 (no methylation) to 1 (full methylation). We analysed our data using 
R/Bioconductor package RnBeads 169. This package permits to analyse DNA 
methylation data from human 450k array comprehensively, including import data, 
filter data, batch correction and identification of differentially methylated sites 
and/or regions. Differentially methylated sites were considered as significant with 
a false discovery rate (FDR) value < 0.05 and an absolute difference in 
methylation higher than 10% (Δβ > 0.10). We also used an analysis module from 
RnBeads that identifies differentially methylated regions (DMRs) when comparing 
groups of CpGs. So, we did not only look at single CpGs for differential analysis, 
but also for pre-defined genomic regions, such as CpG islands, promoters, 
genes, and enhancers. DMRs analysis increases the statistical power to detect 






Genomic Regions Enrichment of Annotations Tool (GREAT) was used to analyse 
the functional significance of differentially methylated enhancer regions by 
association with both, proximal and distal putative target genes. GREAT also 
uses gene annotations from numerous ontologies to calculate statistical 
enrichments in gene ontology terms or metabolic pathways for such associations 
174. Further details of the bioinformatic analyses are given below. 
 
DNA methylation age predictor 
DNA methylation age, also denominated as epigenetic age, was calculated with 
Steve Horvath’s multi-tissue predictor of age, which permits to estimate the 
epigenetic age of several tissues and cell types. Epigenetic age was calculated 
from the methylation level of a set of 353 CpGs, which has been shown to change 
with aging in a wide variety of tissues 175. Epigenetic age allows to compare ages 
of different tissues from the same subject and it may identify tissues with evidence 
of an altered epigenetic age due to disease. We used our DNA methylation data 
from BMSCs (n=39, from which FRX=22 and OA=17) above described, and also 
bone DNA methylation results (n=39, from which FRX=20 and OA=19), 
previously obtained in our lab 87. BMSCs and bone DNA samples were not paired 
because they were obtained at different times and projects.  
Horvath’s software was implemented with R function as described in his tutorial 
(additional file 20, from 175). The relationship of the epigenetic age and the 
chronological age was explored by linear regression analysis.  
 
Relative telomere length analysis 
The relative telomere length was analyzed using a quantitative PCR procedure 
employing β-globin as a control gene and the telomere primer sequences 
proposed by Cawthon 176:  
Primer Name Sequence 
Telomere forward CGGTTTGTTTGGGTTTGGGTTTGGGTT 
Telomere reverse GGCTTGCCTTACCCTTACCCTTACCCT 
β-globin forward GCTTCTGACACAACTGTGTTCACTAGC 
β-globin reverse GGCTTGCCTTACCCTTACCCTTACCCT 





DNA from BMSCs was quantified with a fluorometric assay (Qubit®). Telomere 
and β-globin amplification reactions were performed in quadruplicate in 96-well 
plates in a BioRad iCycler iQ™ Real-Time PCR detection system. The reaction 
mix contained Sybrgreen master mix (Applied Biosystems, Foster City, California, 
USA), 6 ng of DNA and the corresponding primers (100 nM forward and 900 nM 
reverse, for telomeres; 300 nM forward and 700 nM reverse for β-globin). The 
amplification protocol for telomeres included an initial denaturation step at 95ºC 
for 10 minutes, 35 cycles of amplification at 95ºC for 15 seconds and a 
hybridization step of 54ºC for 2 minutes. The β-globin amplification protocol 
included an initial denaturation step at 95ºC for 10 minutes, followed by 35 cycles 
of amplification at 95ºC for 15 seconds and 58ºC for 1 minute 176. In each 
experiment, 3 control samples were run to normalize the results and to 
compensate for inter-assay variability. The relative telomere length of the 
samples was then estimated as 2ΔΔCt. ΔCt for each unknown sample and control 
was estimated as (Ct β-globin - Ct telomere). Average ΔCt of the 3 control 
samples was calculated. Then ΔΔCt was calculated as (ΔCt unknown sample - 
ΔCt controls). 
 
DNA methylation analysis by pyrosequencing 
The DNA methylation level of selected CpGs identified as differentially 
methylated by the methylation array was replicated by pyrosequencing with the 
PyromarkQ24 Advanced System (Qiagen N.V., Hilden, Germany). 
Pyrosequencing is a high resolution quantitative method that allows to determine 






Figure 12. Enzymatic reactions of pyrosequencing in the example of a random bisulfite-treated 
sequence. (A) dGTP is added as nucleotide for extension, but it is not complementary to the 
sequence, therefore no PPi is released and the nucleotide is degraded by the apyrase. (B) dATP 
is added and it is complementary to the template so that PPi is released and used by the ATP 
sulfurylase and Luciferase enzymes generating a signal which level is proportional to the available 
PPi. (C) The ‘R’ in the template sequence corresponds to a CpG with variable methylation levels. 
Thus, after bisulfite treatment and PCR, either cytosine or thymine can be incorporated. First, 
dCTP is added and a signal is released. (D) dTTP is added and another light signal is released; 
in this case three times lower than with cytosine, so that the DNA methylation level in this CpG 
correspond to 75%. 
 
Primers used for PCR amplification and sequencing were designed with the 
PyroMark assay design program (Qiagen N.V., Hilden, Germany), Table 2. Assay 
design software ensures that primers hybridize in a methylation-independent 
manner. Sodium bisulphite modification of 1 µg genomic DNA was performed as 
described above. Bisulphite-converted DNA was eluted in 20 µL, using 1 µL for 
each PCR. Primers sequences were designed to hybridize with CpG-free sites to 





PCR was performed with a biotinylated primer, which permit its purification in a 
single-stranded DNA template, using the PyromarkQ24 Vacuum Workstation 
(Qiagen N.V., Hilden, Germany) (according to manufacturer’s instructions). 
Finally, pyrosequencing reactions and methylation quantification were performed 
in a PyroMark Q24 Advance System 166. The statistical significance of the 
differences between osteoporotic and osteoarthritic patients was tested by t-test 
when normal distribution exists. Instead, when normal distribution does not exist, 
non-parametric Mann-Whitney U tests was used. All reported p values are two-
tailed and with a significance threshold of 0.05. 
















LOXL2-Seq 5’-TTGAATTTAATTTTTTTTAGTTGTG - 
Table 2. Primer sequences of four gene candidates with differential DNA methylation (ID2, 
UNC5B, OPG and LOXL2) for pyrosequencing analysis. The biotinylated primer is marked with 
[Btn]. The third column shows the melting temperature of the PCR.  
 
Transcriptome analysis 
As with genome-wide DNA methylation analysis, in the case of the transcriptome, 
BMSCs at first passages were used for RNA isolation. We used two sets of 
samples that were subjected to high-throughput RNA sequencing RNA (RNA-
Seq). The samples were collected and analysed at different times both from 
practical reasons and to ensure biological and technical replication.  
Thus, the first RNA-Seq experimental set consisted in BMSCs isolated from 10 





(OA). After extraction, RNA samples were extracted as described before, and 
then quantified and studied for their integrity with an Agilent RNA Screen Tape 
analysis. RNA degradation information is given with an RNA Integrity Number 
(RINe) from 0 to 10, and RINe is recommended to be higher than 7 for sample 
quality control in sequencing workflows. Samples were then prepared using the 
NEBNext Ultra Directional RNA Library Protocol (Illumina, San Diego, California, 
USA) and were sequenced on an Illumina Hi-Seq 2000 sequencer (NTX-Dx, 
Gent, Belgium). Library preparation was with ribosomal RNA depletion, paired 
end, stranded and in 100 base pairs fragments. Total paired end reads were 
between 10 and 30 million, excepting a sample with 46 million, all of them with   
a mapping percentage higher than 80 percent. 
The second set of samples used for RNA-seq included 17 predifferentiated 
BMSCs samples (9 FRX and 8 OA). Additionally, we analysed 6 differentiated 
BMSCs samples, after three weeks of osteogenic differentiation in vitro (Table 3). 
In this case, library preparation was done with the kit TRuseq stranded total RNA 
Ribo-Zero (Illumina, San Diego, California, USA) for ribosomal RNA depletion, 
100 base pairs fragments, paired end and stranded. Sequencing instrumental 
was the new Novaseq System (Illumina, San Diego, California, USA), with at least 
30 million reads per sample (Macrogen, Seoul, South Korea).  




JAR1 JAR1 FRX woman PREDIFF 79 1st 
JAR2 JAR2 FRX woman PREDIFF 82 1st 
JAR3 JAR3 FRX woman PREDIFF 82 1st 
JAR4 JAR4 FRX woman PREDIFF 86 1st 
JAR5 JAR5 FRX woman PREDIFF 80 1st 
JAR6 JAR6 FRX woman PREDIFF 86 1st 
JAR13 JAR13 FRX woman PREDIFF 74 1st 
JAR14 JAR14 FRX woman PREDIFF 73 1st 
JAR15 JAR15 FRX woman PREDIFF 92 1st 
JAR19 JAR19 FRX woman PREDIFF 87 1st 
JAR7 JAR7 OA woman PREDIFF 72 1st 
JAR12 JAR12 OA woman PREDIFF 62 1st 
JAR17 JAR17 OA woman PREDIFF 67 1st 
JAR20 JAR20 OA woman PREDIFF 67 1st 









JAR23 JAR23 OA woman PREDIFF 73 1st 
JAR24 JAR24 OA woman PREDIFF 82 1st 
JAR16 JAR16 OA woman PREDIFF 66 1st 
JAR8 JAR8 OA woman PREDIFF 80 1st 
JAR9 JAR9 OA woman PREDIFF 67 1st 
JARM5 2 FRX man PREDIFF 79 2nd 
JARM9 5 FRX woman PREDIFF 77 2nd 
JARM12 7 FRX woman PREDIFF 91 2nd 
JARM21 9 FRX woman PREDIFF 84 2nd 
JARM24 10 FRX man PREDIFF 67 2nd 
JARM32 15 FRX woman PREDIFF 68 2nd 
JARM38 18 FRX woman PREDIFF 76 2nd 
JARM46 20 FRX man PREDIFF 95 2nd 
JARM6 3 OA man PREDIFF 87 2nd 
JARM7 4 OA woman PREDIFF 63 2nd 
JARM10 6 OA woman PREDIFF 72 2nd 
JARM25 11 OA woman PREDIFF 71 2nd 
JARM26 12 OA woman PREDIFF 72 2nd 
JARM29 13 OA man PREDIFF 65 2nd 
JARM50 21 OA woman PREDIFF 73 2nd 
JARM51 22 OA man PREDIFF 68 2nd 
JARM1 1 FRX woman PREDIFF 88 2nd 
JARM2 1 FRX woman 21 88 2nd 
JARM11 6 OA woman 21 72 2nd 
JARM43 19 OA woman 21 75 2nd 
JARM54 23 FRX woman 14 89 2nd 
JARM53 7 FRX woman 14 91 2nd 
JARM14 7 FRX woman 21 91 2nd 
Table 3. Biopsies information of the RNA samples sent to the first and second RNAseq. Column 
6th, ‘differentiation state’, shows the status of BMSCs in terms of osteogenic induction in vitro. 
‘PREDIFF’ refers to the basal state of BMSCs and the numbers ‘14’ and ‘21’ refer to the days with 
osteogenic differentiation media.  
 
In both experimental sets, the analysis started with a general quality control test 
of the raw sample reads using FastQC software from Babraham Institute. FastQC 
looks at the quality of all reads from a sample and gives information for the next 





bases, reads or other artifacts, such as, adapters or library derived sequences. 
Adapter dimers, corresponding to the first 15 nucleotides, were trimmed with 
Fastx trimmer tool (FASTQ/A Trimmer). This tool is used for shortening reads in 
FASTQ files to remove barcodes or noise (http://hannonlab.cshl.edu/fastx 
_toolkit/). These trimmed samples were then used to align reads to mammalian-
sized genomes.  
Sample reads were mapped to the human consortium reference genome build 
37 (GRCh37), also known as hg19, by using TopHat tool. TopHat is “a fast splice 
junction mapper for RNA sequenced reads. It aligns RNA-Seq reads to 
mammalian-sized genomes using the ultra-high-throughput short read aligner 
Bowtie, and then analyses the mapping results to identify splice junctions 
between exons” 178. TopHat uses Bowtie alignment method that permits to 
analyse and detect alternative splicing in the align sequences. After mapping with 
TopHat the following pipeline was followed, as described by Cole Trapnell and 
collaborators 178, and summarized below.  
Mapped reads were assembled to transcriptome using two different ways for the 
final differential expression analysis. One way uses Cufflinks suite of tools that 
assemble transcripts, estimates abundances and tests for differential in all 
samples. Cufflinks suite is composed by several software tools, such as cufflinks, 
cuffcompare, cuffquant, cuffnorm and cuffdiff (http://cole-trapnell-
lab.github.io/cufflinks/manual/). Cufflinks assembles reads into transcripts and 
quantifies their expression. Cuffcompare associates each assembled sample to 
known transcripts, employing a specific reference transcriptome. In this case 
gencode V19 gtf file was applied as a comprehensive gene annotation on the 
reference chromosomes (www.gencodegenes.org/human/release_19.html). 
Cufflinks and cuffcompare output files can be used with cuffdiff to compare 
expression levels of genes and/or transcripts between sample groups. Cuffdiff 
shows up- and down- regulated genes comparing our two conditions (FRX and 
OA), and also which genes have differentially spliced or differentially expressed 
isoforms. However, this step is very computationally expensive, therefore, it is 
recommended to use cuffquant, which save gene and transcripts profiles to files 
that are easier to analyse with cuffdiff and cuffnorm. Cuffnorm was employed to 





Secondly and processed in parallel, those aligned files with TopHat were sorted 
with Samtools sort option, and then HTSeq-count tool was used to quantify the 
expression of the samples in all genes 179. Finally, HTSeq-count output files were 
examined for differential expression between our groups with two free R 
packages (DESeq2 and EdgeR) 180,181. 
The overrepresentation of genes with differential expression in different cell 
pathways (Wikipathways) was obtained from the output of Web-based gene set 
analysis toolkit (WebGestalt) software 182, which incorporates information from 
different public resources. The Gene Ontology enrichment analyses from the 
common terms between differentially methylated enhancers and differential 
expression were done with ArrayTrack software 183. Further details of the 
bioinformatic analysis are given below. 
 
Real Time PCR analysis 
Gene expression was validated by Reverse Transcription followed by a real time 
quantitative polymerase chain reaction (RT-qPCR). Complementary DNA (cDNA) 
was synthetized with the TaKaRa kit PrimeScript RT (TaKaRa, Shiga, Japan). 
We used 1µg of RNA as template, random hexamers and oligo-dT as primers, 
with manufacturers quantities and conditions, which are 2 µL of their buffer and 
random hexamers; and 0.5 µL of enzyme and oligo-dT; 1 µg of RNA in 5 µL of 
sterile and RNAse free water. This reaction mixture per sample is incubated at 
37º for 15 minutes (reverse transcription) and 85º for 5 seconds (enzyme 
inactivation). Then complementary DNA (cDNA) in 10 µL was diluted four times, 
up to a final volume of 40 µL. Transcript abundance of messenger RNAs was 
assessed by RT-qPCR using commercially available Taqman assays 
(Thermofisher Scientific, Waltham, MA, USA) on an Applied Biosystems 7300 
Real-Time PCR System.  
However, for long non-coding RNAs (lncRNAs) analysis, new primers had to be 
designed, by using the “RealTime qPCR Assay Entry” IDT online tool 
(https://eu.idtdna.com/scitools/Applications/RealTimePCR/). For intergenic 
lncRNA reverse transcription was performed with the same protocol as above. 
However, a different protocol was established for analysing the antisense type of 
lncRNAs. In that case, reverse transcription must be strand specific to distinguish 





the same kit without random hexamers and oligo-dT as primers, but with sense 
primers for the antisense strand selection, or vice versa. Specific primers for 
reverse transcription were used with a concentration of 2 µM in the final mix and 
the reverse transcription reaction took place at 50º, instead of 37º, to improve the 
results by increasing the specificity.  
Assays used for the RNA sequencing validation, other bone related genes and 
lncRNA genes are reflected in Table 4. Housekeeping genes GAPDH and 
RPL13A were used for normalization in BMSCs, and GAPDH and TBP for cell 
lines. Threshold cycles (Ct) are the amplification cycles at which the fluorescence 
threshold was reached, and they were estimated for the target and housekeeping 
genes. The average of the housekeeping genes was used as control for 
normalization. Thus, the relative expression of target genes was estimated by the 
2ΔCt method, where ΔCt= average Ct housekeeping – average Ct target gene. 
For statistical results, the data collected from real time qPCR was subjected to 
Shapiro-Wilk normality test. Pearson correlation coefficient was used for the 
correlation analysis when the data were normally distributed. When the data were 
not normally distributed or the relationships were not linear, Spearman rank 
correlation method was employed. 
Gene Assay / Sequence 
ALPL Taqman Hs00758162_m1 
BGLAP Taqman Hs01587814_g1 
COL1A Taqman Hs00164004_m1 
FOXP2 Taqman Hs00362818_m1 
GAPDH Taqman Hs99999905_m1 
IBSP Taqman Hs00173720_m1 
ID2 Taqman Hs04187239_m1 
IGFBP4 Taqman Hs01057900_m1 
LAMC1 Taqman Hs00267056_m1 
LASP1 Taqman Hs00196221_m1 
LOXL2 Taqman Hs00158757_m1 
OPG Taqman Hs00900360_m1 
OSX Taqman Hs00541729_m1 
PPARG Taqman Hs01115513_m1 





Gene Assay / Sequence 
RUNX2 Taqman Hs00231692_m1 
SLC5A3 Taqman Hs00272857_m1 
SPARC Taqman Hs00234160_m1 
SPP1 Taqman Hs00959010_m1 
UNC5B Taqman Hs00900710_m1 
PAPPA-AS1 Fw CCCACCCAACAACAACAATAAC 
PAPPA-AS1 Rv GCCTCAGTAGGTAGACACAAAC 
CTB-51J22.1 Fw AGCTTAGGGATGGTGGAATTG 
CTB-51J22.1 Rv CCCTGCCCACTAAATGCTTAT 
LINC00341 Fw CAATACGCAGAGGGACCATATC 
LINC00341 Rv TCCAATACTGCTTGCCTTCC 
LINC01279 Fw GGAGGCGTGGTAAAGGTATATG 
LINC01279 Rv AATCCCACTGCCCTTATCTTG 
LINC012008 Fw GGTTCCATCCAGCCCAATAA 
LINC012008 Rv CTACAGGTCAACACTGCGATAG 
CTD-2541J13.1 Fw ACAGCGGCAATCCCTAAA 
CTD-2541J13.1 Rv GTTCTCCTTACTCATCCCTCAC 
PACERR Fw CCCTCTCCTCCCCGAGTTCC 
PACERR Rv CAGGGCCGCTCAGATTCCTG 
Table 4. Primers and assays. 
 
Transfection analysis with siRNA and expression vectors 
For transfection analysis in both BMSCs and cell lines, 50,000 cells in 0.5 ml 
medium were seeded in each well of a 24 well plate, so that in the next day they 
were between 70-90% confluent. Then, we prepared the transfection mix with 
lipofectamine 3000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA), 
as recommended by the manufacturer. The mixture is prepared with 1.2 μl of 
lipofectamine 3000; the material to be transfected at the desired concentration 
(for DNA, 500 ng); 1 μl of P3000 Reagent and 50 μl of Optimem (Gibco®, Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) reduced serum media, which is 
ideal for use during cationic lipid transfections. After 5 minutes of incubation, the 
mixture was added dropwise on the centre of the well. In the case of small 





Optimem with 2.75 μL of lipofectamine and 50 nM of siRNA, according to the 
manufacturer’s reccomendations. 
siRNAs were obtained from Guangzhou RiboBio Co., Ltd. (Guangzhou, China), 
lyophilized. For each gene, three tubes with different target sequences were 
obtained, and a negative control (scramble sequence). Each of the three tubes 
of siRNA for the gene to be silenced, were mixed at equal volumes, obtaining a 
final concentration of 20 μM. 




genOFFTM st-h-ID2_001 CGATGAGCCTGCTATACAA 
genOFFTM st-h-ID2_002 GGACTCGCATCCCACTATT 
genOFFTM st-h-ID2_003 TCAGCATCCTGTCCTTGCA 
Table 5. Total of three different sequences of the siRNA of ID2 obtained.  
 
For each transfection, different controls were implemented, some wells without 
transfection mix, and some negative silencing controls with the scramble 
sequence. After cell transfection, RNA was extracted at different time points with 
Trizol as described above and gene expression was determined by RT-qPCR. 
For each transfection well, the cells were lysed with TRIzol™ Reagent for further 
RNA isolation and gene expression analysis. 
 
Plasmid cloning, purification and transfection experiments. 
Mammalian expression cloning vectors pcDNA3.1(+) were ordered with our 
sequences of interests under a cytomegalovirus (CMV) promoter (General 
Biosystems, Morrisville, USA). The expression vectors included the sequences 
of two human genes, PACERR (NR_125801.1) and LINC00341 gene 
(NR_026779.1), respectively. Both plasmids contained two antibiotic resistance 
genes, beta-lactamase gene that confers resistance to ampicillin, and other beta-
lactams; and aminoglycoside phosphotransferase from Tn5 gene that confers 






Figure 13. Mammalian expression vectors with the CMV promoter previous to the gene sequence 
(PACERR and LINC00341, independently). Both plasmids have beta lactamase gene that confers 
resistance to ampicillin and aminoglycoside phophotransferase gene from Tn5 that confers 
resistance to neomycin and kanamycin. 
 
Plasmids arrived lyophilized and were dissolved in nuclease free water at a final 
stock concentration of 100 ng/µL. After reconstitution, stock solution was stored 
at -20ºC for long term storage. A working solution of 1 ng/µL was prepared, and 
10 µL of the working solution were used to transform the plasmids into 50 µL of 
E. coli DH5α competent cells (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). They were gently mixed by flicking the bottom of the tube 
with the fingers and incubated on ice for 30 minutes. Then each tube was placed 
in a water bath at 42ºC for 20 seconds and then put back on ice for 2 minutes. 
Then, 950 µL of Luria-Bertani (LB) Broth media (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) were added, without antibiotic, and maintained 
at 37ºC in a shaking incubator for 1 hour. This step allows the bacteria to produce 
the antibiotic resistance proteins encoded by the plasmid so that they will be 
prepared to grow in an antibiotic containing agar plate. Two LB agar (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) plates with ampicillin were 
prepared, per plasmid, to plate different volumes of the transformed outgrowth in 
LB. Plates were incubated at 37ºC overnight.  
Only the cells that contained the plasmid will be able to grow in the LB agar with 
ampicillin and to form colonies. Single colonies were removed with a sterile 
pipette tip, deposited into 3 mL of liquid LB and maintained at 37°C for 8 hours in 
a shaking incubator. Next, large overnight culture was prepared from each starter 





ampicillin and incubated at 37ºC. Plasmids were purified from cultures with the 
Nucleobond Xtra Midi Plus kit (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany), using high copy plasmid purification protocol, as described by the 
manufacturer. Plasmid concentration was determined by UV spectrophotometry 
and its integrity by agarose gel electrophoresis.  
Plasmids were used for transfection experiments on HEK293T, HOS, MG63 cell 
lines and BMSCs, in a 24 well plates. Lipofectamine 3000 was used for 
transfection as explained above. Lipofectamine 3000 and plasmid DNA 
proportions were 1 µL of Lipofectamine for 0.5 µg of DNA. Transfection efficacy 
was assessed by gene expression analysis by RT-qPCR. 
 
Bioinformatic tools and statistics 
For “wet-lab” experiments standard univariate statistical tests were used 
(Pearson and Spearman for correlation analysis; t-tests and Mann-Whitney tests 
for pair-wise comparisons. Therefore, this sub-section is divided into two parts, 
the first one about the methylation analysis and the second one about the 
transcriptome analysis. In general, the false discovery rate (FDR) method 184 was 
used to minimize the inflation of type I error due to multiple comparisons. 
 
Methylome data 
DNA methylation results from Infinium DNA methylation 450k array, were 
analysed, as explained above, with RnBeads software, which consists in an R 
package for comprehensive analysis of DNA methylation data. RnBeads pipeline 
contain different analysis modules that can be run automatically by only giving 
some annotation characteristics, or they can also be run separately 169. DNA 
methylation analysis modules used for this thesis comprehend: 
-Data Import. In this case data is imported as typically Infinium formats (IDAT 
format files) and normalized by default with Subset-quantile Within Array 
Normalization (SWAN) method 185.  
-Quality control. RnBeads identifies technical and biological biases including 
assay failures and batch effects.  
-Preprocessing. Quality control results determine which samples or CpG sites are 
susceptible to filter out due to low-quality with the objective of reducing risk of 





interfering in DNA methylation levels, and additionally, discards samples and/or 
probes previously included in the normalization, but not in the final analysis 
because of too much missing values or without any variability. 
-Tracks and Tables. Preprocessed data is exported in several formats to use for 
example in data visualization in genome browsers or to use in other software to 
analyse further. Moreover, a table is created summarising simple statistics such 
as the final number of probes (CpG sites), genomic regions involved and number 
of CpG sites per region type.  
-Exploratory Analysis. This module explores sample subgroups, methylation 
profiles in terms of CpG sites and regions, and explores associations with sample 
annotations. It shows through several density plots the genomic regions covered 
in the dataset, their size distributions, number of sites per region and distribution 
of sites across different regions. It also implements two methods for dimension 
reduction, principal component analysis (PCA) and multidimensional scaling 
(MDS). Methylation value distributions are assessed based on sample groups on 
probe and region levels. And finally, this module also creates clustered samples 
on heatmaps using Euclidean distance metric per genomic region.  
-Differential DNA methylation. DNA methylation changes can be analysed at the 
CpG sites level or across genomic regions. Combined estimations in larger 
genomic regions increase statistical power and may arise in more interpretable 
results. On the site level, p-values were calculated using limma’s software 
method that uses hierarchical linear models with the DNA methylation M-values, 
which distribution is more appropriate for this statistical model than the beta 
values. β-values range from 0 to 1, generally used to measure DNA methylation 
percentage. Whereas, M-values are calculated as the log2 ratio of the intensities 
of methylated probe versus unmethylated probe and almost range from -6 to 6 
185. 
With this assumption the difference in mean methylation levels of both groups 
(FRX and OA) were compared and a t-test assessing if methylation values from 
this two groups originate from distinct distributions. In the case of the region level, 
differential methylation was assessed as the mean difference in means across all 
sites in a given region, as well as a combined p-value calculated from all site p-





DNA methylation changes were considered as significant with FDR less than 0.05 
and beta value differences between both groups greater than 0.1, which 
corresponds to a 10%. 
 
Transcriptome data 
The main objective of transcriptome analysis is to find differentially expressed 
genes. Those are genes that are expressed in significantly different quantities 
when comparing distinct groups of samples, for example, disease versus control 
individuals. This analysis is done in a univariate way, so referring on one gene at 
a time and stage. This fact is due to that there are tens of thousands of genes 
and the number of samples used is much smaller, so it is very difficult to fit a 
statistical model that considers all genes as a whole 186. Reads that are 
independently sampled from a population would be expected to follow a Poisson 
distribution, and it has been used to test differential expression. However, 
Poisson distribution assumed that mean is equal to variance and when samples 
are taken from different biological individuals, variance is much higher. This 
means that Poisson distribution is too restrictive and does not control the 
probability of false discoveries. To manage this overdispersed distribution 
problem, it has been proposed a model of negative binomial distributions, which 
is used in the EdgeR and DESeq2 packages 180.  
Mapped reads count to one gene or isoform is proportional with the isoform or 
gene abundance, this means that the more abundant a gene is expressed the 
more reads are sequenced. The problem is that genes and/or isoforms are not 
equal, and this assumption would be so for expressed genes with same length. 
Moreover, sequencing depth differs between samples, which alters the 
comparison of read counts of a given gene in different samples. Therefore, all 
read counts must be normalized to be comparable across genes, gene isoforms 
and samples. Normalization is also used to make expression level distribution 
able to presumptions used in specific statistical methods. There are some 
standards adjustments used for this correction in RNA-seq. The easiest way is to 
correct for gene length, dividing the number of reads by the total number of bases 
in the sequence and multiplying by one thousand, resulting in Reads per Kilobase 
(RPK). RPK does not adjust expression levels across samples. For this, Reads 





are used. RPKM is made for single-end RNA-Seq, where every read is a single 
sequenced fragment, whereas FPKM is made for paired-end RNA-Seq, where 
two reads may correspond to a single fragment. Thus, FPKM considers that two 
reads can map to one fragment and does not count the fragment twice. There 
also exist other commonly used normalization methods, such as, Transcript per 
million (TPM) and Trimmed mean of M values (TMM) that are correcting for 
different compositions of RNA pools. However, the most common used method 
and likewise the one used in this work for expression from RNA-Seq is FPKM 
187,188.  
Differential expression analysis methods are constantly under development and 
there is not an established best method for this analysis. There are some 
controversies about best ways to normalize and statistically analyse gene 
expression. Therefore, in this thesis we explored our data by using different 
softwares. Cuffdiff is frequently regarded as the best choice for differentially 
expressed isoforms study, and this makes cuffdiff, in addition, more appropriate 
on the gene level study because gene level changes are closely related to isoform 
level changes. However, other R/Bioconductor packages were also used (EdgeR 
and DESEq2), because some authors have shown that their performance as 
equal as that of Cuffdiff and may have the advantage that they can work with 
more than a covariate using a generalized linear model, for example, using 
disease and experimental conditions as two independent covariates. This has 
been implemented for differentially expressed genes analysis using pre and post-
differentiated samples as a covariate and disease as a second covariate 189. 
Cuffdiff assumes beta negative binomial distribution and uses t-test for differential 
expression evaluation. EdgeR and DESeq2 use negative binomial distribution 
and exact test for differential expression analysis.  
Significant gene expression changes were considered with an FDR less than 0.05 
and a fold change greater than 2. 
 
Pathways and gene ontology (GO) analysis 
Over representation methods with WebGestalt online software were implemented 
with Wikipathways database for pathways analysis and the gene ontology 
database for biological processes terms 190. Webgestalt uses the hypergeometric 





Enhancer analysis was done with GREAT. GREAT (Genomic Regions 
Enrichment of Annotation Tools) software associates genomic regions to genes 
by using a single transcription start site (TSS) to specify the location of each gene. 
Two options have been used with this software for each gene list obtained in our 
results. The first one consists in the association of ‘two nearest genes’, which 
extends each region given to the nearest upstream and downstream TSS up to 
1000 kilobases in each direction. The other option used was the ‘single nearest 
gene’ association rule, which extends each region to the nearest adjacent TSS, 
up to 1 Mb in each direction. The TSS used is that of the ‘canonical isoform’ of 
the gene as defined by the UCSC Known Genes track. For the enrichment 
analysis of a set of cis-regulatory regions (the regions given as input), GREAT 
implements both, the binomial test (regulatory domain bias) and the traditional 
hypergeometric gene-based test (gene specific enrichment), and it highlights 
ontology terms enriched by both tests separately 174.  
Finally, the ‘CommonPathway’ function in ArrayTrack recognizes the common 
genes between different sets of genes, and identifies which pathway is 
significantly altered for each combination of sets. The statistical significance of 

























Isolation and characterization of BMSCs 
The procedure to isolate BMSCs from the femoral head is described in methods. 
We found a similar success rate in establishing a BMSC culture with samples 
from patients with fractures (FRX: 27 out of 41, 66%) or with OA (22 out of 27, 
59%). Since long-term culture has been previously shown to introduce changes 
in the DNA methylation pattern 191, once isolated from the bone tissue, the 
BMSCs were allowed to proliferate for a short period until confluency and then 
RNA and DNA were collected at first passage. To confirm the stem cell nature of 
the cells used for the study, some cultures were used to check their phenotype 
by flow cytometry using a combination of five different markers (CD45-, CD34-, 
CD90+, CD73+, CD105+) that define the phenotype of BMSCs, as established 
by the International Society for cellular Therapy (ISCT) 192. Cytometry results 
showed that the starting cells for the subsequent transcriptome and methylome 
analysis were obtained from a highly pure population of BMSCs.  
 
Proliferative capacity of BMSCs 
Actively dividing cells express Ki-67 protein, therefore this is a commonly used 
marker for cell proliferation. We tested our cultures of BMSCs, and interestingly 
found that the proportion of Ki-67 positive cells was significantly higher in BMSCs 
isolated from patients with osteoporotic fractures (60%) than in cultures from 
osteoarthritic patients (40%, p=0.0003). These results were confirmed by 
assessing cell proliferation by MTT assay experiments.  
 
DNA methylation profiling 
We used 39 BMSCs samples for the DNA methylation study (22 were isolated 
from osteoporotic patients and 17 from patients with osteoarthritis). Human DNA 
methylation 450k array used for this analysis provided an idat format file per 
sample, were 485577 different probes were detected. The first step for microarray 
data preprocessing analysis is to remove bad quality probes. Thus, 4713 sites 
were filtered out because they were overlapping with SNPs. Technical variation 





methylumi package 193, and the signal intensity values were normalized using the 
SWAN normalization method. Additionally, 3156 probes of distinct specific 
sequence contexts, which are probes dedicated to SNP detection, were also 
removed. Thus, after the filtering procedures, 7869 probes were removed and 
477708 probes were retained for further analysis.  
Besides the single CpG site output, the methylation analysis included CpGs 
grouped in different ways, such as 137536 tiling regions, 30794 gene regions, 
30945 promoter regions and 26649 CpG islands. Single probe analysis revealed 
a bimodal distribution of methylation, as also observed in other studies. However, 
in CpG islands and promoter regions, the unmethylated sites were much more 
common, whereas in gene body regions DNA methylation values were 
intermediate, with a pyramidal distribution peaking at 50 percent of methylation 
levels (Figure 14).  
 
Figure 14. Density plots comparing methylation value distributions (FRX in green and OA in 





RnBeads suite uses two methods for dimensional reduction of DNA methylation 
data, principal component analysis (PCA) and multidimensional scaling (MDS). 
Using all CpG sites, independently of the location, we observed an overall trend 
for the separation of fracture and osteoarthritis groups by both procedures 
(Euclidean distance in MDS or the first and second principal components in PCA) 
(Figure 15).  
 
Figure 15. The scatter plot on the left shows all samples transformed into a two-dimensional space 
using multidimensional scaling approach. Similarly, on the right, a scatter plot with the values of 
the first and second principal components of all samples. In both cases sample groups are 
coloured (FRX in green and OA in orange). 
 
Differential methylation analysis was conducted both at the single probe and at 
region level. Age was included as a covariable because age, as explained above, 
is an important factor for DNA methylation, and per se age may change DNA 
methylation levels in some regions, among other factors. Differential methylation 
at the single site level was analysed by using a t-test that compared the mean 
methylation levels of each CpG in both groups. The resulting p-values were 
corrected for multiple test comparisons, using the false discovery rate (FDR), 
which is a method used to diminish type I errors in null hypothesis testing.  
The average methylation level was similar in both groups as shown in Figure 1. 
However, among all CpG sites analyzed (477708), we found 9038 sites 
differentially methylated, considering a combined FDR<0.05 and β-differences of 
the group mean greater than 10 percent. Of these 9038 differentially methylated 
CpG sites, 4417 were more methylated (hypermethylated) and 4621 were less 





(FRX). These sites were distributed in different genomic regions, specifically 1586 
sites in CpG islands, 1105 in shores, 353 in shelves and 5994 in open sea 
regions. 
In parallel, the analysis at the region level revealed 217 differentially methylated 
gene promoters out of 30877, including 111 hypermethylated and 106 
hypomethylated in FRX in comparison with OA. Furthermore, from these 217 
regions, only 62 correspond to protein coding genes, whereas the majority (155) 
were non protein coding genes. Among CpG islands, 40 regions were 
differentially methylated, from which 16 were hypermethylated and 24 
hypomethylated in FRX. Among gene bodies, 62 were found to be 
hypermethylated and 67 hypomethylated in FRX (Figure 16). 
 
Figure 16. Volcano plots showing different genome regions (Enhancers, gene bodies and CpG 
islands) with significant DNA methylation differences in blue dots (FDR<0.05 and absolute beta 
differences>0.1) between BMSCs obtained from fractured patients (FRX) and OA patients.  
 
In addition to this region level analysis, RnBeads permits to analyze other regions 
according to custom annotations. So, we used this option to retrieve annotation 
data for genomic enhancers specified by a chromatin state segmentation 
approach employed in the ENCODE project. The region level analysis at 
enhancers revealed 1684 differentially methylated regions (out of the 41280 
regions explored), from which 870 were hypermethylated and 814 
hypomethylated in FRX.  
All significant regions have at least a CpG site differentially methylated but in 
some cases there were more sites in the same region, so we looked at the 





402; 1355; 124 and 2425 CpG sites in promoters, gene bodies, CpG islands and 
enhancer regions, respectively (Table 6). 
Differential methylation on the region level analysis 
Genomic regions Promoters Gene bodies CpG islands Enhancers 
Analyzed regions 30877 30725 26649 41280 
Analyzed CpG sites per region 208588 383795 149149 62169 
Differential CpG sites 402 1355 124 2425 
Differential regions 217 129 40 1684 
Hyper-methylated regions 111 62 16 870 
Hypo-methylated regions 106 67 24 814 
Table 6. Distribution of differentially methylated CpGs between BMSCs from fractured patients 
(FRX) and patients with osteoarthritis (OA) in various genomic regions (Promoters, gene bodies, 
CpG islands and enhancer regions). Each analyzed region could have from 1 to several CpGs. 
Significant hyper- or hypo-methylated regions were calculated with the mean difference in means 
across all sites in a region of the two groups being compared, as well as, a combined p-value 
calculated from all site p-values in the region (mean-mean difference > 0.1 and combined FDR < 
0.05). Hyper-methylation refers to higher methylation in FRX than in OA. Some CpG sites could 
have been analyzed in different set of regions.  
 
As previously described, we observed that differentially methylated CpG sites 
were enriched in enhancer regions, 2425 of 9038, which corresponds to more 
than a quarter of all of them.  
We then focused on the differentially methylated enhancer regions and their 
nearest protein-coding gene, which is assumed to be the putative target gene. 
This enhancer-gene association was determined with the Genomic Regions 
Enrichment of Annotation Tool (GREAT), which predicts functions of cis-
regulatory regions. GREAT associates proximal input regions with their target 
genes and uses annotations from several gene ontology databases to associate 
the genomic regions to significant annotation terms 174. We used the significant 
enhancer regions as input in GREAT software and obtained associated genes, 
using the ‘single nearest gene’ option within 1000 kb of distance extended in both 
directions. Thus, 1684 differentially methylated enhancer regions were related 
with 1400 genes, 722 genes linked with hypermethylated enhancers and 678 with 
hypomethylated enhancers. Distances between each enhancer and its 






Figure 17. Distances of the differentially methylated enhancers to the transcription start sites 
(TSS) of the associated genes with GREAT software. The distances to TSS are represented 
versus the mean differences (Beta values) of the enhancer regions when comparing BMSCs from 
fractured patients (FRX) and patients with osteoarthritis (OA). 
 
Genes with differentially methylated enhancers were enriched in stem cell 
development and bone-related pathways such as the Wnt receptor signaling 
pathway (p = 4.5·10−8; binomial test), regulation of osteoblast differentiation (p = 
9.1·10−5), regulation of hMSCs proliferation (p = 7.6·10−6), and bone development 






Figure 18. Bar chart of the gene ontology (GO) enrichment analysis, concerning biological 
processes terms, of those genes associated to differentially methylated enhancers between 
BMSCs derived from FRX and controls with OA. Surrounded in yellow, some interesting bone 
related processes.  
 
Epigenetic aging 
Studies of DNA methylation have shown regions whose methylation level tend to 
change quite consistently with advancing age. Likewise, telomere length is known 
to shorten with aging. Thus, we explored that “epigenetic aging” pattern in our 
BMSCs and bone samples from osteoporotic or osteoarthritic origin. The 
methylation patterns were analyzed with Horvath’s Epigenetic clock software 86, 
based on Illumina DNA Infinium 450k data. As explained above, this software 
employs a set of CpG sites (353 sites) showing age-related changes in DNA 





methylation data were obtained from previous studies of our laboratory. We found 
a significant correlation between the predicted epigenetic age and the 
chronological age (r = 0.64, p = 1.36·10−5). Moreover, BMSCs from osteoporotic 
patients showed an accelerated aging when compared with BMSCs from patients 
with osteoarthritis (p= 0.001). However, there were not differences in DNA from 
bone tissue samples obtained from patients with FRX or OA (p = 0.111) (Figure 
19A).  
Further, we explored the relative telomere length in BMSCs and bone samples 
as for DNA methylation age. Telomeres shortening alters cell proliferation and 
divisions and is considered an aging hallmark, also related with aging-associated 
diseases. There were not significant differences in the relative telomere length of 
either bone samples or BMSCs obtained from patients with osteoporosis or with 
osteoarthritis (Figure 19B). However, the interindividual variation was very large, 
which might limit the power to find statistically significant differences. 
 
Figure 19. Epigenetic marks in bone tissue and BMSCs from patients with hip fractures and with 
hip osteoarthritis. (A) Epigenetic aging as revealed by age-related DNA methylation marks. Dot 
plot with the mean and SD of the residuals (deviation from the overall regression line of epigenetic 
age and chronological age) from bone and BMSCs isolated from osteoporotic fractures (Fx, dark 
gray dots) and osteoarthritis (Oa, gray dots) are shown. Between-group differences were 
compared by ANCOVA, with the chronological age as covariable. Data derived from previously 
reported results (Delgado-Calle et al. 2013; Vidal-Bralo et al. 2016; del Real et al.2017). (B) Violin 
plots showing the distribution of the relative telomere length density from bone and BMSCs 






Gene Expression Profiling 
We used 20 RNA samples from BMSCs (10 FRX and 10 OA) for sequencing with 
the Hi-Seq technology (Illumina), using a paired end library per sample with at 
least 20 million of total reads. Reads were mapped using the star RNA aligner 
v2.3.0 with an efficiency of 81.4 ± 5.6 (Table 7).  
Sample Total Reads Total Paired Reads Mapping % Mapped Paired Reads 
1 26,703,234 13,351,617 82.54 11,020,425 
12 33,815,406 16,907,703 72.23 12,212,434 
2 33,351,538 16,675,769 82.99 13,839,221 
3 44,932,312 22,466,156 80.65 18,118,955 
4 36,214,556 18,107,278 81.18 14,699,489 
5 32,308,526 16,154,263 82.23 13,283,651 
6 92,627,492 46,313,746 82.54 38,227,366 
7 32,164,458 16,082,229 84.33 13,562,144 
8 34,046,988 17,023,494 82.39 14,025,657 
9 31,728,064 15,864,032 82.46 13,081,481 
22 50,920,756 25,460,378 62.05 15,798,165 
23 41,267,446 20,633,723 79.62 16,428,571 
24 56,045,870 28,022,935 86.38 24,206,212 
13 42,720,916 21,360,458 85.89 18,346,498 
14 33,283,220 16,641,610 86.04 14,318,442 
15 28,453,606 14,226,803 81.93 11,656,020 
16 34,283,956 17,141,978 84.6 14,502,114 
17 35,710,624 17,855,312 77.65 13,864,650 
19 33,464,362 16,732,181 86.21 14,424,814 
20 29,907,096 14,953,548 83.44 12,477,241 
 Table 7. Summary of the reads alignment to the human genome (hg19) for each sample.  
 
Among them, 11390 genes were expressed (defined, for the purpose of this 
study, as those having more than 10 reads per group) both in cells from FRX 
patients and in cells from OA patients, whereas 496 genes were expressed only 
in FRX and 1695 in OA. The average number of reads was similar in FRX and 
OA and both groups were comparable regarding the expression of 4 






AltAnalyze analysis pipeline incorporates a program (lineage profiler) that 
calculates lineage correlation (Z-scores) of the samples subjected to 
transcriptome analysis in terms of different tissues 194. This tool showed that the 
expression signature of our samples was typical for hMSCs, as expected (Table 
8).  
 
 FRX OA 
Bone Marrow Mesenchymal Stem Cells 2.42 2.02 
Osteoblasts 2.41 2.11 
Adipocyte Progenitor 2.65 2.10 
Bone Marrow Stem Cells 3.16 2.70 
Astrocytes 2.00 1.54 
Aorta Smooth Muscle Cells 2.23 1.64 
Myoblast 1.19 0.93 
Fibroblasts 1.35 1.00 
Neural Crest Mesenchymal Stem Cells 1.20 0.71 
Table 8. Lineage correlations (Z-scores) of the cells subjected to transcriptome analysis.  
 
Differential gene expression analysis with both, AltAnalyze and EdgeR 
softwares181,194, revealed 338 differentially expressed genes (defined as 
FDR<0.10 and fold change>2). Among them, 99 genes were upregulated, 
whereas 239 were downregulated in FRX (Figure 20 and Appendix 1). 
 
Figure 20. Volcano plot of differential gene expression analysis in BMSCs grown from patients 
with fractures (FRX) and controls with osteoarthritis (OA). Significant genes are those with an 







These genes were subjected to Gene ontology and pathways analysis and we 
observed that upregulated genes in FRX were enriched in hMSCs differentiation 
and bone formation processes, whereas genes that were downregulated in FRX 
are enriched principally in immune related pathways (Table 9)165.  
Upregulated genes  Downregulated genes  
GO: Biological process AdjP GO: Biological process AdjP 
Anatomical structure 
morphogenesis        
1.9E-03 
Immune system process        
1.7E-08 
Angiogenesis        
3.0E-03 
Complement activation, 
classical pathway        
5.0E-08 
Skeletal system 
development        
4.0E-03 
Innate immune response        
5.0E-08 
Anatomical structure 
development        
6.1E-03 
Defense response        
9.1E-08 
C21-stero hormone 
biosynthetic process        
6.1E-03 
Regulation of immune 
system process        
9.9E-08 
Organophosphate catabolic 
process        
8.2E-03 
Response to stimulus        
1.5E-07 
Bone remodeling        
8.2E-03 
Regulation of immune 
response        
2.5E-07 
Negative regulation of 
glucocorticoid biosynthetic 
process        
8.2E-03 
Complement activation        
2.5E-07 
Regulation of bone 
mineralization        8.2E-03 
Humoral immune response 
mediated by circulating 
immunoglobulin        
3.2E-07 
Biomineral tissue development 
8.2E-03 
Leukocyte mediated 
immunity        
3.3E-07 
Table 9. Top ten pathways after enrichment analysis of differentially up- and down-regulated 
genes in FRX. Overrepresentation enrichment analysis was implemented with webgestalt 
software on wikipathways database.  
 
We, then, compared those differentially expressed genes (338 genes) with the 
genes previously found associated with differentially methylated enhancers (1400 
genes). Association between up- or down-expression and hyper- or hypo-
methylation was variable, but there was a trend for an inverse correlation between 
enhancer methylation and the associated gene expression (Appendix 2). In 
Figure 21 we can see that 18 upregulated genes in FRX had 8 hypermethylated 
enhancers and 10 had hypomethylated enhancers, whereas 54 downregulated 
genes had 39 hypermethylated and 15 hypomethylated enhancer regions, all in 







Figure 21. Relationship between DNA methylation and gene expression signatures. Venn 
diagram summarizing the association between differential DNA methylation and differential gene 
expression (comparisons of BMSCs from fractures over BMSCs from controls). As shown, 
enhancers for the same gene with differential DNA methylation may have both changes 
(Hypermethylation and hypomethylation). 
 
ArrayTrack is a bioinformatic tool with multiple possibilities in microarray data 
analysis 183. This tool has the option to analyze common pathways between two 
sets of differentially expressed genes, or, in general, any two sets of genes. We 
hypothesized that pathways that are common to differentially expressed genes 
and differentially methylated enhancers are more likely to be true disease-related 
pathways than other pathways present in just one of those gene lists. By using 
ArrayTrack software, Gene Ontology Enrichment analysis revealed that genes 
with hypomethylated enhancers and upregulated gene expression in FRX are 
enriched in bone related pathways, such as positive regulation of mesenchymal 
cell proliferation, endochondral bone morphogenesis or regulation of bone 
mineralization, as well as some neuron-related pathways (Figure 22A). The three 
other combinations of up- or down-expressed and methylated genes did not 
highlight bone-related pathways, excepting the case of genes with 
hypermethylated enhancers and overexpressed genes in FRX (Figure 22), but 






Figure 22. Relationship between DNA methylation and gene expression signatures. Pathways 
enrichment analysis of genes with differentially methylated enhancers and differentially expressed 
genes, in BMSCs from fractures over BMSCs from controls. All possible combinations are shown. 
(A) Hypomethylated enhancers with overexpressed genes. (B) Hypermethylated enhancers with 
underexpressed genes. (C) Hypermethylated enhancers with over expressed genes. (D) 






DNA methylation and gene expression replication 
After all the above bioinformatic data analysis, we chose some candidates to 
replicate the results of both DNA methylation and gene expression obtained with 
the methylation array and RNAseq procedures, by pyrosequencing and RT-
qPCR, respectively. 
 
Figure 23. Scatter plots showing the correlation of DNA methylation (Beta values) and gene 
expression (FPKM) levels for some representative genes, which have been found to have 
differential expression and DNA methylation patterns when comparing BMSCs isolated from 
patients with FRX (circles) and patients with OA (triangles). Equations shown are calculated with 
a linear regression analysis.  
 
For replication, we selected 10 differentially expressed genes with differentially 











(OPG), ID2, IGFBP4, LASP2 and UNC5B. The inverse correlation between DNA 
methylation and the expression of several genes is shown in Figure 23. 
For the validation of gene expression by RT-qPCR, we used 8 samples previously 
analyzed by RNAseq (4 FRX and 4 OA) and 19 additional samples (9 FRX and 
10 OA), also obtained in our lab with the same procedures. Among the 10 genes 
studied, the results were replicated (i.e., differential expression) in 4, considering 
p<0.05 between sample groups and differences in gene expression in the same 
direction as in RNAseq. Specifically, 3 genes (LOXL2, ID2 and OPG) were 
replicated in the technical validation (8 samples), 2 genes (ID2 and UNC5B) 
considering all ‘new’ samples, and 4 genes (LOXL2, ID2, OPG and UNC5B) when 
the results of both sample groups were analyzed.   
We then designed primers to replicate the differential methylation of enhancers 
associated with those 4 genes by pyrosequencing. The following CpG sites were 
explored: CpG 22489510 (ID2); CpG 26711508 (OPG); CpG 02675344 (UNC5B) 
and CpG 24911388 (LOXL2). We used a total of 24 samples (12 FRX and 12 
OA) for technical replication, therefore all of them were previously used in our 
450k array. The results showed similar average methylation (% values) with array 
and pyrosequencing in OPG (57.6±11.2 and 47.6±9.4, respectively), ID2 
(68.9±15.9 and 75.1±14.3, respectively) and UNC5B (45.8±17.6 and 48.1±13.6, 
respectively). However, for LOXL2 the values obtained with both techniques were 
rather different (80.6±10.5 and 48.8±11.9, respectively) (Figure 24A). 
Nevertheless, the methylation differences between both groups (FRX and OA) 
previously found with the methylation array were replicated by pyrosequencing 







Figure 24. A) Box plot with the DNA methylation levels from the array and pyrosequencing (Pyr) 
of the replicated genes (ID2, LOXL2, UNC5B and OPG). B) Box plot comparing DNA methylation 
levels measured by pyrosequencing in BMSCs derived from fractures (FRX) and controls with 








Figure 24. C) Scatter plots showing the DNA methylation levels correlation between array values 
and pyrosequencing values. Correlation is tested with generalized linear model (linear regression 
analysis). 
 
Once we confirmed that those 4 genes were differentially methylated and 
expressed in BMSCs obtained from patients with FRX and OA, we explored their 
relevance for osteogenic differentiation. 
For these experiments, we used BMSCs grown from 17 patients (8 FRX and 9 
OA), which gene expression patterns were analyzed at baseline and after 21 days 
of osteogenic differentiation in vitro. Pairwise comparisons revealed statistically 
significant differences between pre-differentiated samples and post-differentiated 
samples in ID2, UNC5B and LOXL2 genes (p=0.0346, 0.0063 and 0.0033, 







Figure 25. Box plots showing gene expression levels (deltaCt) of BMSCs in the basal state (white 
boxes) and after 21 days of osteogenic differentiation in vitro (gray boxes). Each point 
corresponds to a sample, which is linked by the line with its pair after differentiation.  
 
Osteogenic capacity of BMSCs 
In parallel experiments, we used RT-qPCR to study the expression of some 
genes typical of the osteoblastic lineage, including RUNX2, OSX, ALPL, SPP1, 
BGLAP, COL1A1 and IBSP. These experiments showed that OSX and BGLAP 
were significantly more expressed in FRX than in OA (p=0.024 and 0.002, 
respectively). Whereas ALPL and SPP1 were significantly more expressed in OA 
than in FRX (p=0.046 and 0.016, respectively). Collagen expression was similar 
in both groups and in the case of adipogenic markers, PPARG was significantly 






Figure 26. A) Bar plots showing the relative expression of some specific osteogenic and 
adipogenic markers by BMSCs from patients with fractures (FRX) and osteoarthritis (OA). B) LPL 
and PPARG genes in both groups of BMSCs (FRX and OA). T test is used for the statistical 
differences.  
 
BMSCs from FRX and OA were differentiated into osteoblasts in vitro, and both 
had the capacity to respond to the osteogenic induction. However, there were 
some significant differences, because the capacity to form a mineralized matrix 
was markedly decreased in BMSCs from FRX (p=0.00015), as shown by alizarin 
red staining (Figure 27A). Additionally, alkaline phosphatase activity was also 
lower in BMSCs from FRX than in those from OA (Figure 27B), and there was a 
positive correlation between matrix mineralization and alkaline phosphatase 
activity (Spearman's r=0.84, p<0.001). Surprisingly, OSX and RUNX2 expression 
tended to be higher in BMSCs isolated from patients with osteoporosis (p=0.34 






Figure 27. Differentiation capacity of BMSCs. (A) Osteogenic differentiation evaluation after 
alizarin red staining of BMSCs from patients with fractures (FRX) and with osteoarthritis (OA), 
semiquantitative analysis by double blind test. (B) Alkaline phosphatase activity in these BMSC 
maintained in osteogenic medium. 
 
Functional experiments with ID2 inhibition 
From our results and also some data in the literature, ID2 seemed to be 
associated with the osteogenic differentiation of BMSCs 195. Hence, we used 
some siRNA sequences to inhibit ID2 expression in our BMSCs. 
 
Figure 28. Relative gene expression levels of genes ID2 (squares), ALPL (triangles) and COL1A1 
(circles) in BMSCs with osteogenic differentiation media. Levels are measured in the days 1, 8, 
15 and 22 after inhibition by siRNA ID2 transfection. They correspond to the basal day and the 
days 7, 14 and 21 after osteogenic differentiation. ΔΔCt is calculated from the differences between 
ΔCt of the samples inhibited with siRNA ID2 and with those transfections with a scramble 
sequence (negative controls). Each ΔCt corresponds to the normalization of the expression with 






We found significant difficulties in transfecting BMSCs, nevertheless we obtained 
some inhibition of ID2 expression. We did not find significant effects on the 
expression of the osteogenic markers COL1A1 and ALPL, neither at baseline nor 
during osteogenic differentiation in vitro. Moreover, we did not observe 
differences in ID2 gene expression before and after osteogenic differentiation of 
BMSCs in vitro (Paired t test; n=17; p=0.0968) (data not shown).  
 
Expression of long non-coding RNAs 
Since ncRNAs are increasingly recognized as important factors in the regulation 
of cell differentiation, we next focused our attention on the non-coding regions of 
the genome. Specifically, the aim of this analysis was to determine the expression 
of lncRNAs in MSCs from patients with FRX or OA and its relation with DNA 
methylation marks and the expression of protein-coding genes.  
DNA methylation analysis showed that the frequency of differentially methylated 
CpG sites (FDR<0.05 and Beta differences >0.1) was similar in non-protein 
coding transcribed regions (946 out of 53084; 1.8%) and in other genomic regions 
(8092 out of 424625; 1.9%).  
Transcriptome analysis using different softwares (EdgeR and DESeq2) showed 
118 non-protein coding genes from 234 total genes differential expressed 
(FDR<0.05; FC>2) with EdgeR software; And 59 non-protein coding genes of a 
total of 140 genes differentially expressed with DESeq2 software. The 
implemented softwares are different as those used in the previous analyses 
(EdgeR and AltAnalyze) because they are using distinct normalization statistical 
methods and they usually have diverse results. This is important to elucidate a 
greater number of possible target genes. 
Among differentially expressed ncRNAs, most of them belonged to the antisense 
type (72%), followed by lincRNAs and sense overlapping lncRNAs. Antisense 
lncRNAs tend to regulate neighboring protein-coding genes (cis regulation). Our 
data are in line with this concept. In fact, approximately 50% of the protein-coding 
genes in cis position of differentially expressed antisense lncRNAs were also 
differentially expressed. Furthermore, enrichment analysis of these associated 
lncRNAs-protein coding genes pairs showed significant overrepresentation in 







Figure 29. Gene ontology (GO) enrichment analysis (biological processes), of those protein 
coding genes linked to differentially expressed antisense lncRNAs of BMSCs derived from FRX 
and controls with OA. Coloured in blue, various interesting bone related processes. FDR=0.05 is 
marked by the red dashed line. 
 
Replication of RNA sequencing  
Given the importance of the noncoding gene expression, we aimed to increase 
our sample size and performed another RNA sequencing experiment including a 
new independent set of BMSC RNAs. Specifically, we analyzed 16 pre-
differentiated samples (8 FRX, 8 OA), as well as 3 post-differentiated samples 
(paired with predifferentiated ones), maintained in osteogenic culture medium for 
three weeks.  
Since RNA sequencing had been performed by two different external companies, 
we re-analyzed the raw data in house to be able to apply equivalent analysis 
procedures to both datasets. 
Before differential gene expression analysis, we performed several quality control 
procedures. Fastq files were checked for their quality on raw sequences data with 
FastQC tool, and all of them passed. Sequences were aligned using the Human 





cufflinks programs were implemented to assemble all transcriptomes and 
quantify their expression. 
Differential gene expression analysis was performed, similarly to the previous 
analysis, with DESeq2, EdgeR and CuffDiff softwares. Before the final analysis, 
additional quality control tests were implemented to detect possible outliers. First, 
the square of the coefficient of variation (CV2) was used to evaluate the quality of 
RNA-seq. The differences in CV2 may result in a low number of differentially 
expressed genes due to a high degree of variability among the FPKMs of the 
estimated replicates. Quite reassuringly, we did not find significant differences 
(Figure 30A).  
Also, we built a dendrogram using all genes to identify samples that were 
separated from the group of origin. We found two samples (1 FRX and 1 OA) 
grouped apart (Figure 30B, marked in red). Next, we implemented dimensional 
reduction, which is a method that serves to cluster samples and explore the 
relationship between conditions. It can be used to identify variability in the data. 
We applied multidimensional scaling (MDS) strategy and found the same two 
samples in apparently different clusters (surrounded in red Figure 30C).  
RNAseq data sometimes contain very large counts that are not related to the 
experimental or study design, and that can be considered outliers. They may 
result from technical or experimental artifacts, mapping problems, and rare 
biological events. We made a box plot of Cook's distances to see if some samples 
were consistently higher than others, and found that the same samples 
considered as potential outliers in the dendrogram and multidimensional scaling 
had a higher cook’s distance (Figure 30D). Hence, we discarded those two 
samples for the differential expression analysis and compared the results with 
and without them. Nevertheless, the results were very similar, suggesting that the 






Figure 30. Various quality tests of the sequenced and aligned samples. (A) The square of the 
coefficient of variation (CV2) of both BMSCs groups (FRX in red and OA in blue). (B) Dendrogram 
using all genes, grouping the samples by hierarchical clustering. Two samples are separated from 
the principal group, surrounded in red. (C) Multidimensional scaling (MDS) test for all samples 
with the same two samples in apparently different clusters (surrounded in red). (D) Box plot 
showing Cook's distances and surrounded in red, both samples surrounded in (B) and (C), with 
consistently higher distances than others. 
 
Replication of transcription analysis and signature of osteogenic 
differentiation 
We found 85 differentially expressed genes when comparing pre-differentiated 
samples, from which 33 were lncRNA type, and relate them with those previously 
obtained in the prior RNAseq. Concerning the three paired samples, pre- and 
post-differentiated, there were 163 genes differentially expressed, from which 99 
were lncRNA type.  
We used the intersected genes (n=53) for further analysis, from which 21 were 
lncRNAs and 32 were protein-coding genes. The intersection group included 





predifferentiated BMSCs from FRX and OA, as well as the group of genes 
differentially expressed between pre- and post-differentiated samples. With this 
intersected gene list we built a Spearman correlation matrix between lncRNAs 
and protein-coding genes (Figure 31). 
 
Figure 31. Correlation plot with lncRNA gene type in the columns and protein coding genes in the 
rows. The size of the circles is proportional to the correlation value (the larger, the higher is the 
value). Coloured in red are the negative correlation coefficients and in blue the positive correlation 
coefficients. 
 
In the following table we show the 21 differentially expressed lncRNAs from the 
intersection analysis explained above, and the cis-associated protein-coding 







GENE logFC FDR Cis.genes 
AL121963.1 -2.88 4.48E-13 COL10A1 
AL645608.1 2.80 3.59E-02 SAMD11 
AP001610.5 -4.50 3.77E-25 MX1 
C7orf49 -1.78 3.30E-03 TMEM140 
CHL1-AS1 2.87 2.37E-04 CHL1 
CTB-51J22.1 -3.70 4.98E-07 ELN 
HCG4P11 -1.50 3.59E-02 HLA-F 
MAMDC2-AS1 -2.74 1.98E-03 MAMDC2 
NCAM1-AS1 -3.53 6.53E-06 NCAM1 
PAPPA-AS1 1.09 7.61E-02 PAPPA 
RP1-71H24.1 -4.27 1.59E-19 OAS1;OAS3 
RP11-1143G9.4 5.10 1.26E-26 LYZ 
RP11-152K4.2 2.36 4.31E-02 CDH6 
RP11-262H14.4 5.83 8.99E-03 Intergenic 
RP11-465L10.10 1.76 8.16E-03 SLC12A5;MMP9 
RP11-519G16.5 -3.29 4.45E-09 C15ORF48 
RP11-69E11.4 -2.84 2.96E-03 BMP8A 
RP3-329A5.8 4.56 4.39E-02 SCUBE3 
SMC5-AS1 -3.05 2.75E-03 MAMDC2 
WTAPP1 -4.68 2.71E-12 MMP1&3 
ZNRD1-AS1 -1.27 2.01E-02 ZNRD1 
Table 10. List of differentially expressed lncRNAs which are common in all performed analysis. 
Predifferentiated samples analysis with FRX and OA, and an analysis with paired pre- and post-
differentiated samples. The fourth column shows the nearest protein coding gene associated to 
each lncRNA. 
 
We used those results to try to select candidates for further replication and 
functional studies. The selection was based upon the following criteria: 
 Candidates show gene expression differences between FRX and OA. 
 Candidates show expression differences between pre- and post-
differentiated samples. 
 The associated protein coding genes (ie, genes in the nearest –cis-
position; or highly correlated in the correlation matrix), are preferentially 
bone-related.  





According to those criteria, we chose two antisense lncRNAs as candidates, 
PAPPA-AS1 and CTB-51J22.1: 
 PAPPA-AS1 was more expressed in OA than in FRX, but there was 
considerable individual variability. In both groups It was expressed more 
abundantly in pre-differentiated MSCs than in post-differentiated cells, 
thus, it is downregulated when MSCs undergo osteogenic differentiation 
(Figure 32A). The PAPPA gene (its antisense protein-encoding gene) is a   
involved in the development of the skeleton. KO mice not expressing 
PAPPA show smaller skeleton and delayed ossification.  
 CTB-51J22.1 was less expressed in FRX than in OA, and was also less 
abundant in differentiated than in pre-differentiated MSCs, although the 
difference was very small in the FRX group (Figure 32B). Elastin (ELN) is 
its antisense protein-coding gene. KO mice for the ELN gene have 
abnormal epiphysis, but the most common affections are those of the 
cardiovascular system. 
Given the relatively small differences in gene expression between FRX and OA 
and the large variability, we decided to select other additional lncRNAs that 
showed marked pre-/ post-differentiation differences. Thus, we chose four more 
lncRNAs to replicate: LINC00341, LINC02008, LINC01279 and PTGS2-AS. 
 LINC00341 is a non-coding long intergenic RNA in the 3'UTR position of 
the SYNE3 gene and 5'UTR of the calmin gene (CLMN). It was similarly 
expressed (very low expression) in FRX and OA, but markedly increased 
in differentiated cells (Figure 32C). In addition, with the BLAT tool for 
alignment on the genome, certain regions are found in common with 
certain coding genes, such as LTBP2, that is involved in bone 
development. 
 LINC02008 is an intergenic long non-coding RNA found in the 5'UTR 
position of GBE1 gene. It was not expressed in the pre-differentiated 
samples, but increased after differentiation (Figure 32D). 
 LINC01279 is a long non-coding intergenic RNA that is located between 
the coding genes CCDC80 and SLC35A5. It is more expressed in pre-





osteogenic differentiation. There were no differences between fractures 
and osteoarthritis (Figure 32E). 
PTGS2-AS is also known as PTGS2 Antisense NFKB1 Complex-Mediated 
Expression Regulator RNA, or P50-Associated COX-2 Extragenic RNA 
(PACERR). It was downregulated after osteogenic differentiation and there were 
not significant differences between FRX and OA (Figure 32F).  
 
Figure 32. Gene expression levels of the selected lncRNA from the RNA sequencing normalized 
data (FPKM), distinguishing between FRX and OA in the basal state (white boxes) and 
differentiated samples after 21 days of osteogenic induction (gray boxes).  
 
Long Non-coding RNA replication and functional studies. 
We replicated the gene expression of the chosen lncRNAs by real time qPCR 
with sybr green and primers, previously designed (Table 4). In all cases 





The expression was validated for two lncRNAs, LINC00341 and PACERR (Figure 
33). 
 
Figure 33. Replication of the gene expression of LINC00341 (on the left) and PACERR (on the 
right) by real time PCR. Comparing BMSCs in the basal state (white boxes) with differentiated 
BMSCs (gray boxes). For the statistical analysis, T test has been used. ΔCt are calculated from 
the difference between Ct of the lncRNAs genes and Ct from the reference genes (GAPDH and 
TBP) 
 
Both lncRNAs are outside protein coding genes, PACERR is upstream head to 
head with the protein coding gene and LINC00341 is intergenic. However, the 
rest of experimented lncRNAs were not replicated by qPCR. As we saw before 
the major part of differentially expressed lncRNA are antisense type, which are 
within the protein coding sequence, and this is the case of PAPPA-AS and CTB-
51J22.1. For distinguishing their transcription from those of the associated protein 
coding gene, we had to use different reverse transcription strategies. In theory, if 
we used random hexamers and oligodT as primers to anneal RNA, we obtained 
cDNA of the complete transcriptome, and in this case it does not permit to study 
the coding and the non-coding fragments independently. Therefore, we had to 
use strand specific reverse transcription with the corresponding primer for each 
strand. Besides, we also used a reverse transcription without primers (only 
enzyme) as a negative control. But, somewhat unexpectedly in all these reverse 
transcriptions we obtained sequence amplicons by qPCR. This fact meant that 
we could not discriminate between both strands in the reverse transcription 






Figure 34. Study of the antisense lncRNA region by real time PCR, using four different reverse 
transcription reactions (graphical scheme on the right). On the left, expression levels after reverse 
transcription theoretically distinguishing both strands of two different antisense lncRNAs. ΔCt are 
calculated from the difference between Ct of the antisense genes and Ct from the reference genes 
(GAPDH and TBP). 
 
Finally, we focused on and the two replicated lncRNAs (LINC00341 and 
PACERR) by real time qPCR experiments to confirm the biological role of those 
genes in bone formation. The strategy used was to transfect expression vectors   
into human cell lines (HOS and HEK-293T) and BMSCs, and subsequently 
studying expression changes in genes centrally involved in bone formation 
(COL1A1 and ALPL). LINC00341 overexpression in HOS cell line induced an 
increase in the bone-related markers (Figure 35A). This effect appeared to be 
specific for cells of the osteoblastic lineage, because in HEK-293T cells these 
changes were not clear (Figure 35C). On the other hand, when PACERR was 
overexpressed, we did not find consistent changes in either COL1A1 or ALPL, 






Figure 35. Gene expression changes after transfection analysis in different cell lines (HOS and 
HEK-293T) with LINC00341 and PACERR expression vectors, at different times (24, 48 and 72 
hours). ΔCt are calculated from the difference between the Ct of the lncRNAs and the reference 
genes (GAPDH and RPL13A). ΔΔCt refers to the comparison with empty vector transfection (ΔCt 
lncRNA vector – ΔCt empty vector). ALPL relative expression is marked with a black triangle. 
COL1A1 (in HOS cells) and COX2 (in HEK-293T cells) are shown with a black circle. Respective 
LINC00341 or PACERR overexpression is reflected with a box with a ‘X’ in inside. (A) Transfection 
of LINC00341 expression vector into HOS cells. (B) Transfection of PACERR expression vector 
into HOS cells. (C) Transfection of LINC00341 expression vector into HEK-293T cells. (D) 
Transfection of PACERR expression vector into HEK-293T cells. 
 
We also tried to transfect BMSCs with both expression vectors (LINC00341 and 
PACERR), independently. Indeed, we tried different methods for transfection, 
including several lipid-based reagents and electroporation. However, the 
transfection efficiency was very low and consequently we could not confirm or 






Figure 36. Gene expression levels of genes COL1A1 (circles), ALPL (triangles) and the 
experimentally overexpressed gene, PACERR or LINC00341 (squares) in BMSCs. Levels are 
measured after overexpression of LINC00341 (left) or PACERR (right) vector transfection. 
Relative gene expression compares those transfected wells with our genes of interest with those 
transfections with an empty vector (negative controls). ΔCt are calculated from the difference 
between the Ct of the lncRNAs and the reference genes (GAPDH and RPL13A). ΔΔCt refers to 



























Osteoporosis as a prevalent complex disorder 
Osteoporosis is a prevalent bone disorder characterized by low bone mineral 
density due to an imbalance in the bone remodelling process. This imbalance 
consists in a predominance in the osteoclastic activity over the osteoblastic one, 
which leads to bone loss. Genetic studies have confirmed that osteoporosis is a 
complex disease with a polygenic pattern of inheritance in which several genes 
are involved, as well as environmental factors, such as nutrition, physical activity, 
aging, hormone functions and exposure to various substances, like alcohol, 
tobacco or some medicines 49,196. Osteoporosis is very common in elderly people, 
with a higher frequency in postmenopausal women than in premenopausal 
women or in men. Bone remodelling regulation mechanisms are remarkably 
complex and include a series of specific gene expression changes that lead to 
cell differentiation along specific pathways, thus allowing specialized cell 
activities.  
Osteoporosis is characterized by an insufficient bone formation, either in absolute 
terms (low turnover osteoporosis), or in relation to the degree of bone resorption 
(high turnover osteoporosis). Bone Marrow Mesenchymal stem cells (BMSCs) 
are pre-osteogenic cells, and have the capacity to differentiate into osteoblasts, 
the bone forming cells. This thesis focuses on the transcriptional and epigenetic 
signatures of BMSCs from osteoporotic patients. 
 
MSCs and aging  
MSCs can differentiate into a variety of cell types, including adipocytes, 
osteoblasts, chondroblasts and myocytes. Recently, it has been identified a 
subpopulation of self-renewing and multipotent MSC that generates progenitors 
of osteoblasts and chondrocytes and stroma, but not fat, and has been termed 
“skeletal stem cells” 41. Osteoblasts are responsible for bone formation. Hence, 
bone formation deficiency in aging individuals may be caused by age-related 
changes in the migration, proliferation and differentiation capacity of MSCs. 
Indeed, several studies suggest that the pool size and function of MSCs 
diminishes with aging 197. BMSCs represent only a minor fraction of the marrow 





to be even smaller in aged subjects 199. MSCs from old individuals appear to have 
reduced proliferative capacity, with longer doubling times, increased senescence 
and apoptosis and reduced number of duplication cycles 200. Also, an aging-
associated reduced capacity of BMSCs to differentiate into osteoblasts, along a 
preferential differentiation towards adipocytes has been reported 201–203. For 
example, Mueller et al found a decline in the differentiation potential of BMSCs 
from individuals over 60 years of age, in comparison with those below 50. The 
mechanisms involved may be multiple, including DNA damage, telomere 
shortening, epigenetic abnormalities, oxidative stress, etc. 43. However, this is by 
no means a fully elucidated question 204. For example, the group of Stenderup et 
al found that MSCs from old individuals have an accelerated aging when cultured 
in vitro, but they maintain a normal capacity of proliferation and bone formation in 
vivo 205–207. This suggests that age-associated changes may depend not only on 
cell intrinsic changes, but on changes in the environment where MSCs develop, 
the so-called “stem cell niche”, and a variety of local and systemic humoral factors 
204,208,209. In this line, the role of cell senescence in age-related bone disorders is 
receiving great attention in recent years. Although the absolute number of skeletal 
senescent cells seems to be rather small, even in old individuals, they may 
negatively impact bone homeostasis through the so-called senescence-
associated phenotype (SASP), which includes a number of secreted factors 
impairing the function of neighbor cells 210. Moreover, MSCs from different 
sources may vary regarding age-dependent changes. Thus, Beane et al. reported 
that BMSCs have impaired proliferation, senescence, and chondrogenic 
response in association with aging, whereas muscle-derived stem cells and 
adipose-derived stem cells exhibited no negative effects 211. While age reduced 
overall cell yield and adipogenic potential of all MSC populations, osteogenesis 
and clonogenicity remained unchanged. 
 
MSCs and osteoporosis 
Several investigators have explored MSC function in osteoporosis. Thus, it has 
been reported that BMSCs from postmenopausal women with osteoporosis have 
a reduced capacity to proliferate and differentiate into osteoblasts, with less 





after osteogenic induction in vitro 212–214. However, such a deficiency has not 
been confirmed in other studies 205. 
In some studies, the impaired differentiation towards an osteoblastic phenotype 
has been accompanied by a parallel increase in the differentiation towards an 
adipocytic phenotype, which might be related to the increase in marrow fat 
frequently observed with aging and osteoporosis 215.  
It is to note that MSCs are present in the bone marrow (BMSCs), but they may 
also be present in the circulation, at least in some circumstances. The number of 
osteogenic circulating precursors has been reported to decrease with aging, 
particularly among frailty subjects 216, but a number of methodological issues limit 
the validity of those studies. In fact, some investigators could not demonstrate the 
presence of bona-fide circulating MSCs in normal conditions, although they did 
in patients with hip fractures or extensive tissue injury and multiple fractures 
217,218. 
Mesenchymal stem cell migration is an essential step for endochondral or 
intramembranous ossification during skeletal development, as well as for fracture 
healing 219. The role of circulating MSCs in diffuse bone disorders such as 
osteoporosis is less clear, but homing of these cells to remodelled areas is of 
course critical for proper bone formation. Likewise, homing of MSCs to damaged 
bone areas is a crucial step when systemic infusion of MSCs is planned for 
regenerative purposes. Thus, new strategies are being applied to enhance MSCs 
migration to bone tissue (osteotropism), so that they can be infused 
systematically to heal generalized bone diseases, such us osteoporosis, as well 
as localized bone defects. In this regard, it is particularly interesting the approach 
by Sackstein and collaborators, who modified the glycosylation pattern of CD44 
ligand to convert it into the so-called hematopoietic cell E-/L-selectin ligand 
(HCELL), which can bind to expressed E-selectin in bone marrow endothelial 
cells, thus increasing osteotropism 220,221.  
Cell differentiation is regulated by biological, physical and environmental 
chemical factors. The biological factors include transcription factors, their 
signalling pathways and miRNAs. Physical or chemical factors include 
mechanical stimulation, radiation or diet among others 222–226. Transcription 
factors CEBP and PPARG appears to be critical for adipocyte differentiation 227, 





In this regard, it is interesting a recent study by Rauch et al showing that BMSCs 
are relatively predisposed to differentiate towards the osteoblastic phenotype, so 
that osteogenesis involves activation of pre-established enhancer, whereas 
adipogenesis is driven by more profound changes of the chromatin and de novo 
activation of enhancers 229. This study is in line with previous observations about 
the tendency of MSCs cultured in vitro to spontaneously differentiate towards an 
osteoblastic phenotype 230. 
We analysed BMSCs derived from the femoral head of patients with osteoporotic 
fractures and controls with osteoarthritis. BMSCs of patients with fractures 
showed higher proliferation rate, which in theory is an attractive feature if these 
cells are to be used for regenerative therapy. This was a somewhat unexpected 
finding. Since BMSCs were obtained from fracture patients, it could be speculated 
that it was a phenomenon related to the response to bone injury. We avoided the 
fractured bone edges, yet a regional or even systemic effect of fracture cannot 
be avoided. In fact, studies suggest that BMSCs are activated and mobilized 
following tissue injury 218,230.  
Despite their higher proliferation rate, BMSCs from patients with fractures 
presented a diminished ability to express some bone makers, such as alkaline 
phosphatase, and to deposit a mineralized extracellular matrix. The mechanisms 
involved are unclear but might be related to an upregulation of the RUNX2 
pathway. In fact, we quantified the expression of several genes by qPCR, and 
observed that the osteogenic transcription master regulators RUNX2 and OSX 
were upregulated in BMSCs from fracture patients. These two transcription 
master regulators target other genes, usually related with osteoblastic phenotype, 
including BGLAP and IBSP and indeed both were also upregulated in fractures. 
However, late-stage genes of the osteogenic process, such as, ALPL and SPP1, 
were downregulated in BMSCs from patients with osteoporosis. This fact could 
be connected with their reduced capacity to differentiate in vitro and form 
mineralized matrix, and maybe due to the tenacious expression of RUNX2. This 
is a critical factor for BMSCs commitment towards osteoblastogenesis, but 
persistent activation may impair the terminal differentiation of osteoblasts 231.    
Thus, in the presence of high proliferation rate but reduced terminal differentiation 
in vitro, it is unclear whether the overall consequence is a preserved bone 





currently ongoing in our laboratory may help solving this issue. It is to note that, 
as expected by their different epidemiology, there was an age imbalance between 
patients with fractures and controls with osteoarthritis. However, it is unlikely that 
it played a role in the observed differences, as we did not find significant age-
related changes in the behaviour of BMSCs, within the age range of the patients 
included in the present study.  
 
Epigenetic marks of MSCs, aging and osteoporosis 
Epigenetic mechanisms are key elements for the gene expression regulation and 
consequently in the regulation of particular cell physiology and cell differentiation 
processes.  
Several studies have explored the role of miRNAs on osteoblastogenesis 79. Most 
miRNAs are negative regulators of osteogenesis and their inhibition is a potential 
therapy to repress their function in bone diseases, including osteoporosis 232. 
Some of this molecules are miRNA-204 and miRNA-211, which bind to RUNX2 
3’-UTR, thereby inhibiting osteogenesis 233. miRNA-103a also inhibits bone 
formation through RUNX2 repression 234. Many more miRNAs have been found 
to regulate bone remodelling, including miRNA-455-3p, -23a, -30c, -34c, -133a,  
-135, -137, -204, -205, -217 and -338-3p 235. 
 
DNA methylation of MSCs, aging and osteoporosis 
Regarding DNA methylation, another important mechanism, Pasumarthy and 
collaborators, observed that BMSCs suffer age-related DNA methylation changes 
associated with gene expression changes. They used BMSCs from young donors 
(20 to 24 years, n=5) and from aged donors (62 to 82 years, n=5) and concluded 
that those changes were frequently found within enhancer regions determined by 
the H3K4me1 histone mark 236. Another study explored the DNA methylation 
profile of BMSCs obtained from individuals from a wide age range (2 to 92 years 
old), and they identified 18,735 hypermethylated CpG sites and 45,407 
hypomethylated sites, associated with aging. The hypermethylated sites were 
enriched in repressive chromatin labels. In addition, hypomethylated CpG sites 
were strongly enriched in the active chromatin brand H3K4me1, related to the 





methylation patterns of BMSCs from young (mean age, 29 years) versus old 
(mean age, 73 years) women. They found significant differences in methylation 
between the young and old subjects surrounding the promoters of 1528 target 
genes that also exhibited significant differences in gene expression 90.  
In our analysis, we have not found any DNA methylation significant differences 
across individuals of different ages. However, as already mentioned, the age 
range was rather limited. Specifically, all subjects were above 60 years of age. 
Therefore, we cannot establish if there are differences in BMSC responses 
between elderly patients and young or middle age subjects.   
DNA methylation levels of specific CpG sites depend on genetic factors, 
environmental factors, and lineage-specific cues, apart from certain random 
variation. Methylation levels also tend to change with aging, and specifically some 
age-related changes are quite universal at some CpG sites. This has led to 
several groups to propose the analysis of those CpG sites as an index of the 
“epigenetic aging” of the individual. There are three main tools for analysing blood 
DNA methylation age. The first one, developed by Hannum and collaborators, 
was built with 450k array data from whole blood of 656 human individuals, ranging 
between 19 and 101 years’ old 238. Another one that has used only blood samples 
is from Weidner and collaborators. They have found three specific age-related 
CpGs and correlated them with chronologic age with an absolute deviation of at 
most 5 years 239. Levine and colleagues have created a software to use DNA 
methylation levels as an epigenetic biomarker of aging phenotypes. The current 
version, called “DNAm PhenoAge” includes a variety of aging-related outcomes, 
all-cause mortality, familiar longevity, socioeconomic status factors, among 
others 240. 
However, the most extensively applied is the method proposed by Steve Horvath. 
Horvath described a set of 353 CpG sites showing age-related changes in a wide 
variety of cells and tissues, which makes this software particularly useful for 
studies of many tissues, not only blood projects 175. There have been many 
studies in recent years, with Horvath’s software. For example, it has been used 
in lymphoma 241, alcohol dependence 242, breast cancer 243, brain tissue in 
Huntington’s disease 244 and cerebellum 245.  
Using Horvath’s software, we have seen that BMSCs isolated from fracture 





controls with osteoarthritis. In theory, we could speculate that such accelerated 
aging could somewhat impair the activity of BMSCs, thus contributing to a 
reduced bone formation. However, in bone tissue there were no differences 
between both groups. This could sound paradoxical, but it is important to note 
that most cells in bone tissue samples are cells of the osteoblastic lineage, and 
specifically osteocytes, not BMSCs. Osteocytes are non-dividing cells with a very 
long lifespan (estimated as 10-20 years). Since changes in methylation may 
occur more rapidly during DNA replication, the methylation of cells in bone tissue 
samples may not reflect the current status of BMSCs and other actively 
proliferating cells. Additionally, osteocytes lifespan is dependent on bone 
turnover. If bone turnover is lower in older patients with osteoporosis, as 
suggested in some studies, osteocytes in patients with fractures may be older 
than those from controls with osteoarthritis of the same age. In other words, when 
current osteocytes were born, patients with fractures were younger than patients 
with osteoarthritis. Nevertheless, for the time being this remains a speculative 
explanation.    
Whatever the real explanation might be, it is important to note that, different from 
genetic features, epigenetic marks vary across tissues. In this line, in a previous 
study in which we collaborated, an accelerated epigenetic aging was observed  
in cartilage cells from patients with osteoarthritis, but not in blood cells 246. 
Additionally, Fernandez-Rebollo and colleagues did not find differences in the 
epigenetic age of blood samples from patients with OP and controls without OP 
247. Similarly, Morris and collaborators that did not find a correlation between DNA 
methylation age in blood and bone mineral density levels 248. Overall, those 
results emphasize that epigenetic marks are not only disease-specific, but also 
tissue-specific.  
DNA methylation is the most studied epigenetic mark, and a huge number of 
studies have demonstrated its important role as a regulator of gene expression 
patterns in multiple tissues. Hence, studying DNA methylation in bone cells in 
normal and pathological conditions may permit to identify new candidate genes 
regulated by these marks, which eventually could be used as new therapeutic 
targets. At the same time, some marks might be helpful for diagnosis and/or 





Other studies have investigated differences in DNA methylation patterns in blood 
samples from patients with osteoporosis versus people without osteoporosis 248. 
However, DNA methylation is a tissue specific mark and diverse studies have not 
found a significant association between blood DNA methylation levels and BMD 
247,248. Thus, blood seems not to be the right tissue to study osteoporosis. 
However, DNA methylation levels in blood of patients with osteoporosis remains 
a controversial issue. Rather surprisingly, in a small study, Cheisvili and 
collaborators found that women at risk of developing osteoporosis can be 
diagnosed by using whole blood DNA methylation analysis 89.  
In a previous study from our lab, we explored genome-wide DNA methylation in 
bone tissue samples using a 27k array. This work used bone samples from 
osteoporotic patients and from osteoarthritic patients as controls, and the  
comparison identified several differentially methylated regions, which were 
enriched in genes associated with skeletal embryogenesis, like homeobox genes, 
indicating the possible existence of a developmental component in osteoporosis 
87.  
In the present study, we looked for DNA methylation differences between BMSCs 
isolated from patients with osteoporosis and controls with osteoarthritis. To our 
knowledge, this is the first epigenome-wide and transcriptome-wide study in 
BMSCs isolated from patients with osteoporosis. There are a few epigenome-
wide studies in osteoporosis in other cell types, such as, bone tissue 87,249 or 
circulating leukocytes 248. 
We explored more than 450000 CpG sites with the lllumina Infinium 450K Human 
Methylation array. We demonstrated that DNA methylation patterns of BMSCs 
isolated from patients with osteoporotic hip fractures and controls showed 
considerable differences at 9038 CpG sites. For the statistical comparison of the 
groups the values considered were an FDR< 0.05 and differences in methylation 
values greater than 10%, as threshold of significance. Those are the standard 
values used for this type of studies. These differentially methylated sites were 
distributed throughout the genome, involving promoter regions (217 regions), 
CpG islands (40 regions), within various gene bodies (129 regions) and enhancer 
regions (1684 regions). Thus, they were enriched in enhancer regions, which are 
commonly associated with the regulation of their genes in cis position. Enhancers 





gene expression; As previously described, DNA methylation marks have been 
shown to vary with aging in enhancer regions. We looked at genes associated to 
the differentially methylated enhancers (approximately 1400 genes) and 
observed that they were enriched among stem cell and bone-related pathways. 
Enhancers regulate the transcription of particular genes, by the action of binding 
proteins (transcription factors) which in turn regulate the transcription process 
through diverse mechanisms. Regarding DNA methylation levels, the most 
common view is that high levels of DNA methylation tend to diminish gene 
expression and vice versa. Nevertheless, we have seen that this relationship is 
certainly variable in enhancer regions, where all four possible combinations of 
DNA methylation and gene expression were observed. Additionally, these data 
suggest that the methylation of regulatory regions, distant from gene bodies, may 
be more important than the methylation of gene bodies in determining cell 
phenotype. 
Recently, a study from Rauch examined the transcriptional and epigenomic 
programming during adipocyte and osteoblast lineage determination of MSCs. 
They observed that during the differentiation of MSCs (independently of the tissue 
of origin), adipogenesis needs changes of a greater number of genes than those 
needed for osteogenesis. They also proved that osteoblast differentiation of 
BMSCs is induced by the concerted action of a subgroup of transcription factors 
(TEAD1, TEAD4, NKX3-1, FLI1, MEF2A, HIF1A and SNAI2), which are already 
active in undifferentiated BMSCs. Further activation of these factors drives 
osteogenesis and blocks adipogenesis. Furthermore, they correlated this gene 
expression changes with enhancer regions defined by DNase I hypersensitive 
sites. Hence, they showed that BMSCs promote osteogenesis by the activation 
of pre-established enhancers, whereas adipogenesis needs the activation of a 
new establishment of enhancers 229. In our dataset, we found some DNA 
methylation changes in 6 of those 8 transcription factors (TEAD1, HIF1A, SNAI2, 
MEF2A, SMAD3 and FLI1). All of them with DNA methylation changes in 
enhancer regions too. However, we did not see gene expression differences in 
these factors (data not shown), so that, both groups (osteoporosis and 






In a hypothesis-free genome-wide approach, using the Infinium methylation array 
and next generation sequencing of the transcriptome, the comparison of BMSCs 
from osteoporotic patients and controls revealed differences in the methylation 
and expression of genes enriched in several pathways related to cell 
differentiation and osteogenesis, thus suggesting that indeed differences in 
methylation marks contributed to differences in BMSC function. Among those 
genes, we chose 10 to replicate by qPCR; 4 of those genes were significantly 
replicated in terms of gene expression (ID2, OPG, SPARC and UNC5B). These 
four genes were also replicated by pyrosequencing, to validate DNA methylation 
results from array. Both techniques, pyrosequencing and qPCR, showed a high 
capacity to replicate DNA methylation values from array and gene expression 
levels from RNAseq, respectively. Some characteristics of these four validated 
genes are explained below. 
 
ID2: DNA-binding protein inhibitor ID2 according to UniProt database 250 is a 
“transcriptional regulator (lacking a basic DNA binding domain) which negatively 
regulates the basic helix-loop-helix (bHLH) transcription factors by forming 
heterodimers and inhibiting their DNA binding and transcriptional activity. It is 
implicated in regulating a variety of cellular processes, including cellular growth, 
senescence, differentiation, apoptosis, angiogenesis, and neoplastic 
transformation. Its role in bone biology is unknown. A study observed that ID2 is 
upregulated by IL-27 in osteoclast precursors, through EGR-2, and this 
upregulation represses RANKL-mediated osteoclastogenesis 251. In our BMSCs, 
ID2 was downregulated in patients with fractures in comparison with those with 
osteoarthritis. Moreover, DNA methylation of the enhancer region associated with 
ID2 was inversely correlated with gene expression, so that the higher the levels 
of DNA methylation, the lower the values of gene transcription. In fact, 
methylation levels of the enhancer region of ID2 were higher in fractures. 
Additionally, we investigated if there were some ID2 gene expression changes 
after culturing BMSCs in osteogenic medium, and we found that ID2 was 
significantly upregulated. Thus, our results and those of the literature suggest that 
ID2 could exert a beneficial effect on bone mass, associated with anti-
osteoclastogenic and pro-osteoblastogenic actions. Unfortunately, our attempts 





whether the increased methylation/reduced expression in BMSCs from patients 
with fractures plays a role in the pathogenesis of bone fragility will need further 
functional studies. 
 
OPG: TNF Receptor Superfamily Member 11b, also known as osteoprotegerin 
(OPG), is a receptor inhibitor normally secreted by osteoblasts and other cells. 
OPG acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its 
function in osteoclastogenesis, inhibits the activation of osteoclasts and promotes 
osteoclast apoptosis in vitro. Thus, bone homeostasis seems to depend on the 
local ratio between TNFSF11 and TNFRSF11B. Because of its important function 
in the bone remodelling process, OPG is a well-studied protein in osteoporosis. 
In a previous study from our lab, Delgado-Calle and collaborators observed that 
the DNA methylation has a repressive influence on the expression of OPG and 
RANKL 166. There is no doubt that the balance OPG/RANKL is important to 
regulate osteoclastogenesis. In fact, in many experimental models, blocking 
RANKL by genetic methods or by the infusion of OPG markedly inhibits 
osteoclastogenesis 22. Also, in this line, denosumab, an anti-RANKL neutralizing 
antibody, is commonly used as an antiosteoporotic drug 252. Several cells in the 
bone microenvironment produce RANKL and OPG. It has been suggested that 
BMSC-produced OPG inhibits osteoclastogenesis in vitro 253. However, its actual 
role in vivo is unknown. In our study, OPG expression was increased in BMSCs 
from fracture patients, which might seem counterintuitive. Additionally, we did not 
see differences between undifferentiated BMSCs and BMSCs differentiated in 
osteogenic medium.    
 
UNC5B: Unc-5 Netrin Receptor B gene is a member of the netrin family of 
receptors. According to RefSeq database 254 “this particular protein mediates the 
repulsive effect of netrin-1 and is a vascular netrin receptor. This encoded protein 
is also in a group of proteins called dependence receptors (DpRs) which are 
involved in pro- and anti-apoptotic processes. Many DpRs are involved in 
embryogenesis and in cancer progression”. Despite its importance in vascular 
functions, netrin-1 and UNC5B axis have been demonstrated to play an important    
role in both, osteoclast and osteoblast biology. In osteoclasts, this axis results in 





UNC5B is expressed is expressed in osteoblasts, and, if it is knocked down in 
combination with other netrin receptors, alkaline phosphatase expression is 
diminished 256. In the case of our BMSCs, UNC5B was upregulated in FRX and 
DNA methylation of its associated enhancer region is significantly 
hypomethylated in FRX. Besides, UNC5B is also significantly upregulated after 
osteogenic differentiation in vitro, which is concordant with literature. Overall, 
these results could be consistent with the concept that UNC5B expression is 
involved in the response of BMSCs to promote osteogenesis after fracture. 
 
LOXL2: Lysyl Oxidase Like 2 gene, is a protein coding gene that according to 
RefSeq “is essential to the biogenesis of connective tissue, encoding an 
extracellular copper-dependent amine oxidase that catalyses the first step in the 
formation of crosslinks in collagens and elastin. A highly conserved amino acid 
sequence at the C-terminus end appears to be sufficient for amine oxidase 
activity, suggesting that each family member may retain this function. The N-
terminus is poorly conserved and may impart additional roles in developmental 
regulation, senescence, tumor suppression, cell growth control, and chemotaxis 
to each member of the family”. LOXL2 is very important for the formation of 
collagen fibers, which are the main component of the osteoblast-secreted bone 
matrix. This gene has been studied in primary mouse calvaria cells during 
osteogenic differentiation, and it is suggested that besides its role in the formation 
of mature collagen fibers, LOXL2 may be an important regulator of osteogenesis 
257. Our transcriptome results showed hypermethylation and decreased 
expression of LOXL2 in BMSCs from fracture patients. Interestingly, LOXL2 was 
downregulated after osteogenic differentiation, which might suggest that this 
gene is necessary for early stages rather than later stages of osteogenic 
differentiation.  
 
MSCs, lncRNAs and osteoporosis 
Accumulating experimental evidence highlights the role of long non-coding RNAs 
(lncRNAs) in bone biology, including osteogenesis. Indeed, in the last decade 
studies in this field have raised exponentially, highlighting the importance of 





and bone. A few studies have explored the role of lncRNAs in osteoblast 
differentiation, but their actual roles remain largely unknown. Some lncRNAs  
promote osteogenesis (H19, MEG3, MODR and MALAT1), whereas other tend 
to inhibit osteogenesis (HOTAIR, DANCR and MIAT) 258,259.  
In our analysis of BMSCs from fracture patients and controls, differentially 
expressed lncRNAs were enriched in the antisense type. Antisense lncRNAs are 
transcribed from the opposite strand (antisense strand), to regulate sense 
transcription. An antisense transcript may act by controlling neighbour protein-
coding genes in the sense strand (cis regulation) or may act on distant genes 
(trans regulation). Recent studies of the tri-dimensional organization of the 
chromatin have shown that DNA looping and organization in topologically 
associating domains (TADs) permit interactions between distant genomic regions 
and their transcripts 79,260. Antisense lncRNAs might also silence the expression 
of its juxtaposed gene, through DNA methylation of the associated CpG island 
261,262.  
We associated the differentially expressed antisense lncRNAs to their cis protein-
coding genes and observed that the majority of them were also significantly 
dysregulated. Moreover, these associations were highly enriched in pathways 
related to bone metabolism. Additionally, we found that differentially methylated 
CpG sites, were similarly distributed between regions corresponding to coding 
and non-coding RNAs, thus suggesting a complex interplay between both 
transcription regulatory mechanisms, DNA methylation and lncRNAs.   
In parallel, we compared pre-differentiated and post-differentiated BMSCs after 
an osteogenic induction, in vitro, for three weeks. This analysis was performed 
with paired pre-post samples. In order to identify candidate lncRNAs potentially 
important in BMSC differentiation and osteoporosis, we compared lncRNAs 
signatures in osteoporosis and controls, as well as in undifferentiated and 
differentiated BMSCs. Then, we chose as potential candidates lncRNAs that a) 
were differentially expressed in fractures and controls; b) were differentially 
expressed following BMSC differentiation; c) were associated to bone-related 
protein coding genes in our own data, in the literature or in knock-out mice and 
other bioinformatic databases 263. Finally, we chose 6 lncRNAs as candidates to 
be taken to further study: 2 antisense type lncRNAs (PAPPA-AS1 and CTB-





lncRNA (PACERR). Since we could not reliably separate the expression of sense 
and anti-sense transcripts by using strand-specific RT-PCR, we finally replicated 
the expression of two lncRNAs (LINC00341 and PACERR).    
Some characteristics of these 2 replicated lncRNAs genes are explained below. 
 
LINC00341: long intergenic non-protein coding RNA 341. It is located in the 
3'UTR position of the SYNE3 gene and 5'UTR of the calmin gene (CLMN). Both 
protein-coding genes are related to the actin binding gene ontology annotation. 
There are just a few studies about LINC00341 in different cell types, including 
endothelial cells 264, vascular smooth muscle cells 265, breast cancer metastasis 
266, bronchial epithelial cells 267 and chondrocytes 268. The functions of this 
lncRNAs are still unclear. Nevertheless, in line with a possible role in bone 
biology, an interesting study found that LINC00341 was coexpressed with the 
transcription factor MEF2C (involved in SOST gene expression) 269. 
In our samples, LINC00341 was similarly expressed (very low expression) in 
undifferentiated BMSCs from fracture patients and controls, but it markedly 
increased in differentiated cells. Overexpressing this gene in human cell lines 
induced a slight increase in the expression of the osteogenic markers ALPL and 
COL1A1. However, to confirm its anabolic role in bone, further studies are 
needed that can demonstrate how knocking down LINC00341 in BMSCs impairs 
osteogenic differentiation. 
 
PTGS2-AS: is also known as PTGS2 Antisense NFKB1 Complex-Mediated 
Expression Regulator RNA, or P50-Associated COX-2 Extragenic RNA 
(PACERR). It consists in a head-to-head antisense (divergent lncRNA), which 
interacts with NFKB1 transcriptional p50 subunit to promote the expression of 
COX-2 in U937 pro-monocytic, human myeloid leukaemia cell line and in U937-
derived macrophages 270. Furthermore, COX-2 may function as an oncogene in 
osteosarcoma. Hence, PACERR promotes the proliferation and metastasis of 
osteosarcoma cells through COX-2 activation 271. Numerous studies suggest that 
COX-2 may have the potential to accelerate the osteogenic differentiation of 
MSCs 272–274. 
However, in our samples, PACERR was downregulated after osteogenic 





controls. After overexpressing this lncRNA in human cell lines (HEK-293T and 
HOS), we did not see any significant change in the expression of COX-2, ALPL 
or COL1A1. Nevertheless, the value of these experiments is limited by the very 
low level of COX-2 expression in the cell lines tested. 
Since we were unable to consistently transfect either expression vectors or 
siRNAs in our primary BMSCs, we could not get definitive evidence for the 
functional roles of these lncRNAs.  
Several studies in the literature have explored lncRNAs expression in relation 
with bone biology and pathophysiology. For example, Wang and collaborators 
studied BMSCs in their basal state and at different days of osteogenic 
differentiation (days 7 and 14) and found that lncRNA KCNQ1OT1 is up-regulated 
during the process of osteogenesis, whereas miRNA-214 is down-regulated. In 
vitro data suggested that KCNQ1OT1 positively regulates osteogenesis by 
regulating BMP2 expression through sponging miRNA-214 275. Another study 
suggested that lncRNA MALAT1 regulates OSX expression through sponging 
miRNA-143 during BMSCs osteogenic differentiation 158. LncRNA MEG3 has 
also been related to osteogenesis, but with controversial results 159,161,276. An 
interesting study by Li et al 277 suggested that lncRNAs Bmncr influences MSCs, 
enhancing commitment towards the osteoblastic linage and reversing the age-
associated switch between osteoblast and adipocyte differentiation. 
We have not found any significant changes in the expression of these lncRNAs, 
nor in other candidate lncRNAs suggested in the literature. Hence, a lack of 
replication in the field is evident. The explanations may be multiple, including 
differences in clinical characteristics of patients, protocols for BMSC isolation and 
culture, other experimental differences, etc. It is to note that single-cell analyses 
show that MSCs are a heterogeneous population showing substantial differences 










Our study has some limitations. Due to practical reasons, we isolated BMSCs 
from patients with fractures and with hip osteoarthritis. So, we used osteoarthritis 
rather than “normal” BMSCs controls. This is certainly a limitation, as in theory 
BMSCs from patients with osteoarthritis may have some disease-related 
features. However, results of studies about gene expression by BMSCs in 
osteoarthritis have been controversial. Normal osteogenesis has been found in 
some studies 279,280, whereas abnormal proliferation and gene expression and 
chondrogenic differentiation have also been reported 281–284. Nevertheless, 
osteoarthritis is mainly a cartilage disease and osteoporosis is a bone disease, 
and several studies have pointed out that osteoarthritis is associated with 
increased bone mineral density (BMD), which is the opposite of osteoporosis 
285,286. It has been suggested that subchondral bone in OA is changing inversely 
to cartilage loss, so to avoid this singularity, we removed the subchondral regions 
before BMSCs isolation. Thus, we thought that osteoarthritis could be regarded 
as feasible, convenient controls for comparison with osteoporotic fractures.  
In addition, as a source of “osteoporotic BMSCs”, we analysed BMSCs from 
patients with hip fractures, also for ethical and feasibility reasons. We tried to 
extract cylinders in the central part of the femoral head, thus avoiding fractured 
areas. However, as discussed above, we cannot exclude that local and systemic 
responses after fracture could exert some influences on BMSCs. In other words, 
any abnormal behaviour of BMSCs in our study could represent changes either 
prior to fracture (ie, osteoporosis-related) or after fracture (ie, related to fracture- 
induced responses). Nevertheless, cells were grown in culture for several weeks 
before the experiments, which may have tempered any fracture-related 
influences.  
On the other hand, culture itself induces a number of changes in cell 
characteristics, including senescence and epigenetic changes 191,230,287,288. To 
diminish this bias, we used cells at two first passages. The small proportion of 
BMSCs among bone cells prevented from using freshly isolated, uncultured 
BMSCs, which could be otherwise ideal.   
Aging is associated with changes in epigenetics marks like DNA methylation, 
which has been shown to gradually diminish with age 237. In our case, patients 





osteoarthritis. We adjusted the DNA methylation values with age as a covariate 
to limit age-related bias.  
Another considerable limitation is that BMSCs proliferate very slowly and are very 
hard to transfect with lipid-based and other conventional procedures. Due to 
practical reasons we could not use lentiviral-based methods, which may be more 
efficient. This precluded us from obtaining meaningful results in loss-of-function 
and gain-of-function experiments.    
In addition, BMSCs cultures are heterogeneous. This means that they are a 
mixed population with somewhat different phenotypes and/or functions 289. This 
variability may limit power to find significant differences in the gene expression 
and methylation patterns, particularly when the sample size is not very large. This 
may be important for the study of lncRNAs, which are frequently expressed at 
low levels.  
Additionally, we found singular difficulties in confirming antisense lncRNAs 
expression by using commonly postulated protocols for strand-specific RT-PCR. 
These drawbacks made us rather cautious when interpreting other published 
results of antisense-type RNAs. 
 
What this thesis adds 
This thesis contributes to the current understanding of how epigenetic 
mechanisms, including DNA methylation and lncRNAs, regulate BMSCs in 
osteoporosis. It is the first DNA methylation and gene expression study, using 
BMSCs obtained from patients with osteoporosis. It included transcriptome 
analysis of both mRNAs and lncRNAs. The analysis of these gene expression 
signatures, epigenetic marks and regulatory networks in osteoporosis suggested 
new protein coding genes involved in the disease. The study points to some new 
signalling pathways that should studied for a better understanding of the disease 
and to find new potential biomarkers and drug targets.   
  
Future perspectives 
Previous data and experimental data from this thesis suggest that epigenetic 
mechanisms have an important influence on the osteogenic differentiation. 





In this sense, the comparison of global DNA methylation and gene expression 
patterns in subjects with bone diseases can lead to the identification of 
differentially methylated regions and differentially expressed genes involved in 
the pathogenesis of the disease. New sequencing technologies, including 
bisulfite-sequencing may help to further elucidate the epigenome of bones in 
skeletal diseases. 
DNA methylation gives a global view on epigenome-wide changes and highlight 
some target regions and gene candidates, which can be useful for diagnosis and 
prevention. RNA transcripts are very state specific, which makes them very prone 
to study as biomarkers. However, sample heterogeneity may complicate the 
study with less precise results. In line with this, single cell RNA sequencing can 
distinguish cell populations, uncover regulatory relationships between genes and 
compare distinct cell lineages 290. An interesting route for future research is to 
conduct more longitudinal studies with paired differentiated samples, at different 
times along BMSCs osteogenic differentiation. This could reveal certain protein 
or non-protein coding genes involved in this process and in osteoporosis. Also, 
analysis of BMSCs from osteoporotic patients without recent fracture would help 
to distinguish pathogenetic form adaptative changes. Likewise, in vivo studies will 
clarify the true potential of BMSCs from osteoporotic patients as an autologous 
























1- BMSCs of patients with osteoporotic fractures appear to maintain good 
proliferation capacity, but diminished capacity for terminal osteoblastic 
differentiation in vitro, in comparison with BMSCs from control patients with 
osteoarthritis. 
2- Combined transcriptome and epigenome analyses, revealed signature 
differences between both patient groups, including 9038 differentially 
methylated CpG sites. DNA methylation differences were enriched in 
enhancer regions, thus suggesting that epigenetic mechanisms may 
particularly target enhancer regions to modulate gene transcription.  
3- Enhancer regions showing differential methylation were associated with 
differentially expressed genes enriched in pathways related to BMSCs 
growth, osteoblast differentiation and bone formation.   
4- Among differentially methylated and expressed genes we identified 
LOXL2, ID2, OPG and UNC5B.  
5- The epigenetic age of BMSCs, from patients with osteoporotic hip 
fractures, was accelerated in comparison with cells from patients with 
osteoarthritis. The mechanisms involved and the actual consequences for 
bone formation in vivo remain to be elucidated. 
6- Almost 50% of differentially expressed genes in BMSCs derived from 
patients with osteoporotic hip fractures, belonged to the lncRNA class of 
genes. Among them, 72% were of the antisense type.  
7- Approximately half of the protein-coding genes in cis position of 
differentially expressed antisense lncRNAs, were also differentially 
expressed. These lncRNAs-protein coding genes pairs showed significant 
overrepresentation in bone related pathways.  
8- Experimental difficulties for transfecting BMSCs and for reliable strand-






9- Overall, our results suggest that epigenetic mechanisms, and specifically 
the methylation status of enhancer regions and lncRNAs play significant 
roles in determining the gene expression pattern of BMSCs and may 
represent additional targets to enhance bone anabolism in patients with 
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Appendix 1: List of differentially expressed genes 
List of differentially expressed genes in BMSCs grown from patients with fractures 
(FRX) and controls with osteoarthritis (OA). Significant genes are considered with 
an FDR<0.1 and an absolute fold change > 2 between BMSCs obtained from 
FRX and OA.  
 
Gene Expression upregulated in 
Osteoporosis 
 
Gene Expression downregulated in 
Osteoporosis 
Gene_name logFC FDR  Gene_name logFC FDR 
IBSP -2,60 2,81E-03  ELN 2,64 4,59E-04 
GLB1L3 -3,01 4,60E-03  LAYN 1,82 7,24E-04 
SLC29A1 -1,46 6,32E-03  LYZ 4,18 1,59E-03 
KLRC2 -3,16 8,29E-03  SYNPO2 4,44 1,84E-03 
LGR6 -3,54 8,29E-03  EDIL3 2,15 1,84E-03 
AMOT -1,92 1,29E-02  OSBPL1A 1,94 2,11E-03 
SH3GL1P3 -1,33 1,33E-02  ID4 3,50 2,79E-03 
ACAD8 -2,32 1,43E-02  ZNF518A 2,37 5,24E-03 
NCAM1 -1,87 1,51E-02  SLC19A1 2,40 5,83E-03 
PKD1P6 -2,87 1,63E-02  LPAL2 3,47 5,83E-03 
FBXL13 -1,76 1,83E-02  PPP1R14A 2,67 5,83E-03 
WNT5B -1,42 1,93E-02  TGFBI 2,80 6,09E-03 
BGLAP -3,36 2,26E-02  CD27-AS1 3,53 7,63E-03 
EPHA2 -1,50 2,30E-02  HPS3 2,93 8,17E-03 
UNC5B -1,16 2,74E-02  LRRC16A 2,83 8,17E-03 
STMN3 -2,03 2,74E-02  KLF9 1,55 8,17E-03 
ENPP1 -1,56 2,80E-02  DMD-AS1 2,23 1,22E-02 
KIAA1324L -1,10 2,84E-02  HCG4P11 1,90 1,25E-02 
PCDH10 -1,80 2,84E-02  IGHG3 4,65 1,28E-02 
CXorf57 -1,61 2,84E-02  AMPD3 1,69 1,29E-02 
ABCA3 -1,84 2,84E-02  ACSL5 2,34 1,29E-02 
INSC -2,51 2,84E-02  FMO3 2,80 1,29E-02 
COL8A2 -2,04 2,84E-02  DGAT2 1,98 1,29E-02 
TNFRSF11B -1,87 2,84E-02  VGLL3 2,97 1,33E-02 
SGCD -1,42 2,84E-02  HLA-F-AS1 2,30 1,33E-02 
MYO1D -1,19 2,89E-02  SCRN1 2,88 1,43E-02 
GALNT3 -1,86 2,89E-02  FAM110B 2,34 1,51E-02 
LSP1 -1,24 3,39E-02  ENTPD1 3,01 1,58E-02 
SORCS2 -2,51 3,83E-02  BASP1 1,24 1,63E-02 
TRIM7 -1,96 3,84E-02  TXNRD1 2,87 1,73E-02 
SLC12A7 -2,32 3,86E-02  PAPPA-AS1 1,69 1,73E-02 
RTEL1 -2,53 3,99E-02  SLC24A3 3,93 1,82E-02 




Gene Expression upregulated in 
Osteoporosis 
 
Gene Expression downregulated in 
Osteoporosis 
Gene_name logFC FDR  Gene_name logFC FDR 
SHROOM2 -1,40 3,99E-02  LAMA4 2,05 1,83E-02 
DKK3 -1,12 4,40E-02  FAM212B 1,23 1,83E-02 
STARD5 -1,20 4,40E-02  IGHA1 4,09 1,99E-02 
LETM2 -1,30 4,40E-02  CTSL1 1,99 1,99E-02 
WDR90 -1,46 4,53E-02  FNBP1L 1,38 2,01E-02 
LSP1P2 -2,25 4,56E-02  MUC15 3,25 2,04E-02 
FMN1 -1,40 4,74E-02  CHL1-AS2 3,22 2,07E-02 
GNG2 -1,09 4,86E-02  CHL1 4,50 2,24E-02 
BMPER -1,29 4,86E-02  IGJ 3,83 2,27E-02 
CUBN -1,13 4,95E-02  RBPMS 1,23 2,29E-02 
PDPK2 -1,06 4,97E-02  ADAMTS2 1,81 2,30E-02 
BMP2 -2,27 5,10E-02  LOXL2 2,22 2,42E-02 
P2RX6 -1,62 5,10E-02  COL4A1 2,02 2,42E-02 
CADM1 -1,35 5,10E-02  EFEMP1 1,93 2,42E-02 
SOX9 -1,48 5,40E-02  HLA-B 1,78 2,42E-02 
SRPX -1,14 5,44E-02  CELF2 1,89 2,47E-02 
DNLZ -1,04 5,46E-02  ANXA5 2,45 2,47E-02 
TYMP -1,10 5,74E-02  CCR7 1,85 2,47E-02 
GNGT1 -3,18 5,74E-02  RNF43 2,05 2,58E-02 
STXBP6 -1,86 5,80E-02  VCAN 1,95 2,58E-02 
DNAJC22 -1,65 5,86E-02  RNF141 2,14 2,65E-02 
HOMER2 -1,17 5,88E-02  LAMC1 2,17 2,70E-02 
ARVCF -1,34 5,99E-02  BST2 2,09 2,74E-02 
GALNTL4 -1,16 5,99E-02  IGHG4 6,97 2,74E-02 
RANBP3L -2,88 6,04E-02  HERC5 1,93 2,74E-02 
SERPINF1 -1,54 6,09E-02  MAN1C1 2,14 2,74E-02 
CKM -1,15 6,24E-02  SLC22A3 3,10 2,74E-02 
CCDC158 -1,27 6,27E-02  CD4 1,88 2,74E-02 
LRRC46 -1,08 6,42E-02  IGHD 5,83 2,79E-02 
DNM1 -2,22 6,42E-02  MRVI1-AS1 2,08 2,82E-02 
DLX6-AS2 -1,12 6,50E-02  SERPINB9 1,81 2,84E-02 
CMKLR1 -1,22 6,51E-02  IGHGP 5,43 2,84E-02 
KIAA1217 -1,06 6,54E-02  MAOB 2,90 2,84E-02 
TDG -1,30 6,64E-02  CRISPLD2 3,50 2,86E-02 
C1QTNF9B -1,45 6,69E-02  PDK1 2,15 2,95E-02 
SYT12 -1,74 6,86E-02  PTGFRN 1,52 2,96E-02 
LNX1 -1,03 6,86E-02  CP 3,40 3,01E-02 
GALNTL1 -1,90 6,86E-02  TES 1,26 3,22E-02 
EMBP1 -1,81 6,86E-02  GUCY1B3 1,25 3,32E-02 
TNNC1 -2,03 7,03E-02  NME7 1,13 3,36E-02 
FOXP2 -1,38 7,06E-02  ARHGAP20 3,20 3,37E-02 
LRP4-AS1 -1,07 7,42E-02  NUAK2 1,73 3,37E-02 




Gene Expression upregulated in 
Osteoporosis 
 
Gene Expression downregulated in 
Osteoporosis 
Gene_name logFC FDR  Gene_name logFC FDR 
MEOX2 -1,83 7,97E-02  LARP4B 2,95 3,39E-02 
RNF112 -1,87 7,97E-02  TM4SF19-AS1 2,64 3,39E-02 
GRIA1 -2,02 8,06E-02  IGHMBP2 2,19 3,39E-02 
TRIM59 -2,21 8,15E-02  CNTNAP2 2,77 3,45E-02 
PRTG -1,30 8,24E-02  RPS6KA2 2,95 3,45E-02 
OSBP2 -2,32 8,24E-02  EFNB2 2,03 3,48E-02 
LRRC17 -2,01 8,54E-02  ADCY2 3,19 3,48E-02 
RAET1G -1,06 8,54E-02  MED16 1,84 3,49E-02 
LRRC15 -1,71 8,84E-02  PMP22 3,05 3,58E-02 
BTBD11 -1,95 9,24E-02  CDKN1C 3,05 3,70E-02 
SERINC2 -1,33 9,24E-02  CHRDL1 4,00 3,72E-02 
PNPLA3 -1,09 9,24E-02  PPP1R3C 2,67 3,76E-02 
ARHGAP22 -1,41 9,29E-02  MMP9 2,86 3,77E-02 
C1GALT1 -1,05 9,45E-02  SPARC 2,03 3,77E-02 
ARFRP1 -1,95 9,50E-02  MAF 1,55 3,77E-02 
MRPS14 -1,29 9,54E-02  IGHG2 3,42 3,80E-02 
ARHGEF19 -1,15 9,61E-02  B2M 2,12 3,87E-02 
CACNA1G -1,97 9,72E-02  C1orf183 1,29 3,91E-02 
TCEAL7 -1,82 9,72E-02  EFR3B 1,53 3,99E-02 
IL16 -1,21 9,72E-02  ADA 1,06 3,99E-02 
GLRB -1,24 9,79E-02  CHI3L1 1,95 3,99E-02 
LOXL4 -1,80 9,79E-02  PAPPA 2,23 4,02E-02 
ETV1 -2,25 9,79E-02  ANO3 2,80 4,06E-02 
    ATXN1L 3,26 4,29E-02 
    IGFBP4 1,44 4,40E-02 
    SHC2 2,69 4,40E-02 
    TNS1 2,89 4,53E-02 
    CYP1B1 2,29 4,53E-02 
    XYLT1 2,23 4,53E-02 
    STK3 2,23 4,53E-02 
    FTL 2,06 4,53E-02 
    MPZL1 1,98 4,53E-02 
    PTX3 1,78 4,53E-02 
    LGMN 2,69 4,56E-02 
    LASP1 1,90 4,59E-02 
    MED11 2,50 4,63E-02 
    IL32 3,57 4,74E-02 
    TFRC 2,98 4,83E-02 
    DERL3 3,70 4,86E-02 
    EYA1 1,75 4,86E-02 
    FSTL1 1,79 4,86E-02 
    GALNTL2 2,03 4,94E-02 




    
Gene Expression downregulated in 
Osteoporosis 
    Gene_name logFC FDR 
    WASF2 2,61 4,97E-02 
    GPM6B 2,74 5,10E-02 
    KCNE4 1,48 5,10E-02 
    FBN2 1,51 5,15E-02 
    IGKV1-5 4,44 5,18E-02 
    COL14A1 2,94 5,31E-02 
    LMOD1 1,46 5,33E-02 
    TINAGL1 2,23 5,37E-02 
    PPARG 1,35 5,40E-02 
    PTMA 2,05 5,42E-02 
    STK38L 2,59 5,60E-02 
    TMTC3 3,38 5,76E-02 
    NDE1 3,38 5,77E-02 
    EDNRA 1,47 5,80E-02 
    GLIPR2 1,04 5,80E-02 
    COL3A1 1,73 5,81E-02 
    PEAR1 1,95 5,86E-02 
    NTRK2 2,85 5,86E-02 
    ID2 1,21 5,86E-02 
    IGKV2-28 5,44 5,96E-02 
    ITGA4 1,13 5,96E-02 
    IFI27 2,62 5,96E-02 
    GRK5 1,43 5,96E-02 
    RP11-145A3.1 1,37 5,99E-02 
    PREX2 2,27 6,12E-02 
    SPON2 2,12 6,12E-02 
    SAMD11 1,77 6,12E-02 
    IGHJ4 5,60 6,24E-02 
    TGFB3 1,22 6,24E-02 
    APBA2 1,88 6,24E-02 
    IGKV1-6 4,44 6,24E-02 
    MRVI1 2,28 6,25E-02 
    RP11-428C6.1 1,00 6,41E-02 
    VAMP8 1,73 6,42E-02 
    PTGES 1,14 6,42E-02 
    IL21R 1,13 6,42E-02 
    ID1 1,70 6,44E-02 
    KIT 2,43 6,50E-02 
    PRDM1 2,02 6,51E-02 
    DMD 2,60 6,51E-02 
    CPA3 3,96 6,51E-02 
    TCF7L1 1,07 6,51E-02 




    
Gene Expression downregulated in 
Osteoporosis 
    Gene_name logFC FDR 
    RND3 2,68 6,64E-02 
    CALCOCO2 2,54 6,64E-02 
    EMP1 2,28 6,80E-02 
    OSR2 2,37 6,85E-02 
    BLNK 2,52 6,85E-02 
    CCDC81 1,80 6,85E-02 
    MYOM1 1,27 6,85E-02 
    SLC22A4 1,20 6,86E-02 
    SLC5A3 3,28 6,87E-02 
    CDC5L 2,94 7,00E-02 
    PTBP3 2,62 7,02E-02 
    CALD1 1,83 7,02E-02 
    LYN 1,14 7,03E-02 
    ACTG2 3,60 7,11E-02 
    FAM89A 1,45 7,11E-02 
    DUSP1 1,05 7,31E-02 
    PPP2R5C 2,15 7,42E-02 
    JAG1 1,85 7,42E-02 
    ARHGAP23 1,48 7,42E-02 
    KREMEN1 2,97 7,69E-02 
    FAM65C 2,34 7,72E-02 
    APBB1IP 2,50 7,79E-02 
    AC017048.3 1,26 7,79E-02 
    LRRC28 2,74 8,03E-02 
    TNS3 1,94 8,06E-02 
    IGKV4-1 4,73 8,06E-02 
    ICAM1 1,61 8,09E-02 
    MORF4L1P1 2,09 8,18E-02 
    SLC2A5 2,36 8,19E-02 
    ARRB1 1,27 8,24E-02 
    IGKV3D-20 3,21 8,24E-02 
    ISLR 1,05 8,24E-02 
    CSF2RB 1,51 8,24E-02 
    C2 1,43 8,24E-02 
    CD74 1,16 8,27E-02 
    LEPR 2,14 8,45E-02 
    ANXA1 2,09 8,45E-02 
    GPRC5A 1,62 8,45E-02 
    STX12 3,27 8,50E-02 
    RBM3 2,31 8,50E-02 
    COL5A3 2,50 8,55E-02 
    ST5 1,31 8,56E-02 




    
Gene Expression downregulated in 
Osteoporosis 
    Gene_name logFC FDR 
    ARL6IP5 2,72 8,65E-02 
    TMED2 2,12 8,65E-02 
    PFDN5 2,14 8,82E-02 
    AKAP12 2,38 9,08E-02 
    IFI30 1,25 9,09E-02 
    IRF4 2,96 9,11E-02 
    MGST1 1,04 9,24E-02 
    CPNE5 2,67 9,24E-02 
    TMEM176A 3,68 9,35E-02 
    ADAM10 2,47 9,35E-02 
    CNTN1 2,13 9,49E-02 
    HSD17B6 1,69 9,49E-02 
    CANX 1,96 9,50E-02 
    CCDC41 1,43 9,50E-02 
    ANK3 2,82 9,54E-02 
    ADAM9 1,82 9,54E-02 
    STC2 1,91 9,56E-02 
    IGLC3 3,89 9,67E-02 
    GM2A 2,67 9,67E-02 
    KLHL13 1,24 9,72E-02 
    CD38 3,03 9,72E-02 
    CSTA 1,15 9,72E-02 
    NUB1 2,53 9,75E-02 
    ZNF423 2,15 9,75E-02 
    SMOC1 1,93 9,75E-02 
    MDM2 1,91 9,75E-02 
    HIST1H2AC 3,26 9,89E-02 
    SLC2A3 2,57 9,89E-02 
    TTC3P1 2,29 9,90E-02 
    INHBA 2,14 9,90E-02 
    ANP32A 1,88 9,90E-02 
    IGLC2 4,43 9,92E-02 
    LDHA 1,89 9,93E-02 






Appendix 2: List of genes from the intersections 
List of genes from the intersections between differentially methylated enhancers and differentially expressed genes in BMSCs 
isolated from FRX and controls with OA. Some genes may have both hypomethylated and hypermethylated regions. 
Hypermethylated and 
hypomethylated 
KCNMA1; TNIK; FOXP4; EHF; GRAMD1B; CGNL1; MSC; EDIL3; CBLN1; SLC25A37; EFNA5; NXN; MAX; TMEM174; SRP14; KIAA0513; 
PRL; TSKU; FAM65B; TLE3; FGGY; RHOU; DNAJC15; CCNY; SNX9; GMPR; LYVE1; SELPLG; FAM76B; PDZRN3; TBL1XR1; ADAMTS9; 
TMEM167A; CPEB4; PTPRG; TBX3; NRP2; MSI2; PLEC; ZNF423; DCP2; CBR4; ZBTB20; SLC41A2; DYNC1I1; ZEB2; GRHL2; EIF4E3; 
FBXL7; NOS1AP; DYRK2; ABCA4; MAP2K6; CYP26B1; TSPAN18; SP3; AZIN1; SOX9; GLI2; ZFPM2; OXNAD1; TGFBR2; ANKRD46; 
CLDN20; SH3GL3; TCF7L2; FGFR2; PTPRJ; FOXP1; SPRY4; BOC; XXYLT1; IRX1; TPM1; KITLG; WBSCR17; UBE2V2; TNFRSF19; SPECC1; 
PTPN14; TNS1; EPAS1; SPATS2L; THSD4; TJP1; ARHGAP26; ERRFI1; BCAT1; CDH11; FAM20C; CHST2; SLC45A1; CPN2; AUTS2; GAB1; 
PFN4; CALM1; COL13A1; ANGPT1; IRF2BPL; SMAD6; RPH3A; NR2F2; TMTC2; ZNF608; CUL1; LBR 
Hypermethylated and 
overexpressed 
LRRC17; NCAM1; SOX9; RNF112; GRIA1; C1GALT1; BMPER; ARHGAP22 
Hypermethylated and 
underexpressed 
VAMP8; PTMA; EDIL3; SYNPO2; LAYN; TNS3; INHBA; LOXL2; ISLR; NME7; SERPINB9; AKAP12; PAPPA-AS1; ZNF423; CHI3L1; ST5; 
ID2; RBPMS; EYA1; LMOD1; GM2A; MPZL1; NUAK2; DUSP1; ANK3; ARRB1; SPARC; ANO3; LAMA4; RND3; TNS1; IGFBP4; SLC19A1; 
TFRC; SLC5A3; CRISPLD2; LASP1; LAMC1; PRDM1 
Hypomethylated and 
overexpressed 
FOXP2; UNC5B; ENOX1; TNFRSF11B; TNNC1; SLC29A1; SGCD; FMN1; SOX9; LRRC15 
Hypomethylated and 
underexpressed 
EDIL3; FNBP1L; CPNE5; KREMEN1; CNTN1; ZNF423; CNTNAP2; CELF2; APBA2; PDK1; SCRN1; TNS1; APBB1IP; ARHGAP23; XYLT1 
Hyper and hypomethylated 
and overexpressed 
SOX9 
Hyper and hypomethylated 
and underexpressed 
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To the Editor:
We have read with great interest the recent article in the
Journal of Bone and Mineral Research “Primary Osteoporosis Is
Not Reflected by Disease-Specific DNA Methylation or Acceler-
ated Epigenetic Age in Blood.”(1) The authors analyzed age-
related DNA methylation profiles in peripheral blood cells and
did not find significant differences between osteoporotic
patients and non-osteoporotic controls.
DNA methylation is an epigenetic mechanism that regulates
gene expression and cell differentiation and activity. Horvath
described a set of specific CpGs that show age-related changes
in methylation in a variety of cell types and tissues and therefore
represent an index of the epigenetic aging of those tissues.(2)
The results by Fernandez-Rebollo and colleagues suggest that
there are not differentially methylated age-related CpG sites in
blood from osteoporotic patients when compared with blood
from non-osteoporotic subjects. These results are in line with a
previous report by Morris and colleagues, who did not find
significant associations between DNAmethylation in blood cells
and bone mineral density.(3)
However, it is important to emphasize that epigenetic marks,
including DNA methylation, are tissue specific, so in disorders
like osteoporosis, methylation marks in leukocytes may not
necessarily represent methylation signatures in other cells and
particularly in those cells in bone tissue. In fact, we have
previously shown that there are differences in the DNA
methylation signature of bone tissue samples andmesenchymal
stem cells (MSCs) between patients with fragility fractures
and controls with osteoarthritis.(4,5) Quite interesting, when
we analyzed age-related methylation marks in patients with
fractures and with osteoarthritis, we found an accelerated
epigenetic aging in cartilage cells in the latter group, without
significant differences in bone cells (Fig. 1A). These results would
suggest that accelerated epigenetic aging is disease- and tissue-
specific.(6)
Despite the lack of differences in age-related epigenetic
marks in DNA extracted from bone tissue, an accelerated
epigenetic aging in bone cells cannot be completely excluded.
Bone is a complex and heterogeneous tissue, and analyzing
whole bone samples may miss changes taking place in some
cells. In fact, when we studied MSCs, an accelerated aging was
evident in those grown from patients with osteoporotic hip
fractures, in comparison with cells grown from patients with
osteoarthritis (Fig. 1A).(5) These results would be consistent
with the concept that the potential role of epigenetic aging in
Fig 1. Epigenetic marks in bone tissue and MSCs from patients with hip
fractures and with hip osteoarthritis. (A) Epigenetic aging as revealed by
age-relatedDNAmethylationmarks. Dot plotwith themeanandSDof the
residuals (deviation from the overall regression line) from bone and
human mesenchymal stem cells (hMSCs) isolated from osteoporotic
fractures (Fx, dark gray dots) and osteoarthritis (Oa, gray dots) are shown.
Between-group differences were compared by ANCOVA, with the
chronological age as covariable. Data derived from previously reported
results (Delgado-Calle et al. 2013; Vidal-Bralo et al. 2016; del Real et al.
2017). (B) Violin plots showing the distribution of the relative telomere
length density from bone and MSCs isolated from osteoporotic fractures
(in gray) and osteoarthritis (in white).
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osteoporosis is more important at the precursor cell stage than
in differentiated bone-forming cells. In theory, it could limit
the pool of bone-forming cells and therefore the overall bone
formation capacity, despite normal functioning of individual
mature osteoblasts.
Telomeres shorten with cell divisions and may result in cell
senescence when a length threshold is reached.(7) Therefore,
telomere length is also considered as a biomarker of aging
and age-related diseases. So, we explored the relative
telomere length in bone and in MSCs. We analyzed telomere
length by real-time qPCR using a single copy gene (b-globin)
as comparator as suggested by Cawthon.(8) The results in
each run were normalized in comparison with a set of three
control DNAs. However, we did not find significant differ-
ences in the relative telomere length of either bone samples
or MSCs of patients with fractures or with osteoarthritis
(Fig. 1B).
Overall, the results of Fernandez-Rebollo and colleagues and
those from our own group are consistent with the concept of an
accelerated epigenetic aging, and specifically DNA methylation
marks, in MSCs from osteoporotic patients that does not
translate into blood leukocytes, which do not derive fromMSCs,
nor even inmature bone cells, at least whenwhole bone tissue is
analyzed. This emphasizes the complexity of epigenome
association studies, related to the cell and tissue specificity of
epigeneticmarks. Further studies in individual mature bone cells
will be needed to clarify the role of DNA methylation and other
aging-related epigenetic changes in the pathogenesis of bone
disorders.
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